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Bottom-up biofabrication approaches for fabricating engineered tissue 
constructs are emerging strategies in tissue engineering. Few technologies have 
been developed that are capable of assembling tissue units into 3D Plotted scaffolds. 
We developed an integrated and automated 3D Bioassembly system for 
bioassembling engineered tissue constructs. The developed automated bioassembly 
system consisted of a (i) singularisation module and (ii) an injection module 
integrated into a commercial 3D bioprinter. The fluidic-based singularisation 
module delivered single Ø1 mm sized tissue unit at a time to the injection module 
and the injection module together with the 3D positioning system of the 3D 
bioprinter delivered the tissue unit into a predefined pore in the 3D Plotted scaffold. 
The developed automated bioassembly system was capable of either fabricating a 
construct via a two-step top-down bioassembly approach (fabricating a complete 
scaffold and insertion of tissue units) or a multistep bottom-up bioassembly 
approach (alternative layer-by-layer scaffold fabrication and tissue unit co-
assembly). The automated bioassembly system was validated for application in 
cartilage and tumour engineering using tissue units (microspheres and micro-
tissues). For cartilage engineering, Ø1 mm sized cartilage micro-tissues were 
fabricated utilising a previously demonstrated high-throughput 96-well plate 
format and Ø1 mm sized chondrocytes or chondroprogenitor cells-laden GelMA 
(gelatin-methacryloyl)-HepMA (methacrylated heparin) (9.5%-0.5%) hydrogel 
microspheres were fabricated utilising an adopted microfluidic system. For tumour 
engineering, a co-culture of cancer cells with fibroblasts using a liquid overlay 
technique was required to fabricate compact spherical Ø1 mm micro-tissues that 
could be handled by the automated bioassembly system and cancer cell-laden 10% 
GelMA hydrogel microspheres were fabricated utilising the adopted microfluidic 
system. Reliable handling of the tissue units was demonstrated by the automated 
bioassembly system. Bottom-up bioassembly of tissue units into 3D Plotted 
PEGT/PBT polymer scaffolds was demonstrated with the automated bioassembly 
system. No difference in viability was observed between the constructs assembled 
manually and with the automated bioassembly system. The flexibility of the 
automated tissue bioassembly system was shown by assembling constructs with 
coloured microspheres (denoting microspheres of different types) in various 





construct was also demonstrated. Neocartilage formation was observed in the 
chondrocyte-laden individual microspheres and assembled constructs when 
cultured in vitro for 35 days. Neocartilage formation was also visualised in the 
assembled graduated constructs fabricated with human articular chondrocytes 
(HAC) and mesenchymal stromal cells (MSC). In the in vitro micro-tissue tumour 
model, individual micro-tissues had higher chemoresistance compared to cells in 2D 
and the co-culture assembled construct had higher chemoresistance compared to 
individual co-culture micro-tissues. Similarly, in the in vitro microsphere tumour 
model, the assembled constructs were the most chemoresistant followed by 
individual microspheres and the cell in 2D had the lowest chemoresistance. The 
novel and flexible automated bioassembly technology that we have developed 
provides a pathway for fabricating a larger number of anatomically shaped clinically 
relevant constructs with precise control of the spatial position of the tissues units 
for application in cartilage engineering and for fabricating in vitro cancer models for 
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From time immemorial, humankind has been on a quest to cure the ailments 
that plague both the body and mind. From the first description of skin grafting in 
300 BC to the development of the first tissue-engineered skin constructs in the early 
1980s, progress in medical research has come a long way [1, 2]. There is a desperate 
need for transplantable tissues and organs and millions of people could benefit from 
laboratory-grown autologous tissues or organs that are ready to be transplanted. 
The ability to create artificial tissues would also be highly beneficial for the progress 
of medical research and discovery.  
 
Tissue engineering is a very self-explanatory term where the fundamental 
intention is to engineer tissues to restore, maintain, or enhance tissue function [3]. 
Unlike other solutions such as drug based therapies, tissue engineering hopes to 
provide a permanent solution to organ and tissue failure [4]. However, there are a 
lot of technical challenges and barriers associated with manufacturing an artificial 
tissue [4]. Apart from the raw materials required to manufacture the laboratory-
grown off-the-shelf tissue such as cells, growth factors and biodegradable 3D 
scaffold, there is a need for state-of-art technologies to manufacturing the tissue [3-
6].  
 
Although there exist various bioassembly and biofabrication techniques to 
fabricate a tissue construct, as far as we are aware of, there exists no technological 
platform that can assemble tissue subunits together into a 3D plotted scaffold with 
the intention of creating a larger organised tissue construct. In this thesis, the 
primary objective was to develop and validate a bioassembly technology, with 
special emphasis on cartilage tissue engineering and on 3D cancer models for drug 




1.2 Thesis objectives and chapter outline 
The focus of this thesis was to develop a novel automated bioassembly system 
capable of fabricating tissue constructs. The overall objectives of the thesis were to: 
I. Design, develop and validate an automated tissue bioassembly system.   
II. Validate the system for application in cartilage tissue engineering. 
III. Validate the system for fabricating a proof-of-concept 3D cancer model and 
to characterise the model. 
 
The general outline of the chapters in the thesis is as described below.  
 
The literature regarding fabrication approaches in tissue engineering, 
cartilage engineering, cancer models and the need for an automated 3D Bioassembly 
system was reviewed in Chapter 2. The specific aims of this thesis are described at 
the end of Chapter 2. 
 
Chapter 3 focuses essentially on the development of the integrated and 
automated 3D Bioassembly system. The aim of this chapter was to describe in detail 
the design and development of the prototype automated bioassembly system. A 
complete description of the architecture of the mechanical and electronic systems 
was explained here.  
 
Chapter 4 reports the validation of the developed integrated automated 
bioassembly system for application in cartilage tissue engineering with micro-
tissues (i.e. spherical aggregates consisting of only cells). The aim of this chapter was 
to demonstrate and validate the automated bioassembly of cartilage micro-tissues 
without adversely affecting the living micro-tissues.  
 
Chapter 5 presents the work on bioassembly of microspheres fabricated 
utilising a micro-fluidic system for application in cartilage tissue engineering. The 
aim of this chapter was to fabricate cell-laden hydrogel microspheres (i.e. spherical 
hydrogel bead with encapsulated cells) for application in cartilage engineering, 
validation of the microspheres with the bioassembly system, demonstrate the 
flexibility of the bioassembly system and demonstrate cartilage tissue formation in 




Chapter 6 presents the work on biofabrication of a proof-of-concept in vitro 3D 
cancer model with micro-tissues. The aim of this chapter was to develop, validate 
and characterise a micro-tissue based in vitro 3D cancer model that can be 
assembled with the bioassembly system.    
 
Chapter 7 reports the work on biofabrication of a proof-of-concept in vitro 3D 
cancer model with microspheres. The aim of this chapter was to develop, validate 
and characterise a cancer cell-laden microsphere based in vitro 3D cancer model 
that can be assembled with the bioassembly system.    
 
Finally, Chapter 8 presents the conclusions drawn from the thesis and makes 
recommendations for future work 
 
Chapters 4 and 5 primarily focus on cartilage engineering and Chapters 6 and 
7 focus on in vitro cancer models. Chapters 4 and 6 are based on micro-tissues 
(spherical aggregates consisting of only cells, see note below) as the modular tissue 
unit for bioassembly, whereas Chapters 5 and 7 are based on cell-laden hydrogel 
microspheres (spherical hydrogel bead with encapsulated cells) as the modular 
tissue unit for bioassembly. 
 
Please note: aggregates of tumour cells, which is usually referred to as tumour 
spheroids in the literature has been referred to as micro-tissues in this thesis to keep 
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The progress of modern medicine has been highly intertwined with science 
and technology and the advancement in medical research has led to the 
extraordinary capacity of being able to engineer artificial tissues in the laboratory. 
The primary goal of engineering a tissue is to provide a permanent solution to tissue 
and organ failure [1, 2].  However, the application of engineered tissues is not only 
being confined to restoring, maintaining, or enhancing tissue functions but is being 
investigated for application in other avenues such as 3D in vitro tissue models for 
studying disease or high-throughput drug screening e.g. cancer research [1, 2]. 
Engineering an artificial tissue is a highly complex process and not only requires the 
raw materials such as cells, growth factors and biodegradable 3D scaffold but also 
requires cutting-edge technologies to biomanufacture the synthetic tissue [1-4]. 
Presently a spectrum of futuristic technologies exist to manufacture an artificial 
tissue, but to our knowledge, we are not aware of a technological platform that can 
assemble tissue subunits together into a 3D plotted scaffold with the intention of 
creating a larger engineered tissue. In this thesis, the primary objective was to 
develop and validate a bioassembly technology platform, with special emphasis on 
application in cartilage tissue engineering for joint resurfacing and in tumour 
engineering for drug discovery.  
2.2 Tissue engineering and regenerative medicine 
Tissue engineering is a relatively young field in health science that aims at the 
repair and restoration of damaged or degenerated tissue and organs [4, 5]. It is a 
complex and multidisciplinary area that applies the principle of engineering, 
physical sciences and medicine to create ex vivo tissues and organs substitutes 
functionally analogous to natural tissue [1]. The typical tissue engineering paradigm 
involves in isolating the required cells or the substitute cell type with the possible in 
vitro expansion of the cells, seeding the cells with growth factors within a 
biodegradable 3D scaffold or into a tissue inducing substrate in vitro, and then 
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implanting the artificially engineered construct into the target site [1, 3, 4]. See 



















Figure 2-1. Tissue engineering strategies for organ development. Reproduced from 
Gholipourmalekabadi et al. [6].   
 
Regenerative medicine, on the other hand, aims at the repair and restoration 
of damaged or degenerated tissues and organs by regenerating the part in vivo or ex 
vivo. This might require a combination of cells, natural or artificial scaffolding, 
growth factors, gene manipulation [7-9]. Although the terms “tissue engineering” 
and “regenerative medicine” have often been used interchangeably and are related 
with similar objectives, regenerative medicine is oriented more toward the cellular 
aspect of tissue replacement and tissue engineering is more focused on the 
engineering and manufacturing aspects of tissue replacement [10]. Tissue 
engineering can be considered as a partial subset of regenerative medicine [7]. To 
sum up, the primary aim of both tissue engineering and regenerative medicine is to 
restore the function of a pathological or damaged tissue or organ [1].  
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2.3 Cartilage engineering  
2.3.1 Structure and function of articular cartilage 
Articular cartilage is a load-bearing viscoelastic tissue at the ends of a bone 
that provides a smooth, low friction and lubricated surface for movement [11]. It is 
an avascular, aneural and alymphatic tissue consisting of chondrocytes and 
extracellular matrix (ECM) [11]. The extracellular matrix is synthesised, maintained, 
and secreted by the chondrocytes and consists of water, dissolved salts, collagen, 
hyaluronan and proteoglycan, and in lesser quantities non-collagenous proteins and 
glycoproteins [12, 13]. Collagen is the most abundant structural and load-bearing 
macromolecule in the extracellular matrix and collagen II is the most abundant type 
of collagen fibrils. Other types of collagen such as collagen type V, VI, IX, X, XI, XII and 
XIV are found in lower quantities [13, 14]. Proteoglycans are the second most 
abundant structural and load-bearing macromolecule in the extracellular matrix 
after collagen. Articular cartilage is composed of a variety of proteoglycans such as 
aggrecan, decorin, biglycan, and fibromodulin, and aggrecan is the most abundant 
proteoglycan by weight [13, 15]. The proteoglycan aggregates are entrapped in the 
fibrils formed by collagen interaction [14]. This composition of articular cartilage 
with negatively charged proteoglycans aids retention of water in the extracellular 
matrix and gives cartilage its mechanical properties [12, 13]. The hydrophilic nature 
of the proteoglycans aids retention of water and creates a swelling pressure which 
is balanced by the tensile strength of the collagen matrix at equilibrium. During 
compression, the interstitial fluid pressure in the cartilage opposes the compressive 
load and dampens the mechanical impulse [16]. On removal of the compressive load, 
the interstitial fluid is absorbed back into the cartilage and the cartilage reverts to 
its original structure. This circulation pattern between the synovial fluid and the 
tissue is essential for waste and nutrient exchange [17].  
 
Cartilage has a highly organised structure and can histologically be divided 
into 4 different zones -  the superficial zone, the middle zone, the deep zone, and the 
calcified zone [18]. See Figure 2-2 for an illustration of articular cartilage. The 
superficial zone makes up the articulating surface and protects the deep layers from 
shear stress [18]. Unlike the other layers, the superficial layer consists of 
chondrocytes that have a more elongated and fibroblast-like morphology [13, 18].  
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This layer consists of a relatively higher quantity of collagen type I and lesser 
proteoglycan. The collagen fibres of this layer are packed tightly and are aligned 
parallel to the surface, thereby resisting the tensile forces generated by friction 
between joints [19]. The middle zone is in between the deep and superficial zone. In 
this layer, the chondrocytes are more spread out with a lower population density 
and have a more rounded morphology compared to ones in the superficial layer. The 
collagen fibres of this layer are arranged obliquely. The deep zone consists of 
collagen fibres that are parallel to the articular surface. The chondrocytes are 
arranged in a column fashion. This layer provides the highest resistance to a 
compressive load. The calcified cartilage is distinguished from the deep zone by a 














Figure 2-2. Illustration of articular cartilage showing the distribution and 
orientation of collagen fibres (left) and chondrocytes (right) within the superficial, 
middle and deep zone. The GAG/DNA content, safranin O staining for GAG, 
immunohistochemistry for collagen type II and type I for bovine articular cartilage 
is shown in the box on the right. Reproduced from Woodfield et al. [20].  
 
2.3.2 Damage and repair strategies  
Due to the avascular nature and low chondrocyte density, cartilage has a 
limited capacity for repair. Injury to articular cartilage can cause morbidity in young 
and old patients [13, 14]. Damage to articular cartilage can either be superficial 
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(Figure 2-3 a) which is a partial thickness defect or can extend till the subchondral 
plate which is an osteochondral or full-thickness defect (Figure 2-3 b and Figure 2-4) 
[14]. Superficial defects fail to heal spontaneously and osteochondral defects elicit 
tissue repair response which produces a mechanically inferior fibrocartilage instead 








Figure 2-3. Illustration of (a) a superficial partial thickness defect and (b) a full-
thickness defect that extends into the subchondral bone in articular cartilage. 











Figure 2-4. Arthroscopic image of a 20 x 30 mm full-thickness cartilage defect to the 
medial femoral condyle. Reproduced from Kuroda et al. [22]. 
 
Many repair strategies have been developed in an attempt to treat articular 
cartilage defects with the end goal of being able to reduce the patient's symptoms 
and restore the function of the joint [14]. Studies have suggested that arthroscopic 
repair procedures such debridement (removal of damaged or calcified tissue) and 
lavage (irrigation of the joint) do not induce cartilage repair and the results are 
comparable to placebo [21, 23]. With the microfracture technique (debridement of 
Articular cartilage 
Subchondral bone 
(a) Partial thickness defect (b) Full-thickness defect 
Full-thickness cartilage defect 
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damaged tissue down to the subchondral bone), the clinical long-term outcome has 
been reported to be varied due to the variable nature of the fibrous repair tissue [21, 
24]. Clinical results have shown that osteotomy which is the realignment of the 
articulating surface deteriorates with time, causing recurrent pain and progressive 
osteoarthritis  [25, 26]. With soft tissue grafts where perichondrial/periosteal grafts 
are placed in the defect, studies have shown better outcomes in young patients and 
poorer outcomes in older patients [27, 28]. Osteochondral transplantation (Figure 
2-5) or mosaicplasty, on the other hand, showed donor site morbidity and the 















Figure 2-5. Illustration of osteochondral transplantation. Reproduced from 
Redman et al. [21].  
 
Total/partial arthroplasty is the resurfacing of the articulating surface with 
metal and plastic components and is one of the most common procedures. However 
the drawback is the requirement of extensive surgery and as it functionally lasts only 
for about 10-15 years it is limited to older patients [31, 32]. Autologous chondrocyte 
implantation (ACI), which is a cell-based therapy has shown better outcome 
compared to other surgical outcomes. The ACI process (Figure 2-6) involves 
harvesting a healthy biopsy from a non-load bearing region, extracting chondrocytes 




chondrocytes under a periosteal flap [33]. Considerable cost of the procedure, highly 
invasive nature of the surgery, donor site morbidity, long rehabilitation time, and 
limited success in patellar defects are the disadvantages associated with ACI [21]. 
The matrix-assisted chondrocyte implantation (MACI) is a similar technique to ACI, 
where cells are immobilised within a collagen-based matrix and the matrix is then 
implanted into the defect. The use of periosteal flap as in ACI is omitted. However, a 

















Figure 2-6. Illustration of the autologous chondrocyte implantation (ACI). 
Reproduced from  Brittberg et al. [36].  
 
Although some of the above-described procedures are effective in providing 
symptomatic relief and improved joint function in certain circumstances, there is a 
need for a strategy with good long-term outcomes. A strategy that can cater to a 
range of population and lifestyles and tissue engineering and regenerative medicine 
is one of the areas being looked into.  
Autologous chondrocyte implantation 
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2.3.3 Tissue engineering and regenerative approaches in cartilage 
engineering  
Cartilage engineering aims at fabricating replacement scaffolds or constructs 
that have a similar structure, composition and mechanical properties to the native 
tissue to restore the function of a joint [37]. Although current tissue engineering and 
regenerative medicine strategies such as ACI and MACI have shown better outcomes 
compared to other surgical repair strategies, the implanted tissues lack the 
mechanical properties and organisation of native cartilage and other approaches are 
being looked into [33-35, 37].  
 
Typically, tissue engineering strategies for cartilage repair adopt either a 
scaffold only or a scaffold with cell strategy. In repair strategies utilising only 
scaffolds by themselves, the scaffold material and geometry is designed so that the 
host progenitor cells would infiltrate into the absorbable scaffold placed in the 
defect and induce neocartilage formation [38]. For the scaffold with cell strategy, the 
tissue engineering paradigm for engineering a cartilage involves culturing 
chondrocytes or chondroprogenitor cells along with chondrogenesis inducing 
growth factors within a biodegradable 3D scaffold in vitro and then implanting the 
engineered construct into the target site in vivo [3]. The fabricated scaffolds for 
cartilage engineering can either be a single-phase scaffold – which is a scaffold 
containing a single or several materials but is uniform through or a biphasic or 
multiphasic scaffold – which is a scaffold where two different materials are used, one 
for the cartilage phase and the other for the subchondral bone or bone phase [39]. 
 
During the expansion of chondrocytes on a 2D surface, chondrocytes undergo 
dedifferentiation, change from a rounded to fibroblastic morphology, and the ratio 
of collagen type II to I production decreases [40]. The in vitro culture of chondrocytes 
in a 3D environment guides chondrocytes to redifferentiate, have a more rounded 
morphology, and produce cartilage extracellular matrix such as collagen type II, GAG 
and aggrecan [41]. There are two main strategies by which we cultured 
chondrocytes or chondroprogenitor cells in a 3D environment in this thesis – a 
micro-mass or pellet culture to fabricate micro-tissues, and the encapsulation of 
cells in a hydrogel [42]. In a micro-mass or pellet culture, the condensed cellular 
environment typical during the developmental stages of cartilage growth is 
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replicated, and this induces the production of hyaline-like neocartilage [42]. In a cell 
encapsulated hydrogel, the hydrogel provides a hydrated environment, aids the cells 
in maintaining a rounded morphology, imitates the features of native cartilage and 
can promote or direct a chondrogenic phenotype [43, 44]. 
2.3.4 Challenges in cartilage engineering  
Presently significant research is ongoing in the area of cartilage repair and 
there exist numerous challenges in engineering a cartilage. This includes the source 
of cells, quality of ECM production in the engineered construct, optimal scaffold 
design, fabricating constructs with similar mechanical properties to native cartilage, 
recapturing the native microarchitecture, and the automated biofabrication of large 
complex and constructs [39, 45].   
 
One of the biggest challenges in cartilage engineering is obtaining the required 
number of cells to fabricate cartilage constructs of clinically relevant size. As the 
number of chondrocytes that can be isolated from a biopsy is limited, obtaining a 
large number of cells would require cell expansion. Chondrocytes have a limited 
proliferative potential and when autologous cells are cultured in 2D, they 
dedifferentiate and lose their chondrogenic phenotype [40]. Chondrocytes isolated 
from articular cartilage is the most commonly used cell source in cartilage 
engineering. Apart articular cartilage, chondrocytes can be isolated from the nasal 
septum [46]. The use of nasal chondrocytes can be advantageous as nasal septum 
biopsies can be isolated more easily than articular cartilage biopsies. Nasal 
chondrocytes have been shown to have a faster proliferation rate and increased 
chondrogenic capacity compared to articular chondrocytes, and the quality of 
engineered cartilage from nasal chondrocytes does not seem to depend on the age 
of the donor, contrary to articular chondrocytes [46-49]. Mesenchymal stromal cells 
(MSCs) can also be a considered as an alternative source for cartilage engineering as 
they can be easily isolated, expanded and differentiated into chondrocytes [50]. 
However, MSCs derived from bone-marrow have a disadvantage in that they have a 
tendency to undergo hypertrophy and calcification [51]. 
 
Designing an optimum scaffold is a challenge for cartilage engineering. The 
substrate used for the fabricating the 3D cartilage construct could affect the quality 
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of the tissue in many ways [52]. The scaffold should have a controllable degradation 
rate, promote cell viability, differentiation and ECM production, should integrate 
with the surrounding native in vivo cartilage, and provide the required mechanical 
properties for the construct [45]. A wide range of materials have been investigated 
for scaffold material, including alginate [53], agarose [54], collagen [55], fibrin [56], 
poly(ethylene glycol) (PEG) [57], poly(ethylene oxide) (PEO)[58] and poly(vinyl 
alcohol) (PVA) [59] and poly-lactic-glycolic acid (PLGA) [60]. 
 
One of the emerging strategies in cartilage engineering is to assemble cartilage 
micro-tissues into a 3D plotted scaffold (described later). Utilising micro-mass or 
pellet culture, hyaline-like neocartilage micro-tissues can be fabricated [42]. 
However, manually assembling a construct of a clinically relevant size (i.e. Ø25 x 2.4 
mm) would be extremely tedious in a clinical environment [42, 61, 62]. Moreover, 
there is a need to be able to fabricate anatomical constructs of complex architecture. 
The ability to assemble constructs with complex architecture would mean that the 
fabrication of an osteochondral construct with the zonal arrangement of native 
articular cartilage, and constructs with a gradient of cell types, bioactive molecules, 
mechanical properties, hydrogel types or varying cell densities, could potentially be 
possible [44, 61, 63-67].  
2.4 Tumour engineering  
2.4.1 Cancer and cancer microenvironment   
With 14.1 million new cases in 2012 and with the number of new cases per 
annum expected to reach over 20 million as early as 2025, cancer is a major cause of 
morbidity and mortality thereby making research in cancer highly critical [68, 69]. 
Cancers are generally classified based on the normal cells that they originate from 
[70]. The commonly diagnosed cancers in 2012 were lung, colorectal and stomach 
[68, 69]. The most common cause of cancer mortality in 2012 were lung, liver and 
stomach cancers [69]. Cancer is a group of diseases that can affect any part of the 
body and the hallmark of cancer is the abnormal growth of cells, loss of architecture 
and function [69, 71]. The development of cancer has been attributed to the 
progressive accumulation of genomic changes which lead to the loss of tumour 
suppression function in the cells [72]. These genomic changes can be caused by 
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physical (i.e. ultraviolet light), chemical (i.e. asbestos, tobacco or arsenic) or 
biological (i.e. certain viruses, bacteria or parasites) carcinogens [69]. A high body 
mass index, a diet with a low fruit and vegetable content, lack of physical activity, 
tobacco use and alcohol use are behavioural and dietary risks that can increase the 
incidence of cancer [69]. Approximately 80% of all human cancer cells are 
carcinomas (originate from epithelial cells) [70]. The other 20% include sarcomas 
(originate from mesenchymal cells),  leukaemias (arise from hematopoietic), and 
lymphomas (originate from the lymphoid) [70]. 
 
Tumours in vivo are heterogeneous and comprise a complex 
microenvironment (see Figure 2-7) [73]. In general, tumours primarily consist of 
tumour cells and the supporting connective tissue (stroma) [70]. The cell types in a 
tumour are heterotypic and include cancer stem cells (CSC) [74], primary stem cells, 
fibroblasts [75, 76], cancer-associated fibroblasts (CAFs) [75, 77, 78],  endothelial 
cells [79] and immune cells [76, 80]. Fibroblasts play an important role in cytokine 
secretion, the deposition of ECM, tumour capsule formation, in the proliferation and 
metastasis of cancers, and are associated with cancer in all stages of progression [75, 
81-83]. Fibroblasts that are activated and are associated with malignant tumours are 
called cancer-associated fibroblasts and are known to enhance cancer progression 
[75, 77, 78]. The growth of tumours beyond 1 - 2 mm require vascularisation [70]. 
Tumours in vivo have deficient or abnormal vascularisation and this can cause a 
gradient in gases, pH, growth factors, nutrients, and drug [84, 85]. The reduction of 
oxygen in a growing tumour causes the upregulation of hypoxia-inducible factor 
(HIF1α) and this promotes transcription of angiogenic factors, including vascular 
endothelial growth factor (VEGF) [86]. The upregulation of VEGF causes the 
migration of endothelial cells which form new blood vessels that aid in the 
transportation of nutrients and oxygen that helps in the proliferation of cancer cells 
[86].  The presence of immune cells in the tumour also aids neovascularisation by 
synthesising pro-angiogenesis factors at specific locations [86, 87]. The association 
of cancer cells and immune cells has been known for a long time [80]. As immune 
cells produce cytokines, chemokines, pro-angiogenic mediators, metalloproteinases, 
reactive oxygen species, histamine and other bioactive molecules, the immune cells 
that infiltrate the tumour play a crucial role in the inhibition and progression of 
cancer cells [80]. Immune cells inhibit tumour cells by antitumour cytotoxic T-cell 
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activity and cytokine-mediated lysis of tumour cells [80]. Immune cells promote 
tumour growth via regulatory T cells that suppress antitumour T-cell response and 
by the increase in chronic inflammation in the tumour microenvironment caused by 
the humoral immune responses [80]. 
 
Genetic heterogeneities in cancer cells and variation in physical properties (i.e. 
presence of physical borders) in a tumour microenvironment can result in the 
formation of a range of biological and phenotypical zones within the tumour [73, 88, 
89]. As mentioned earlier,  deficient or abnormal vascularisation in tumours can 
cause a gradient in gases, pH, growth factors, nutrients and drugs, which cause the 
cells to adopt different metabolic strategies resulting in the formation of biological 
and phenotypical zones [84, 85].  Likewise, due to extensive ECM deposition, 
physical borders such as fibrotic areas and tumour capsules are formed in most 
benign solid tumours dividing the tumour into different zones [73]. These 
undisrupted physical borders can also inhibit tumour invasiveness and can act as a 











































Figure 2-7. Illustration of tumour microenvironment showing (a) the cellular 
components together with the stromal and extracellular components, and (b) the 
chemical gradients, physical borders and the biological/phenotypical zones and 
niches. Reproduced from  Thoma et al. [73].  
2.4.2 Cancer drug development  
Treatments for cancer can include a combination of surgery, radiotherapy or 
chemotherapy [69]. There is a need for better treatment strategies including new 
anticancer drugs [92]. The use of chemotherapy began at the start of the 20th century 
and has become standard clinical practice [93]. Clinically used drugs fail either 
because they do not work or because they are not safe and there is a search for safer 
and more effective drugs [94]. Drug discovery aims at the development of anticancer 






cancer cells [95]. The main steps involved in drug discovery are: (i) identification 
and validation of a target – a target could include proteins, genes or RNA and the 
structure on which the candidate drug would act on, (ii) hit identification – a hit is 
identified as a compound which shows the desired activity, hit-to-lead phase – to 
refine each hit series to try to produce more potent and selective compounds, and 
(iii) lead optimisation phase – where the properties favourable in the lead 
compounds are maintained and deficiencies in the lead compound are addressed 
[94].  
 
The cost of developing a new drug has been estimated to be about US $ 2.6 
billion out of which US $ 1.4 billion is spent on research [96]. As the cost of drug 
development increases drastically during animal testing, it is essential to identify 
poor cancer drug candidates earlier rather than later [97]. A potential drug that 
presently enters Phase I trials has a probability of only 8% to be approved for clinical 
treatment [98]. Clinical trials of cancer drugs have been associated with being highly 
risky and cancer models have an increasingly important role to play before clinical 
trials on humans are carried out [99-102]. Tumour models, apart from being an 
invaluable tool in the development and screening of chemotherapeutic agents, 
would also aid translational research in cancer [103].  
 
Presently, high-throughput screening (HTS) is the most widely applicable 
technology delivering chemistry entry points for drug discovery programmes [102]. 
HTS is a process of rapidly testing a large number of chemical compounds against a 
target to deliver accurate data based on which a decision is made to identify a hit 
and lead [94, 104]. HTS is an integral part of pharmaceutical research and is 
currently the most widely applicable technology delivering chemistry entry points 
for drug discovery [102]. Commonly used anticancer drugs were discovered by 
random HTS of synthetic and natural compounds [95]. It is imperative that the 
models used in HTS are capable of predicting the right candidate drugs so that high 
fall-out rates in the later stages of drug discovery can be reduced. Quite often the 
development of drugs has been dependent on high-throughput screening in 2D 
monolayer system for identifying a potential lead compound, because of the deficit 
in better 3D models [105, 106]. However, 2D monolayer based HTS has a limited 
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potential for predicting the in vivo efficacy of anticancer drugs as 2D models do not 
recapitulate the native in vivo environment [97]. 
2.4.3 Tumour models  
The two tumour model tools that scientists have long depended on to conduct 
cancer research have been animal models and two-dimensional (2D) monolayer 
culture systems. The regulatory and legal requirements and strong clinical tradition 
have made animal models the gold standard in cancer research [97, 107]. However, 
animal models tend to be expensive, need ethical approval, are complex and contain 
many multivariable uncontrollable factors like the presence of the host immune 
response, differences in liver toxicity, differences in telomerase regulation, contain 
non-human host cells, differences in hemodynamics, and production of endogenous 
growth factors [103, 107-109]. Even if a new drug has been tested in an animal 
model there is no assurance that it would be safe in humans. 
 
On the other hand, the simplicity and convenience of traditional 2D monolayer 
culture systems have made them a favourable in vitro model for cancer research 
[110]. Native tissues are 3D structures, and it is well recognised that 3D models 
mimic real tissue better than 2D models [110-112]. The behaviour of cells in a 2D 
monolayer is unlike the behaviour in a 3D in vivo environment, where the cells are 
in an organised 3D structure surrounded by matrix and other cells.  Cells cultured as 
a monolayer lose the tissue-specific architecture, metabolic gradient, cellular 
differentiation, cell cycle control, mechanical and biochemical cues, three-
dimensional cell–cell and cell–matrix interactions [112, 113]. When the cells are 
cultured in 3D these physiological interactions are more likely to be re-established 
[112]. The gene expression of cells cultured in 3D is also known to be different from 
that of cells cultured in 2D [112]. Most importantly, 2D monolayer cultures are less 
resistant to anticancer drugs compared to their 3D counterparts, resulting in a lower 
predictive power of the 2D monolayer model to the drug [114, 115]. It has been 
reported that over 85% of cancer research groups still routinely use 2D culture 
systems such as tissue-culture plates, Petri dishes or coverslips and the research 
outcomes might not be significant in an in vivo scenario [116].  Figure 2-8 shows 













Figure 2-8. Microscope images of human mesotheliomoa cell line (NCI-H226) (a) 
cells in 2D and (b) 3D multicellular spheroid (micro-tissue). Scale bar = 400 µm. 
Reproduced from Kim et al. [117]. 
 
Currently, the two major trending and favoured in vitro 3D cancer platforms 
can be broadly divided to include gel systems which involves in embedding cells in 
gels made of reconstituted basement membrane protein (Matrigel or reconstituted 
type I collagen) [118, 119] and the use of multicellular spheroids (micro-tissues) 











Figure 2-9. Microscope images of renal cancer cell line (HEK 293) (A) micro-tissue 
(3D multicellular spheroid) and (B) cells embedded reconstituted basement 
membrane protein. Scale bar = 500 µm. Reproduced from Ivascu et al. [120]. 
 
(a)  (b)  
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Micro-tissues are aggregates of cells that can be formed from a broad range of 
cell types and are the most widely used human tumour model [106]. The size of a 
micro-tissue varies from 20 µm to 1 mm depending on the cell type, fabricating 
technique and growth condition [106]. The use of micro-tissues for investigating the 
action of radiotherapy and chemotherapy drugs has been used since the 1970s 
[111]. Micro-tissues have been utilised for a wide range of applications including 
drug screening, research in drug transport and binding, cancer research, tissue 
morphogenesis, differentiation, tissue engineering, regenerative medicine and stem 
cell research [121-126].  
 
Hydrogels aid the 3D support of cells in vitro, help to recreate the in vivo 
physical and structural environment and can be of natural or synthetic material 
[110]. Cell-laden hydrogels are advantageous in that 3D models can be fabricated 
from cell types that do not form micro-tissues [120, 127-129]. Moreover, as micro-
tissues only recapitulate certain aspects of the in vivo microenvironment alternative 
hydrogel based substrates are being utilised [106]. The hydrogel themselves can 
transduce ECM signalling to the cells, but the ECM component can be variable and 
undefined [106, 110]. The other benefits of hydrogels are that cells can remodel 
certain hydrogels, cells can be aligned by applying strain to the hydrogel, and the 
contractions caused by the cells can increase the matrix density [86]. Factors such 
as the type and composition of the hydrogel and mechanical stiffness are known to 
affect the cell response [130-133]. Hydrogels can be made from alginate [53], 
agarose [54], collagen [55], poly(ethylene glycol) (PEG) [57], or poly(vinyl alcohol) 
(PVA) [59]. Hydrogels are appealing as they can provide a hydrated tissue-like 
environment and are structurally similar to the native extracellular matrix of many 
tissues [134, 135]. Other types of hydrogel include basement membrane hydrogels 
such as Matrigel, Cultrex, or EHS matrix [119]. 
2.4.4 Challenges in tumour engineering  
The idea of engineering tumours for drug discovery and cancer research has 
gained considerable momentum. Tumour engineering has been defined previously 
by Ghajar and Bissell et al. as “the construction of complex culture models that 
recapitulate aspects of the in vivo tumour microenvironment to study the dynamics of 
tumour development, progression and therapy on multiple scales” [71]. Many tissue 
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engineering and regenerative medicine platforms and strategies developed can be 
easily translated for application in tumour engineering and overlapping challenges 
exist. The challenges include optimal scaffold design, recapturing the native 
microarchitecture, and the automated biofabrication of large and complex 
constructs [86].  
 
Native tumours in vivo are complex tissues and consist of different cell types 
which include cancer stem cells [74], primary stem cells, fibroblasts [75, 76], 
endothelial [79] and immune cells [76, 80]. The importance of the interactions 
between cancer cells and non-malignant cells in supporting tumour growth, 
invasion and metastasis are well known [76]. The presence of non-malignant cells 
in the in vitro model can alter the drug response of the tumour model [76, 136]. Co-
culture models would be more representative of models in vivo  [76]. In tumour 
biology, most work is done culturing just the tumour cells and the co-culture of more 
than 3 cell types are rarely reported in the literature [76, 137]. Thus, there is a need 
for cancer models composed of heterotypic cell types. 
 
Apart from the presence of non-malignant cells, the matrix properties can also 
affect the behaviour of the cells. The stiffness of the matrix can affect growth rate, 
viability, resistance to apoptosis, the state of differentiation, motility, alignment and 
protein expression of the cells [138, 139]. The cell response to a specific hydrogel is 
known to be cell dependent [140]. The response of the cell is also known to depend 
on the type of matrix [141, 142]. Therefore, it is essential to choose the right matrix 
properties to fabricate the desired 3D models.  
 
Tumours in vivo are large and have a complex architecture with the average 
size ranging from 2 to 5 cm in stage II breast cancer [143] to 4.6 to 11.8 cm in ovarian 
cancer depending on the stage [144]. Cancer micro-tissues are comparatively 
smaller and the arrangement of cells and the tissue architecture in the gel system 
and the micro-tissue are less complex than actual tumours that are found in vivo 
[145, 146]. Thus there is a requirement for the ability to fabricate large tumour 
models of complex architecture comparable to tumours in vivo that can be adapted 
for application in a high-throughput system. The ability to fabricate a cancer 
construct with an automated system would mean that constructs with a gradient of 
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cell types, bioactive molecules, mechanical properties, different hydrogel types can 
potentially be fabricated in a high-throughput fashion [66, 76, 147].   
2.5 Tissue engineering fabrication strategies   
Tissue engineering fabrication strategies can be divided into top-down and 
bottom-up strategies.  
2.5.1.1 Top-Down tissue engineering fabrication strategy  
The top-down approach is a more traditional tissue engineering approach in 
which cells are seeded into a scaffold and stimulated with bioactive molecules with 
the intention that they would produce the desired extracellular matrices (Figure 
2-10) [148]. Sculpting a statue from stone could be thought of a top-down approach 
of creating an object. The overall design is created first and then the finer details are 
added further along. The problem with this approach is the difficulty and challenges 
in recreating the microstructural features of tissues [148]. 
2.5.1.2 Bottom-up tissue engineering fabrication strategy or modular 
tissue assembly 
In the bottom-up tissue engineering strategy or modular tissue assembly, 
smaller nanoscale or microscale functional tissue subunits or modules are 
assembled to create a macroscale construct with specific microstructural features 
(Figure 2-10) [148-150]. Using off the shelf parts to assemble a computer can be 
thought of as an analogy for the bottom-up approach. These modules could 
potentially be designed to be of different types and could be precisely assembled 
either by self or direct assembly to create a construct [149, 151]. The challenge with 
the bottom-up tissue engineering approach is to assemble modules of specific 
microstructure into a macroscale construct [148]. There is a strong biological basis 
for using a modular assembly based approach for creating a tissue as many native 
tissues are often composed of small repeating units that are assembled over several 
scales, from the molecular level to cell and tissue level [148, 152]. Modular assembly 

























Figure 2-10. A Schematic outline of bottom-up or modular assembly based tissue 
engineering approaches and top-down or traditional tissue engineering approaches. 
Reproduced from Tiruvannamalai-Annamalai et al. [153].  
 
2.5.2 Biofabrication 
Biofabrication is a special branch of tissue engineering and is a technological 
platform [4]. It is a broad field that describes fabricating materials by living 
organisms, and with regards to tissue engineering, the most obvious application 
would be the bioengineering and manufacturing of human tissues and organs for 
implantation [154, 155]. It is a complex and multidisciplinary field requiring 
extensive knowledge and skills in cell biology and anatomy, mechanical engineering 
and material science [154].  
 
The elementary units used are living cells, cell aggregates, tissues, 
decellularized organ, extracellular matrices, biological molecules, and engineered 
25 
 
biomaterials and the manufactured products are functional living tissue constructs 
[154, 155]. It essentially involves the use of computer-aided 3D manufacturing 
strategies such as 3D printing or additive manufacturing for assembling living and 
non-living material with the desired architecture [4, 155]. This makes it essential to 
have sophisticated hardware and software. The development of biofabrication 
technologies would assist the development of organ assembly lines, thereby aiding 
a smoother commercialisation process. Apart from tissue engineering and 
regenerative medicine, biofabrication can be potentially applied to a range of cell 
and tissue-based applications including drug discovery, in vitro models of human 
development and human diseases, and biochips and biosensors [154]. Typical 
biofabrication approaches for biofabricating bioinks or hydrogels (Figure 2-11) 
include (a) laser-induced forward transfer, (b) inkjet printing and (c) robotic 










Figure 2-11. Illustration of the three most common biofabrication approaches: (a) 
laser-induced forward transfer, (b) inkjet printing and (c) robotic dispensing.  
Reproduced from Malda et al. [4]. 
 
 Laser-induced (Figure 2-11 a) forward transfer bioprinting is a high-
resolution nozzle free approach capable of printing with single-cell resolution with 
bioinks of a wide range of viscosities  [4, 156]. Laser-induced forward transfer 
printers typically consist of a pulsed laser beam, a focusing system, a ‘ribbon’ which 
is typically a donor slide covered with an energy absorbing layer and a layer of 
biological material (i.e. cell suspension) to be printed, and a target substrate [157]. 
The printing process involves focusing the laser light onto the ribbon and the cell 
containing material that interacts with the laser is guided and propelled forward 
onto the target substrate [157, 158]. Although laser-induced forward transfer has a 
(a)  (b)  (c)  
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high printing resolution, preparation of the ribbon is time-consuming, 
contamination of metallic residues in the printed construct from the energy 
absorbing layer might occur, and the high-resolution printing requires rapid gelation 
kinetics to achieve high shape fidelity, which results in a relatively low overall flow 
rate [4, 157].   
 
Inkjet printing (Figure 2-11 b)  involves the precise dispensing of controlled 
volumes of bioink onto a predefined position on the substrate through a small orifice 
[4, 157]. Commonly used inkjet printers for cells are either thermal or piezo-electric 
based [4, 159, 160]. In thermal printing, a small volume of bioink is vaporized by a 
micro-heater and this creates a pulse that expels the bioink from the print head [4, 
159]. The generated heat is detrimental to the cells as transient pores in the cell 
membrane are formed [4, 159]. In the piezo-electric based approach, the piezo-
electric actuator applies a mechanical force to the fluid in the nozzle and this forces 
the bioink through the nozzle [4, 160]. Limitations in inject printing include an upper 
viscosity limit of 0.1 Pa s-1 that can be used for the bioink [161] and the need for 
using bioinks with low cell concentrations (<5 × 106 cells/ml) to avoid cell clogging 
[162]. Moreover, the building up of a 3D construct would be challenging as during 
the printing process the low viscosity inject droplets would spread upon impact on 
the surface [4].     
 
Robotic dispensing (Figure 2-11 c) is the most commonly employed 
biofabrication technology [157].  With robotic dispensing anatomical structures can 
be fabricated [163]. Robotic dispensing consists of a temperature controlled 
dispensing system, a 3D positioning system and a build platform [157]. In robotic 
dispensing, high viscosity bioinks are dispensed from a syringe either by pneumatic 
extrusion, by piston-driven extrusion or screw-driven extrusion onto a build 
platform [4]. Piston-driven extrusion or screw-driven extrusion gives better control 
of the bioink extruded compared to the simpler pneumatic extrusion [157].  
Materials that possess shear thinning properties and can be either thermally or 
photo crosslinked are quite often chosen for biofabrication applications [4, 157, 
163]. Robotic dispensing is a promising biofabrication technological platform as it 





The above-described methods have been employed for biofabricating bioinks 
or hydrogels. Where bioink are defined as cytocompatible hydrogel precursor 
formulations that allow the 3D printing or plotting of living cells [164, 165]. Bioinks 
can include cell-laden hydrogels, decellularized ECM-based solutions and cell 
suspensions [164]. To fabricate thermoplastic scaffolds, however, 3D plotting and 
Fused deposition modelling (FDM) are commonly employed [166].  
 
3D plotting is an additive manufacturing technology and is a versatile method 
for fabricating porous scaffolds with control of the interconnecting structures for 
tissue engineering applications [166]. 3D plotting is similar to robotic dispensing. 
3D plotting systems consist of a temperature controlled dispensing system, a 3D 
positioning system, and a build platform [157, 166]. The material is extruded by the 
dispensing system and deposited via a layer-by-layer process to fabricate a 3D 
structure. Fused deposition modelling (FDM) is also an additive manufacturing 
technology similar to 3D plotting except that the material is fed in the form of a 
filament [167]. The filament is heated to a semi-molten form and is extruded to 
create a structure utilising the layer-by-layer approach [167]. Rapid prototyping 
techniques such as 3D plotting and fused deposition modelling (FDM) can overcome 
limitations of conventional scaffold fabrication techniques such as solvent casting 
and particulate leaching, gas foaming, fibre meshes and fibre bonding, phase 
separation, melt moulding, emulsion freeze drying, solution casting and freeze-
drying which are incapable of precisely controlling pore size, pore geometry, pore 
interconnectivity, spatial distribution of pores, and construction of internal channels 
within the scaffold [167].  
 
3D plotting is a highly flexible platform and complex hybrid scaffolds can be 
fabricated together with hydrogel bioinks and thermoplastic polymers [168]. 
Hydrogels can provide a hydrated tissue-like environment that is structurally similar 
to the native extracellular matrix. However, hydrogels have a limited mechanical 
strength and need to be reinforced for load-bearing applications [169]. 
Thermoplastic polymers can reinforce the hydrogel with mechanical strength 
thereby overcoming the limitation to fabricate constructs with complex shape and 
size [170]. Kang et al. [170] developed an integrated tissue-organ printer (ITOP) 
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system (Figure 2-12) capable of fabricating 3D hybrid constructs with cell-laden 
hydrogels and biodegradable thermoplastic polymer (poly(ε-caprolactone) (PCL)) 
[170]. The ITOP system consisted of a 3D positioning system (3-axis stage 
controller), multiple cartridges for dispensing different materials (PCL, 2 types of 
cell-laden hydrogel and sacrificial material), and a temperature and humidity 
controlled closed chamber [170]. Data from medical imaging (CT or MRI) was used 
to generate the 3D CAD/CAM model from which a text-based motion control 
program was generated to control 3D positioning system and other 3D plotting 
parameters of the system [170]. With the ITOP system the fabrication of mandible 
and calvarial bone, cartilage and skeletal muscle of clinically relevant size with 
different types of patterning was demonstrated [170]. Various biofabrication 
approaches for fabricating hybrid constructs have been reported in the literature 














Figure 2-12. Illustration of the (a) integrated tissue-organ printer (ITOP) system, 
(b) the architecture of the 3D plotted construct, and (c) the CAD/CAM process for 
automated fabrication of anatomically shaped tissues or organs. The ITOP system 
consists of a 3D positioning system (3-axis stage controller), multiple cartridges for 
dispensing different materials, and a temperature-humidity controlled closed 
chamber. Reproduced from Kang et al. [170].  





Technique Material Cell line Application Comments Author 
3D plotting - 
ITOP system 
Thermoplastic polymer – PCL 
Hydrogel – mixture of gelatin, 
fibrinogen and glycerol 








(bone, cartilage and 
skeletal muscle) 
The ITOP system was used to fabricate 
constructs with cell-laden hydrogels and PCL. 
Microchannels were incorporated into the 
construct to facilitate diffusion of nutrients to 
printed cells. See Figure 2-12.  
Kang et al. 
[170] 
3D plotting – 
ITOP system 
Thermoplastic polymer – 
blend of PCL and PLCL 






Tubular scaffold was fabricated with the 
thermoplastic polymer and UC-laden hydrogel 
and SMC-laden hydrogel was delivered into the 
inner and outer layer of the scaffold 
respectively to fabricate a urethra construct.   
Zhang et al. 
[171] 
3D plotting Thermoplastic polymer - PCL 
Hydrogel - Alginate 
C20A4 Broad range including 
musculoskeletal 
engineering 
3D plotting of alternate layers of PCL and cell-
laden alginate. The alginate was cross-linked 
with calcium chloride solution.  
Schuurman et 




Thermoplastic polymer – PCL 
and Pluronic F-127 
Hydrogel – mixture of fibrin 
and collagen 
RPAC Cartilage engineering Electrospinning of PCL fibres was alternated 
with inkjet printing of rabbit primary auricular 
chondrocyte-laden fibrin-collagen hydrogel.  
 
Xu et al. [172] 
3D plotting  Thermoplastic polymer – 
mixture of pHMGC and PCL 
and mixture of 
methacrylated pHMGC and 
PCL 
Hydrogel – GelMA 
PHC Cartilage engineering  A blend of thermoplastic polymers were 3D 
plotted and was infused with cell-laden GelMA 
solution and photopolymerised.  
Boere et al. 
[169] 
Table 2-1. Various biofabrication approaches for fabricating hybrid constructs and their potential application.  






Abbreviations: C20A4 - Human Chondrocyte Cell Line, 3T3 - mouse embryonic fibroblasts, hAFSC - human amniotic fluid-derived stem cells, 
RPAC - rabbit primary auricular chondrocytes, C2C12 - mouse myoblasts, PHC - primary human chondrocytes, L-929  - mouse fibroblast cell 
line, ITOP - integrated tissue-organ printer, pHMGC - poly(hydroxymethylglycolide-co-e-caprolactone), GelMA - gelatin methacrylamide, CMEP 






Technique Material Cell line Application Comments Author 
3D plotting - 
CMEP system 
Thermoplastic polymer - PCL 
Hydrogel - alginate 
L-929 Muscle and nerve 
repair  
A construct was fabricated by melt extruding  
cell-laden alginate/PCL co-axial fibres using 
the CMEP system   
Cornock et al. 
[173] 
3D plotting Thermoplastic polymer – 
PCL, PLA and PLGA 
Hydrogel - alginate 
3T3 Tissue engineering PLA or PLGA was layers were 3D plotted and 
alternately cell-laden alginate was deposited in 
the space. PCL was 3D plotted to act as a 
thermal protective layer for the cell-laden 
alginate from the PLA or PGLA being 3D 
plotted. The fabricated construct was 
immersed in calcium chloride solution to 
crosslink the alginate.  
Kim et al. [174] 
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With respect to biofabrication strategies in tissue engineering and 
regenerative medicine, biofabrication can be thought to consist of two main 
complementary strategies:  
 
1. Bioprinting  - where the minimum fabrication level is molecular [155]. It has 
been defined by Guillemot et al. [155] as “the use of computer-aided transfer 
processes for patterning and assembling living and non-living materials with a 
prescribed 2D or 3D organization in order to produce bioengineered structures serving 
in regenerative medicine, pharmacokinetic and basic cell biology studies”. 
 
2. Bioassembly - where the minimum fabrication level is with cell containing 
units [155]. It has been defined by Groll et al. [155] as “the fabrication of hierarchical 
constructs with a prescribed 2D or 3D organization through automated assembly of 
pre-formed cell-containing fabrication units generated via cell-driven self-
organization or through preparation of hybrid cell-material building blocks, typically 
by applying enabling technologies, including microfabricated moulds or microfluidics”. 
2.5.2.1 Bioprinting  
Bioprinting is one of the major subdivisions of biofabrication. When the 
minimum level of fabrication is at the molecular level, it can be classified under 
bioprinting [155, 175]. In the macro scale, the motive of bioprinting is to create 
anatomically similar structures [175]. Bioprinting is a 3D printing technique used 
for the fabrication of 3D structures. A layer-by-layer approach is used deposit 
biomaterials, biomolecules and living cells onto a substrate with precise spatial 
control to create a predefined architecture [157, 175]. The ITOP system (Figure 
2-12) previously described is an example of bioprinting.  
2.5.2.2 Bioassembly  
Bioassembly is the other major subdivision of biofabrication. When the 
minimum level of fabrication consists of prefabricated cell containing building 
blocks that are large enough to be handled by an automated system, it can be 
classified as bioassembly [155]. Bioassembly is a bottom-up modular approach in 
which a 3D functional tissue or organ is manufactured using a layer-by-layer process 
with cell containing units as the building block [176]. Figure 2-13 shows the 
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approach for bioassembling tissue units to fabricate a tubular construct either in air 
or in a hydrogel (biopaper) using a bioprinting technology. Figure 2-14 illustrates 















Figure 2-13. Bioprinting technology for bioassembling constructs. Illustration of (a) 
general view of the bioprinter, (b) bioprinter nozzle, (c) before the tissue unit 
dispensing process, (d) the tissue unit dispensing process, (e) continuous 
dispensing in air (f), continuous dispensing in a biopaper, (g) single tissue unit 
dispensing in air (h) single tissue unit dispensing in a biopaper, and (i) the approach 
for sequential layer-by-layer bioassembly of a tubular construct. Reproduced from 




































Figure 2-14. Illustration showing the concept of bioassembly based organ printing 
or robotic additive biomanufacturing. Reproduced from Mironov et al. [176].  
 
Numerous bioassembly approaches have been reported in the literature to 
fabricate higher order assembled constructs using tissue subunits and some of these 
have been listed in Table 2-2. These approaches have been demonstrated for an 
extensive range of applications including tumour models [177], vascular 
engineering [178, 179], cardiac tissue engineering [180, 181], bone tissue 
engineering [182], trachea tissue engineering [183], dermal tissue engineering 
[184], liver tissue engineering [185] and cartilage engineering [186].  
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A spectrum of tissue module types can be fabricated for tissue assembly and 
this includes cells sheets [180, 187], micro-tissues or cellular aggregates [42, 178, 
179, 185, 188], cell-laden microgels [151, 189], microspheres [190] or tissue-rings 
[183]. The techniques for assembling the modules into a scaffold includes placing 
micro-tissues in a mold and allowing for tissue fusion [188], stacking of cell sheets 
[180], random packing of microgels [191], utilising hydrophobic effect for 
assembling microgels [151], physical manipulation of individual cell-laden 
microgels [192] assembling micro-tissues into a 3D plotted scaffold [42], vacuum 
moulding [184, 193], stacking rings on a tube [183]. In this thesis, the two types of 
fabricated subunits or modules utilised were: 
 
1. Spheroids or micro-tissues 
These consist of an aggregation of cells that can be formed by a broad 
range of methods including hanging drop technique [194], liquid overlay 
technique [195], spinner flask [196], pellet culture [42], micromoulding 
[197] and NASA rotary system [198]. In this thesis, to form chondrocyte 
micro-tissues, we utilised a high-throughput 96-well plate centrifugation 
approach and for cancer micro-tissues, we utilised the liquid overlay 
technique.  
 
2. Cell-laden hydrogel microspheres  
These consist of cells embedded in a hydrogel and can be formed with 
a wide range of techniques including emulsification [199], photolithography 
[200], solvent evaporation [201], jetcutting [202], jet breakup [203], and 
electrostatic droplet generation [204], microfluidic synthesis [190], and 
micromoulding [189]. In this thesis, a microfluidic system was adapted to 
generate both chondrocyte or mesenchymal stromal cell encapsulated 
microspheres and cancer cell encapsulated microspheres.  
  
Our approach toward modular tissue assembly involved assembling the tissue 
modules or subunits into a 3D plotted scaffold.










Material Cell type Application Comments Author 







Micro-tissues were fabricated utilising 
hanging drop culture. Micro-tissues were 
assembled using a micro-tissue assembly 
device.  
Kelm et al. 
[178] 










Micro-tissues were fabricated utilising 
hanging drop culture. The micro-tissues were 
assembled in a ring-shaped mould.  
Kelm et al. 
[179] 




and cell sorting 
Micro-tissues were fabricated utilising 
micromoulds. Larger structures were 
assembled by resuspending micro-tissues into 
a second micromould.  












Hepatocyte spheroids were fabricated 
utilising microwells, were collagen-coated and 
covered with HUVEC. A larger structure was 
formed by trapping the spheroids in a 
polyester mesh filter in a culture chamber.  
Inamori et 
al. [206] 





Aggregates were fabricated in microwell 
arrays. The endothelialized aggregates were 
assembled by packing them in a perfusion 
bioreactor.  
Pang et al. 
[185] 
Table 2-2. Various bioassembly approaches and their potential application.  









Material Cell type Application Comments Author 
Micropellets Microwell 
platform 




Micropellets were fabricated in a microwell 
platform. The micropellets were cultured 
separately in chondrogenic medium or 
osteogenic medium depending on the 
direction of differentiation required. The 
micropellets were assembled on separate days 







Gelatin hMSC Trachea tissue 
engineering 
Self-assembled cartilaginous rings using 
annular agarose wells/moulds. The construct 
was assembled by stacking the rings on 





Microbeads Modified double 
emulsion 
technique 
Gelatin HDF Dermis 
equivalent 
tissue 
Microbeads were fabricated using an emulsion 
technique and cells were seed into them. The 
construct was assembled vacuum moulding. 
Imparato 









Microbeads were fabricated using water-in-oil 
emulsion technique. A multiphase construct 
was assembled using centrifugation process 
or vacuum moulding.  
Caldwell 
et al. [193] 
CultiSpher S 
Microcarriers 
Microcarriers Gelatin hAMSC Bone tissue 
engineering  
Off-the-shelf gelatin microcarriers were 
seeded with cells. Modules were placed in a 
cylindrical perfusion culture chamber and 
assembled through the pulsatile flow of 
medium. 
Chen et al. 
[182] 
Gel Soft-lithographic 
moulding of gels 
Collagen 3T3 
HepG2 
Tumour  model Gel modules fabricated on patterned 
hydrophilic PDMS membrane. Gel modules 
assembled in a microchannel. 
Bruzewicz 
et al. [177] 







Cell-laden gel modules were cast. Modules 
were placed on a nylon mesh to form an 













Material Cell type Application Comments Author 






in a construct  
Fabricated by gel rods by slicing tubing 
containing cell-laden collagen. Modules were 
randomly assembled in a larger tube and 











Osteon-like concentric double ring modules 
were fabricated with containing HUVECs in 
the middle and osteoblast-like cells on the 
outside. The modules were assembled in a 
hollow tube. 




Photolithography PEG 3T3  Tissue 
engineering 
Fabrication of cell-laden microgels using 
photolithography. Assembling the microgels 
by utilizing hydrophobic effect. 
Du et al. 
[151] 








Fabrication of cell-laden microgels via 
micromoulding. Microgels were physically 
arranged in a pattern to assemble a construct.  









Temperature-responsive detachment of 
confluent cell sheets. Cell sheets were 
assembled by stacking the sheets on top of 
each other.  
Shumizu 
et al. [180] 
Hydrogel 
sphere 
Dispensing nozzle Alginate CPC Cartilage 
engineering 
Cell-laden alginate scaffold was 3D plotted 
with a co-axial nozzle and the cell-laden 
alginate sphere was deposited with a 




Abbreviations: PDMS – Polydimethylsiloxane, PLLA - poly-L-lactic acid and PEG - poly(ethylene glycol). Cell types:  HepG2 - human liver 
hepatocellular carcinoma, 3T3 - mouse embryonic fibroblasts, hMSC - human mesenchymal stromal cells, HDF - human dermal fibroblasts, 
HUVEC - human umbilical vein endothelial cell,  HAF - human artery-derived fibroblasts, CM-rich cell mixture - primary neonatal rat 





cardiomyocytes and fibroblasts, hAMSC - human amniotic mesenchymal stem cells, NHF - normal neonatal foreskins human fibroblasts, H35 - 
rat hepatoma cells, ASM - human airway smooth muscle, HMF - human myofibroblasts, PAC -  pig articular chondrocytes, HAC - human articular 
chondrocytes and C2C12 - mouse myoblasts, MG63 - osteoblast-like cells, CPC - Cartilage progenitor cells. Table adapted from Schon et al. [209].




2.6 Thesis Aims: 
Presently, biofabrication techniques to fabricate large constructs that mimic 
the microarchitecture in native tissue are limited. The ability to fabricate large 
complex constructs with an automated bioassembly system would be highly 
beneficial for advancement in tissue engineering. As seen from Table 2-2, there 
exists no automated technology that enables the assembly of tissue units (i.e. micro-
tissues or microspheres) into a 3D plotted scaffold. We aimed at developing an 
automated bioassembly system that can assemble tissue units into a 3D plotted 
thermoplastic scaffold for application in two areas – cartilage engineering and 
tumour engineering. For cartilage engineering, the engineered cartilage construct 
can potentially aid joint resurfacing of damaged and degenerated joints. In tumour 
engineering, the developed cancer construct can potentially be employed for the 
high-throughput screening of anticancer drugs. The following aims form the basis 
for the body of work presented in this thesis. 
 
Aim 1:  The design and development of a prototype integrated system for 
automated 3D Bioassembly of tissue units for biofabrication of tissue 
engineered constructs (Chapter 3). 
 
Aim 2:  Validation and characterization of an integrated system for automated 3D 
Bioassembly of micro-tissues for biofabrication of tissue engineered 
cartilage constructs (Chapter 4). 
 
Aim 3:  Validation of an integrated system for automated 3D Bioassembly of cell-
laden microspheres for biofabrication of tissue engineered cartilage 
constructs, including proof-of-concept and chondrogenic characterisation 
of the assembled construct (Chapter 5). 
 
Aim 4:  Validation of an integrated system for high-throughput fabrication and 
automated 3D Bioassembly of micro-tissues for biofabrication of an in vitro 
cancer model, including proof-of-concept characterisation of the assembled 
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tumour construct compared to existing 2D and 3D in vitro models (Chapter 
6). 
 
Aim 5:  Validation of an integrated system for automated 3D Bioassembly of cell-
laden microspheres for biofabrication of an in vitro cancer model, including 
proof-of-concept characterisation of the assembled tumour construct 
compared to existing 2D and 3D in vitro models (Chapter 7). 
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Chapter 3 Development of an integrated system for 
automated 3D Bioassembly  
 
 
   
3.1  Abstract 
Presently there exist few technologies that can precisely assemble spherical 
tissue units (TU, micro-tissues or hydrogel microspheres) into a 3D plotted scaffold. 
We developed a novel automated and integrated 3D Bioassembly system capable of 
assembling tissue units into a 3D plotted scaffold. The developed automated 
bioassembly system consisted primarily of a singularisation module and an injection 
module. The singularisation module was designed to deliver one tissue unit at a time 
to the injection module. The injection module was designed to insert the tissue units 
into the pores of the 3D plotted scaffold with the aid of a 3D positioning system. The 
mechanical and electronic systems required for the functioning of the fluidics-based 
automated bioassembly system were designed and manufactured and a prototype 
of the bioassembly system was successfully constructed and integrated with a 
commercial Bioscaffolder. The developed prototype would allow us to validate the 
potential of an automated bioassembly system for application in cartilage 
engineering and tumour engineering.  
3.2  Introduction 
Many international tissue engineering centres focus primarily on the biology 
of tissue culture rather than process engineering and product realization, and this 
has led to tissue engineering currently being in an inconvenient position to transit 
from a development-stage industry to a full-fledged one [1]. Automated robotic 
approaches have been important in the successful development of new 
commercially profitable automobile and microelectronic industries and would also 
be highly beneficial to the regenerative medicine and tissue engineering industry 
[2]. Presently, the development and investigation of tissue engineered constructs 
are in its early stages. The development of bioassembly technologies would not only 
benefit current research but would help in laying out the manufacturing process for 




manufacturing processes way earlier than during the commercialisation phase as a 
tissue engineered product created via a new manufacturing process might require 
regulatory reapproval [1]. Likewise, platform technologies developed for tissue 
engineering can be translated for application in tumour engineering as similar 
challenges exist [3]. The utilisation of an automated bioassembly system would 
reduce production variations due to the elimination of human error, would be 
cheaper and cost-effective as a result of less human involvement, would be easier 
for large-scale production of complex designs and would provide the necessary level 
of flexibility for patient-specific, customized organ biofabrication [2, 4]. For the 
bioassembly technology to become a reality, the design and implementation of an 
automated system would be the first step, after which the advantages of the 
developed biofabrication strategy over existing strategies would have to be 
demonstrated.  
 
A detailed literature search revealed that automated bioassembly technology 
is still in its infancy, so similar technology that can be translated or adapted for 
applications in bioassembly was looked into. This included separation and delivery. 
Much of the developed technology related to the separation of bioparticles was 
targeted more at single cells separation rather than larger bioparticles. Nomura at 
al. demonstrated a fully automated on-chip imaging flow cytometry system using a 
micro-fluidic based non-destructive cell-sorting system [5]. Grover et al. showed 
single-cell sorting based on optical trapping and manipulation [6]. Huang et al. 
demonstrated a biochip that can catch, separate and transport bioparticles using 
dielectrophoretic forces created by non-uniform electric fields [7]. Freyer et al. took 
this one step further and modified a fluorescence-activated cell sorting (FACS)  
instrument to demonstrate the sorting of multicellular spheroids into uniformly-
sized populations with diameters in the range of 50-100 µm [8].  
 
Though there has been not much literature relating to the technology for the 
separation or singularisation of particles, there has been development relating to 
the automated production of micro-tissues. The automated production of a variety 
of micro-tissues for efficacy testing in a standard 96-well format was shown by 
Drewitz et al. [9]. Rezende et al. presented data showing that the scalable robotic 




liquid handling robots to culture spheroid utilising the traditionally tedious hanging 
drop technique [11]. 
 
Tanol et al. and Ozbolat et al. developed the two closest technologies that 
employed spheroids in bioprinting. Tanol et al. developed a 3D printing technology 
to deposit microdroplets of alginate solution on calcium-containing substrates in a 
layer-by-layer fashion to prepare ring-shaped 3D hydrogel moulds [12]. Ozbolat et 
al. developed a system where a cell-laden alginate scaffold was 3D plotted with a co-
axial nozzle and cell-laden alginate spheres that formed at the tip of the dispensing 
nozzle were deposited within the scaffold [13]. Currently, to our knowledge, there 
exists no technique or system that can handle macro-sized particles or spherical 
tissue units (TU, micro-tissues or microspheres) for applications in bioassembly or 
bioprinting.  
 
To fill in this gap that exists presently in the area of bioassembly, we looked 
into developing a prototype of an automated tissue assembly system, which is the 
specific aim of this chapter. Presently, 3D Bioprinters or Bioscaffolders have already 
the capability to 3D plot biodegradable scaffolds, and essentially to complete the 
system, all that was needed was a device that can insert tissue units into the pores 
of the 3D plotted scaffold.  
 
It was crucial and imperative that the designed system included the following 
aspects: (i) it should be able to insert a spherical tissue unit into the desired pore of 
the 3D plotted scaffold, (ii) the mechanical stress on the tissue unit while the system 
is handling it should be as low as possible to avoid destructive effects on the cells in 
the tissue units, (iii) the tissue units should always be hydrated to prevent drying of 
the cells which would otherwise have an adverse effects on the cells, (iv) the system 
should be able to handle slight variations in tissue unit diameter and (v) the system 
should be capable integration with the Bioscaffolder, and (vi) the system should be 
capable of handling tissue units with a range of stiffnesses and densities.  
 
Previously Lang et al. investigated a mechanical-based and a fluidics-based 
tissue handling system [14-16]. However, the mechanical based tissue handling 




comparatively gentle fluidics-based system that handles tissue units by varying the 
hydrodynamic forces was thought would make a more fitting design for an 
automated bioassembly system [15]. Moreover, the fluid in the fluid system would 
be able to keep the tissue units in a hydrated environment. The design of an 
automated bioassembly system involved the development of a system consisting of: 
(i) a singularisation module that can take up a large number of engineered spherical 
tissue units and then deliver a tissue unit individually at a time to the injection 
module, and (ii) an injection module which can seed the tissue unit into a 
predetermined pore within the 3D plotted scaffold with the aid of a 3D positioning 
system.  
 
The development of this system was made with the intention that it would be 
able to handle various types of spheroid-based tissue units primarily for application 
in cartilage engineering and tumour engineering. With regards to cartilage 
engineering, the tissue units would include micro-tissues formed with chondrocytes 
or chondroprogenitor cells or hydrogel microspheres encapsulated with 
chondrocytes or chondroprogenitor cells for fabricating an assembled living 
construct suitable for clinical implantation. In tumour engineering, the tissue units 
would include micro-tissues formed from cancer cells or hydrogel microspheres 
encapsulated with cancer cells for fabricating a cancer construct which could be 
utilised for application in translational research in cancer and/or for high-
throughput screening (HTS) of drugs. 
 
The specific objective of this chapter was the design and development of a 
prototype automated 3D bioassembly technology capable of biofabricating tissue 
engineered constructs. This involved (i) the design and fabrication of the mechanical 
and electrical components of the fluidics-based automated bioassembly system, (ii) 
programming of the control module, (iii) assembly and construction of the 
components of the automated bioassembly system together, and (iv) the calibration 
of the prototype automated 3D bioassembly technology.  
3.3  Methods 
The automated bioassembly system consisted mainly of a singularisation 




singularised tissue unit into a predetermined pore within the 3D plotted scaffold) 
which was assembled to create the tissue unit injection head. The primary 
mechanical components (the singularisation chamber, pressure tanks and the 
injection system), the control system components (hardware and software), the 
tissue unit sensor, the Bioscaffolder-singularisation device communication and the 
assembly of the tissue unit injection head are described here in the methods section. 
Work performed previously by Lang et al. [14-16] on the automated bioassembly 
system included: (i) the design and fabrication of the mechanical components of the 
fluidics-based singularisation system and injection system and (ii) the validation of 
the singularisation and injection process. Existing components from the previous 
work which included (i) the singularisation chamber and (ii) the primary 
components of the injection system were reused here. The remaining components 
of the prototype were newly fabricated.  
3.3.1  Singularisation chamber 
The singularisation chamber was where the singularisation process (i.e. the 
process whereby one tissue unit is released at a time from a collection of tissue 
units) took place through the manipulation of the hydrodynamic forces within the 
chamber. The singularisation chamber was fabricated from a polycarbonate block 
using conventional machining techniques. See Appendix 3.A for mechanical design. 
Polycarbonate was selected, as the material allows the economical fabrication of the 
singularisation chamber utilising conventional machining techniques. Moreover, 
polycarbonate has a higher resistance to ethanol (for sterilisation of the system) 
compared to materials such as Poly(methyl methacrylate)(PMMA). The work on the 
singularisation device was based on previous work conducted by Lang et al. [14-16]. 
The block consists of three small vertical ports and a horizontal main chamber (see 
Figure 3-1). The horizontal main chamber was sized to a diameter of 1.3 mm so that 
it accommodated tissue units with a diameter of approximately 1 mm. The vertical 
channels were designed to be 0.7 mm in diameter so that the tissue units did not 
enter the port but the port was big enough to hold the tissue units in position. The 
vertical pressure ports – flush port 1, flush port 2 and capture port were fluidically 
connected to electronically regulated pressure tanks. The fluidic pressure in the 
vertical pressure ports was controlled by switching ON/OFF the five fluid isolation 




flush valve 2 (F2), capture port pressure valve (CP) and capture port vacuum valve 
(CV) (see Figure 3-1). The relative position of the flush port 1 and the capture port 
was such that when a tissue unit was captured at the capture port, the occurrence 
of dead volume between the two ports where another tissue unit could potentially 
be trapped in between the space was minimised. A pinch valve (Sirai, Italy) located 
downstream from the singularisation chamber not only aided in the control of the 
hydrodynamic forces but also acted as a gate that allowed the singularised tissue 
unit to pass through to the injection system. The piping and instrumentation 
diagram of the singularisation device is shown in  Figure 3-2. For a more detailed 





















Figure 3-1. Schematic of the singularisation chamber. (H) hopper valve, (F1) flush 
valve 1, (F2) flush valve 2, (P) pinch valve, (CP) capture port pressure valve and (CV) 



















The tubing was coupled to the horizontal main chamber of the singularisation 
chamber using a flangeless ferrules system (VICI Jour, Canada). The flangeless 
ferrules system was utilised to ensure a relatively seamless constant inner diameter 
connection, and to accurately position the tubing. Stainless steel connectors were 
utilised to connect the tubing to the vertical ports of the singularisation chamber 
and to the fluidic valves. White nylon luer lock or barb connectors (Nordson 
medicals, USA) were used for the remaining connections. The fluidic connections 
were made utilising 1.6 x 3.2 mm flexible Tygon tubing (Saint-Gobain, USA). For the 
pinch valve section that ran downstream from the exit of the singularisation device 
to the injection device traversing the pinch valve, 1.6 x 3.2 mm flexible Tygon tubing 
(Cole-Parmer, USA) compatible with the pinch valve was used. For the fluidic 
connections to the inlet and outlet of the positive pressure tank and the inlet of the 
negative pressure tank, polyurethane tubing (Festo, Germany) sized 6 x 8 mm tubing 
was used. The polyurethane tubing was connected using push-in connectors (Festo, 
Germany). 






3.3.2  Pressure tanks 
The manipulation of the tissue unit was performed by varying the 
hydrodynamic forces within the singularisation chamber. The hydrodynamic forces 
were varied by switching ON/OFF valves supplying pressurised fluid from the 
pressure tanks to the singularisation chamber. To supply fluid of different pressures 
to the singularisation chamber, two electronically regulated pressure tanks were 
designed - a positive pressure tank and a negative pressure tank. The positive and 
negative pressure tanks were positive and negative relative to atmospheric 
pressure. The piping and instrumentation diagram is shown in Figure 3-3. For the 
positive pressure tank, compressed air line of set pressure (7 bars) was connected 
to the inlet of the tank. The pressure sensor measures the pressure in the tank and 
proportional valves (Clippard, USA) which act as release valves were opened as 
needed by the control system to regulate the pressure in the tank and to obtain the 
desired set pressure. For the negative pressure tank, a vacuum ejector converts the 
compressed air line into vacuum. The proportional valves were fed by the output of 
the vacuum ejector, and the valve was proportionally opened by the control system 
to maintain the desired vacuum in the tank. The system was controlled by a 








































3.3.3  Injection system 
The injection system was designed to insert tissue units into the pores of a 3D 
plotted scaffold with the aid of a 3D positioning system. The injection system 
consisted primarily of a nozzle and an expanding rod. The expanding rod was 
mechanically attached to a solenoid controlled by the singularisation and injection 
system control module. The downward movement of the expanding rod was 
designed to aid the movement of the tissue unit and to help in press fitting the tissue 
unit into the pore of the 3D plotted scaffold. The expanding rod also helps to 
maintain a smooth profile for the nozzle so that the nozzle does not damage the 
scaffold fibres during the injection process and also the expanding rod protects the 
nozzle during the placement of the nozzle on the 3D plotted scaffold fibre. The nozzle 
was designed to have an inner diameter of 1.06 mm so that it could accommodate 
(a) 
(b) 
Figure 3-3. Piping and instrumentation diagram showing the layout of the (a) 




tissue units with a diameter of 1 mm. The remaining components that made up the 
injection system were for the support of the functional components. For the primary 
components of the injection system and assembly refer Appendix 3.A. The 
components of the injection system were machined using either 316 Stainless steel 
or 7075 Aluminium.   
3.3.4  Hardware development of the control module 
The core of the control module consisted of the National Instruments myRIO-
1900 which is a portable reconfigurable I/O (RIO) device that can be graphically 
programmed. As the output lines of myRIO had a low output voltage and amperage, 
driver circuits were essential to power the solenoids in the system. The driver 
circuits were designed keeping in mind the operating voltage and amperage of the 
various components and were electrically isolated if required. Power MOSFET 
(International Rectifier) based driver circuits were wired to run the fixed input 
voltage injection solenoid and fluid isolation micro solenoid valves. High-Voltage, 
High-Current Operational Amplifier (Texas Instruments, USA) based driver circuits 
were rigged to power the variable input voltage proportional valves. The signals 
from the singularisation chamber and tank pressure sensors (Freescale 
Semiconductor, USA) were amplified using instrument amplifiers (Texas 
Instruments, USA) and inputted to the myRIO. A potentiometer was used to set the 
gain of the instrument amplifier for the singularisation chamber pressure sensor so 
that the gain could be adjusted if required. The photomicrosensor (Omron, Japan) 
to detect singularised tissue units was biased and the output signal was inputted to 
the myRIO. Two one-way communication signal lines, a myRIO to Bioscaffolder line 
and a Bioscaffolder to myRIO line linked the Bioscaffolder with the myRIO. The 
communication signal lines were optically isolated and keeping in consideration the 
different operating voltages (Bioscaffolder – 24 V and myRIO – 5/3.3 V). The 
hardware circuitries were all fabricated on stripboards. Refer Appendix 3.C for all 
circuit diagrams and connections. After the hardware was set up, we proceeded to 
program the system.  
3.3.5  Software development of the control module  
The myRIO was programmed using LabVIEW. Standard LabVIEW programs or 




control circuit. The front panel of LabVIEW program consisted of controls (input) 
and indicators (output) defined by the programmer and was controlled and viewed 
by the user via a personal computer (PC). Whereas the back panel of LabVIEW 
program contained the graphical source code. 
 
The LabVIEW virtual instrument that controlled the automated system was 
programmed so that it consisted of independent sections that ran in parallel to 
ensure smooth running and to eliminate any cross-talk. The independent sections 
consisted of the virtual circuits for the control systems for the positive and negative 
tank, control of the fluid isolation valves and the injection solenoids, the 
photosensor detector and tissue unit counter, and other processes that would aid in 
the initialisation and efficient working of the system. The circuit was rigged so that 
default operating values were hardwired through the back panel and relevant 
operating values could be modified if required by the user through the front panel 
while the program is running.  
 
For the pressure tank control system, the PID virtual instrument in LabVIEW 
which is basically a PID algorithm was utilised as a PI controller to control the 
system. The process variable for the controller was the amplified pressure sensor 
voltage and the output of the controller was sent to the driver circuit to control the 
proportional release valves.  
 
The functions of the various controls and indicators in the front panel of the 
program are explained in detail in the results section.  
3.3.6  Tuning of the PI controllers for the pressure tanks 
The PID controller virtual instrument in LabVIEW served as the PI controller 
for the pressure tanks. The PI controller for each pressure tank was manually tuned. 
First, the proportional gain (Kp) and integral gain (Ki) was set to 0. Then the Kp was 
increased until the response to a disturbance was a steady oscillation. The value of 
Kp was set to half this value. The Ki was then increased to correct any offset in 
sufficient time. After this, the response of the controller was tested by checking the 




values were refined so that the control system worked with the response that we 
desired.  
3.3.7  Tissue unit sensor  
The output tubing of the singularisation device carrying the tissue unit to the 
injection system was made to transverse through a transmissive photomicrosensor. 
The photomicrosensor (Omron, Japan) circuit, was designed and biased so that 
every time a tissue unit passed through the sensor, there was a change in the output 
voltage. To detect a tissue unit and to differentiate it from the background noise 
caused by the flow of liquid through the tubing, the output voltage was sampled 
every 200 ms and a value of 0.6 V was added to the average of the last 10 samples, 
this value was calculated to be the baseline voltage. Whenever the continuously 
sampled photosensor voltage increased above this baseline voltage, the system 
would recognise that a tissue unit had passed through.  
3.3.8  Communications 
Communication between the Bioscaffolder and the myRIO was to be achieved 
using two lines - Bioscaffolder ready flag (BRF) and a singularisation device ready 
flag (SRF). When the Bioscaffolder is in position and ready, the next G-code in the 
Bioscaffolder would then turn the BRF high and wait, this would indicate to the 
singularisation device that it should begin the cycle of singularisation and injection. 
After the singularisation and injection process has been completed, the 
singularisation device would switch the SRF flag high indicating to the Bioscaffolder 
that it can proceed to the next line of the G-code. Both flags would turn low after a 
fixed time. For the detailed schematic of the communication, circuits refer Appendix 
3.C. The circuit was designed so that the Bioscaffolder and myRIO were optically 
isolated to avoid any power surges. Although the communication lines between 
Bioscaffolder and the myRIO were designed and made ready, they could not be 
interconnected to each other as the manufacturers of the Bioscaffolder had not yet 
provided us with the architecture of the input and output interface.  
3.3.9  Tissue unit injection head 
The low-temperature head of the commercial Bioscaffolder (SYS ENG, 
Germany) was modified so that the injection system could be mounted on it, after 




assembly primarily consisted of the singularisation chamber, the injection assembly 
and solenoid, the singularisation chamber sensor and circuitry, the fluid isolation 
and pinch valves, and the photosensor circuit to detect the singularised tissue unit. 
Detachable electric and fluidic lines linked the pressure tanks and circuits located 
outside the Bioscaffolder to the tissue unit injection head. The system was calibrated 
so that the length of the new lines was taken into account.  
3.4  Results and Discussion  
3.4.1  Overall design  
The block diagram overview of the whole bioassembly system is illustrated in 
Figure 3-4. The bioassembly system can be divided into two sections, the 
Bioscaffolder – around which the whole system is centred – and the singularisation 
and injection system. The Bioscaffolder is essentially an additive manufacturing 
device that can generate a physical 3D structure by a layer-by-layer extrusion 
process. The Bioscaffolder was controlled by the user using the Bioscaffolder 
program which runs on a PC. Designed CAD files that describe surface geometry of 
a 3D object such as an STL file was inputted into the Bioscaffolder program with the 
desired and/or optimised print parameters. The Bioscaffolder program converts the 
STL file and print parameters into G code (a numerical control programming 
language for automated machines). Complete control of the polymer deposition 
head to print a polymer-based scaffold can be executed using this approach. The 
tissue unit injection head was also positioned in space by the Bioscaffolder’s 3D 
positioning system. The Bioscaffolder has a tool changing system by which the 
polymer deposition head or the tissue unit injection head can be loaded onto the 
Bioscaffolder’s 3D positioning system and this was controlled by G codes. The 3D 
positioning system allows movement in X, Y and Z direction enabling control in the 
three dimensions with a positional and repositioning accuracy of 0.05 mm. As an 
algorithm for the G-code generation for the tissue unit injection head has yet to be 
developed, the G-code to control the tissue unit injection head was written by the 
user. The primary components of the tissue unit injection head – the singularisation 
and injection system was controlled by an external control module consisting of a 
myRIO embedded design device and driver circuits to power the components of the 
















3.4.2  Singularisation chamber 
The primary function of the singularisation device was to deliver a single 
tissue unit at a time to allow complex 3D Bioassembly of tissue units in a layer-by-
layer process. The fundamental component of the singularisation system, where the 
whole singularisation process takes place is the singularisation chamber. The 
singularisation system was designed to work in a way that it would first try and 
capture a tissue unit from a train of tissue units that are stored upstream in a tank. 
Next, the uncaptured tissue units were sent back upstream into the tank and the 
single captured tissue unit in the singularisation chamber was released 
downstream.  
 
The singularisation system was successfully assembled. Preliminary tests 
showed that spherical tissue units could be successfully singularised. The actual 
working and validation of the singularisation system are described in the next 
chapter.  
3.4.3  Injection System 
The main function of the injection system was to reliably deliver with ease a 
singularised tissue unit within the pore of a 3D plotted scaffold and to ensure that 
after the tissue unit had been delivered within the pore it remains securely in place.  






For the initial design, the injection system was designed so that when the 
expanding rod and nozzle together was positioned on the scaffold pore, they would 
first expand and elastically deform the scaffold fibres (Figure 3-5i a and b). After 
which, when the expanding rod was retracted (Figure 3-5i c), creating an 
unimpeded path for the delivery of the tissue unit within the scaffold pore (Figure 
5i d and e). The idea behind this was that there would be minimal physical stress 
exerted on the tissue unit decreasing the likelihood of damaging the cells in the 
tissue unit. This method of injection had a couple of drawbacks. For example, as the 
nozzle needed extremely thin walls machining the nozzle was challenging, and 
although the nozzle could be fabricated, it was structurally delicate and needed 
extreme care while handling it. Given that the tissue unit needed to have a snug fit 
in the scaffold, the size of tissue unit or the fibre could not be compromised at the 
cost of a successful injection device. Furthermore, preliminary trials showed that 
the scaffold fibres had a tendency to be slightly damaged as the thin wall of the 
nozzle behaved very similar to a drill punch.  
 
To overcome the above issues, the injection method was modified to a more 
press fit style (Figure 3-5ii). The nozzle would be placed on the topmost fibre that 
makes the scaffold pore (Figure 3-5ii a-c) by moving the injection head using the 3D 
positioning system of the Bioscaffolder. Then the singularisation system would 
singularise a tissue unit and the expanding rod aided with hydrodynamic forces of 
the liquid flowing through the nozzle would press fit (Figure 3-5ii d-f) the tissue unit 
within the predetermined pore of the scaffold. This method of inserting the tissue 
unit was comparable to the process of manually press fitting a tissue unit into the 
scaffold. The advantage of utilising the press fit method was also that nozzles with 
thicker walls could be fabricated if required without affecting the performance of 
the injection system. The actual operation and validation of the injection system is 




















3.4.4  Hardware development of the control module 
myRIO was chosen as the core of the control model due to the flexibility in 
rigging up the hardware, the ease with which it can be graphically programmed and 
the ability to conveniently modify the timing, control, flow and other required 
aspects in real-time during the development of the prototype. After the hardware 
was set up, a simple test to check if the hardware worked as intended was carried 
out. The driver circuits, when operated by myRIO via LabVIEW, were successful in 
powering the injection solenoid, the fluid isolation micro solenoid valves and the 
proportional release valves. LabVIEW via myRIO was able to detect a change in the 
value of the pressure sensors when a change in pressure at the pressure or vacuum 
port occurred. The obstruction of the aperture of the photomicrosensor was also 
detected on LabVIEW via myRIO. The myRIO-Bioscaffolder communication line 
circuits functioned well, however, the two systems were not linked presently as the 
hardware blueprint of the various input/output lines of the Bioscaffolder and the 
corresponding G-codes were not yet available. The whole system was enclosed in a 
box for protection to make it aesthetically pleasing.  
3.4.5  Software development of the control module  
The software for myRIO was programmed using LabVIEW - which is a 
graphical dataflow language. The front panel (Figure 3-6) of the myRIO control 
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 Figure 3-5. The two injection approaches. The (i) elastic deformation based 






system program that controls the singularisation and injection systems consisted of 
controls (input) and indicators (output).  
 
The default operating pressure and timing values obtained from preliminary 
tests were hardwired through the back panel. However, the virtual instrument was 
programmed such that the hardwired values could be modified by the user if 
required while the program was still running. This could be done through the front 
panel by either using the increment/decrement button or entering a desired 
numerical value in the required data field. The ability to modify the data values was 
extremely useful while debugging the system or while determining the optimum 


















The functions of all the buttons and indicators in the front panel of the 
designed program are as described below.  
 
Figure 3-6. Screenshot of the front panel of the myRIO control system that controls 





The manual valve controls allow the user to manually control the fluid 
isolation valves, pinch valve and the injection solenoid.  
 
In the hopper tank section, the fill button increases the fluid level in the hopper 
tank and the empty button decreases the fluid level in the hopper tank. The 
fill/empty time could be set so that hopper tank was filled/emptied with a 
predetermined volume of liquid.  
 
In the process control section, the start button manually starts the 
singularisation cycle. The auto/man switch could be used to choose either automatic 
singularisation (normal working) or manuals singularisation. During the 
singularisation cycle, if the switch was in manual singularisation, the program does 
not automatically move to the next singularisation step and this was helpful while 
debugging or optimising the system.  
 
The request ON/OFF switch could be used to choose whether the start of the 
singularisation cycle was triggered either by the Bioscaffolder via the Bioscaffolder-
myRIO communications (BRF line) or manually by the user. When the Bioscaffolder 
sends a request to myRIO, the request indicator turns ON.  
 
Air bubbles in the singularisation device could inhibit its normal working and 
could also result in erroneous tissue unit detection by the photomicrosensor. To 
remove the bubbles, the clear bubbles button switches ON/OFF the valves so that 
the bubbles in the singularisation device were cleared.  
 
Air bubbles in the line to the negative pressure tank could severely handicap 
the functioning of the singularisation device and the clear-bubbles – vacuum 
channel button specifically removes any bubbles in the line to the negative pressure 
tank.  
 
In the manual process control section, the functions of the buttons are defined 
so that each button executes each of the steps in the singularisation cycle. The timing 
for switching ON and OFF the various valves, the pressure of the tanks and the 




when the program is running through the front panel. In the automatic mode, the 
buttons are wired so that the 4 primary steps of the singularisation step (Figure 3-7) 




















Agitation – this removes any blockages that might be present in the 
singularisation chamber and hopper tank, dislodges tissue units stuck to the sides 
of the hopper tank, and causes the tissue units to float making the singularisation 
process easier. This step works by sending fluid upstream into the hopper tank 
through the ports of the singularisation chamber. The agitation was initiated for a 
set period of time.  
 
Capture leading TU – during this step an attempt was made to try and capture 
the leading tissue unit at the capture port. This step takes place right after the 
agitation step so that the tissue units are not very close to each other. An attempt to 
capture a tissue unit was made by changing the valve sequence so that there was a 
slight negative pressure at the capture port. If a tissue unit was captured at the 
captured port, it causes a reduction of pressure at the capture port, which was 
detected by the singularisation chamber sensor. The singularisation chamber 
sensor then triggered the clear lagging TU step. If there was a failure to capture a 
tissue unit at the capture port within the set time, the timeout indicator turns ON 




and the agitation step was retriggered. If the capture leading tissue unit and 
agitation enters an infinite loop, the stop button could be switched ON by the user 
to break the loop.  
 
Clear lagging TU – by maintaining the negative pressure at the capture port the 
captured tissue unit is held in place. However by increasing the pressure in flush 
port 1 and flush port 2. The lagging tissue units behind the captured tissue units are 
sent back upstream into the hopper tank.  
 
Release leading TU – the injection solenoid was switched OFF causing the 
spring-loaded expanding rod to retract. This cleared the path for the captured tissue 
unit to the injection chamber. The capture tissue unit was then released 
downstream to the injection chamber. It is here that the photomicrosensor detects 
whether a tissue unit has been singularised or not and if it has, the tissue unit 
detected indicator turns green and the number of tissue units singularised were 
updated in the tissue units processed counter.  
 
Apart from the 4 buttons described above that execute the primary 
singularisation steps, the other buttons aid the various steps. The initialise valve 
button switches off all valves and sets the desired pressure values in the tank to the 
desired initial value. The equalise chamber button flushes the singularisation 
chamber, detects if there is an abnormal pressure reading in the singularisation 
chamber sensor, initialises valves, checks tissue unit counters and switches ON the 
injection solenoid thereby lowering the expanding rod. Check counter checks if 
there is a mismatch between the tallied number of singularisation cycles and tissue 
unit processed. 
 
In the pressure control sections, the V-PI and P-PI buttons were used to switch 
ON the pressure tank control system and valves. If the input compressed air or 
vacuum to the tanks were too high or low for the controller, the high/low 
pressure/vacuum indicator would turn from green to red. When the indicator 
turned red, necessary adjustments had to be made by the user to the compressed 

































3.4.6  Tuning of the PI controllers for the pressure tanks: 
Manually tuning of the PI controllers for the pressure tanks gave an 
approximate range of the gains. Fine-tuning the gains around the obtained 
approximate range by checking the response to a disturbance or change in set-point 
gave us the most favourable Kp and Ki values for the controllers. The fine-tuned 
optimal Kp and Ki values were determined to be (i) 1.17 and 0.004 for the positive 
tank PI controller, and (ii) 0.6 and 0.2 for the negative tank PI controller. As long as 
the input pressure line to the vacuum ejector was about 7 bars and the input 









Figure 3-8. Photograph of the (a) positive and negative pressure tank setup and (b) 
the box containing the control system module showing the (i) negative pressure 
tank, (ii) positive pressure tank, (iii) proportional release valves, (iv) pressure 
regulator, (v) enclosure containing the pressure ejector, (vi) myRIO and (vii) 




control system with the above gains was stable during the normal operation of the 
singularisation device. With the above input pressure and gain vales, the control 
system was also sufficiently quick enough to respond when the set-point value was 
changed.  
3.4.7  Tissue unit injection head 
The singularisation system and injection system was successfully integrated 
with the low-temperature head of the Bioscaffolder. This included the placement of 
the singularisation chamber, the injection assembly and solenoid, the 
singularisation chamber sensor and circuitry, hopper tank, the fluid isolation and 
pinch valves, and the photosensor. The head was mounted on the tool magazine and 
preliminary tests showed that the head could be moved in space by the 3D 
positioning system without any problem or obstacles. The communication lines 
between the Bioscaffolder and the myRIO could not be connected to each other as 
the manufacturers of the Bioscaffolder did not provide us with the architecture of 
the input and output interface of the Bioscaffolder which was required for the 
integration of the communication lines. To overcome this the Bioscaffolder ready 
flag (BRF) and a singularisation device ready flag (SRF) were manually switched 
ON/OFF. However, the communication between the devices should be possible once 
we have the details of the lines input and output interface. Further testing of the 
device has been explained in detail in the next chapter. Photograph of the injection 





































3.5  Conclusions  
We have described an approach undertaken to design and successfully build 
and construct a prototype, fluid-based automated bioassembly system. This 
included the complete architecture of the mechanical and electronic systems 
required for the functioning of the device. The constructed singularisation module 
had the capability to take up large numbers of engineered tissue units (micro-tissue 
or microspheres) and then deliver a tissue unit individually at a time to the injection 










Figure 3-9. Photograph of the injection head with labels showing the position of (i) 
hopper tank, (ii) singularisation chamber sensor and circuitry, (iii) Bioscaffolder 3D 
positioning head, (iv) fluid isolation, (v) injection solenoid, (vi) photosensor, (vii) 





to a predetermined pore within the bioscaffold. The immense flexibility of the 
constructed prototype allowed for the adjustment and optimisation of the essential 
soft parameters with ease. The ability to tailor these soft parameters allowed the 
easy and effective optimisation of the system for handling different types and sizes 
of tissue units. This prototype allowed us to further validate the capabilities of the 
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Chapter 4 Integrated system for automated 3D 
Bioassembly of micro-tissues for biofabrication of hybrid 




The work from this chapter has contributed to the manuscript that is currently 
in the process of being submitted to the journal Biofabrication.  
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Integrated system for automated 3D Bioassembly of micro-tissues for biofabrication of 
hybrid tissue engineered constructs. Biofabrication. (in submission). 
4.1 Abstract 
Bottom-up biofabrication approaches combining micro-tissue fabrication 
techniques with 3D plotted scaffolds are emerging strategies in tissue engineering. 
These strategies promote cell-cell/stem cell interactions and cell differentiation 
capacity. Few technologies have been developed to automate the precise assembly 
of micro-tissues into 3D plotted scaffolds. We developed a cutting-edge automated 
3D Bioassembly system capable of fabricating: (i) simple constructs via a two-step 
top-down bioassembly strategy and (ii) complex hybrid hierarchical constructs via 
a multistep bottom-up bioassembly strategy. The prototype automated micro-tissue 
bioassembly system consisted of a fluidics-based singularisation and injection 
module incorporated into a commercial 3D bioprinter. The singularisation module 
delivered individual micro-tissues to an injection module, for insertion into specific 
locations in a 3D plotted scaffold. Chondrocytes were isolated and Ø1 mm micro-
tissues were generated utilising a high-throughput 96-well plate format. Micro-
tissues were singularised with an efficiency of 96.0 ± 5.1%. There was no significant 
difference in size, shape or viability of micro-tissues before and after automated 
singularisation and injection. A layer-by-layer approach or aforementioned bottom-
up bioassembly scheme was employed to fabricate a bilayered construct by 
alternatively 3D plotting a PEGT/PBT polymer scaffold and inserting pre-
differentiated chondrogenic micro-tissues utilising the bioassembly system. No 
significant difference in viability between the construct assembled utilising the 




This technology provides an automated and scalable pathway for Bioassembly of 
both simple and complex 3D, multicellular tissues of clinically relevant size and 
shape.  
4.2 Introduction 
Physical impact or degenerative diseases such as osteoarthritis and related 
disorders can damage articular cartilage causing severe pain, deformity and loss of 
joint motion [1]. Cartilage, being an avascular tissue structure with constrained 
oxygen supply has a limited capacity for self-repair [2]. Many repair strategies such 
as microfracture, mosaicplasty, autologous chondrocyte implantation, and matrix-
assisted chondrocyte implantation have been developed in an attempt to treat 
articular cartilage defects, although short-term clinical results are satisfactory long-
term results are typically associated with the formation of fibrocartilage which has 
inferior mechanical properties compared to native hyaline cartilage [3-5]. This has 
prompted the search for alternative treatments based on tissue engineering 
strategies and other approaches to circumvent the limitations of existing therapies 
[6, 7].  
 
The typical tissue engineering paradigm for cartilage involves growing 
chondrocytes or chondroprogenitor cells (e.g. mesenchymal stromal cells isolated 
from bone marrow) in combination with cell phenotype modulating growth factors 
within a biodegradable 3D scaffold in vitro and then implanting the engineered 
construct into the target site [8]. This approach may offer advantages over existing 
surgical techniques in that the desired scaffold shape can be tailored to meet the 
needs of an individual patient while providing the initial mechanical properties, cells 
and extracellular matrix (ECM) components required to elicit regeneration and 
repair. Ideally, over time the biodegradable scaffold would be completely replaced 
by mature ECM deposited by the cells, resulting in a functional cartilage repair [7]. 
Although significant advances have been made in tissue engineering, major 
challenges are yet to be conquered before cartilage tissue engineering strategies can 
be applied in a clinical setting [9].   
 
Chondrocytes, however, need to be guided to prevent dedifferentiation and 




complex cellular and extracellular matrix (ECM) organisation in native hyaline 
cartilage to allow normal load bearing and long-term function of the joint [10]. 
Micro-mass or pellet culture of chondrocytes or chondroprogenitor cells are well-
established methods for generating small micro-tissues of cartilage tissue, and more 
recent studies have investigated high-throughput approaches for micro-tissue 
formation [11, 12]. A previous study by Schon et al. [11], demonstrated a high-
throughput technique for producing ex vivo cartilage-like micro-tissues. In these 
micro-tissue, the 3D niche promotes a large number of cell–cell interactions [13], 
thereby replicating the cellular condensation environment typical during 
developmental stages of cartilage growth, allowing the production of hyaline-like ex 
vivo neocartilage expressing collagen type II and aggrecan [11] typical of mature 
hyaline cartilage. A large body of work around the high-throughput generation of 
micro-tissues exists and has been demonstrated with hanging drop technology for 
cartilage engineering [14], with a 96-well plate format for cartilage engineering [11], 
to assess chondrogenesis [15, 16] and for the screening of antirheumatic compounds 
[17], and with a 384-well plates format for high-throughput screening (HTS) of 
chondrogenesis in mesenchymal stromal cells [18]. Therefore, a significant 
opportunity exists if high-throughput cultured micro-tissues could be assembled 
into a scaffold to obtain a functional tissue engineered construct consisting of a large 
number of pre-differentiated micro-tissues primed for promoting ECM formation.   
 
In tissue engineering and regenerative medicine (TERM), the conventional 
“top-down” strategies revolve around populating cells in a scaffold [19]. Recreating 
the microarchitecture of native tissue utilising top-down approaches is however 
challenging [19]. This drawback can be addressed by undertaking a “bottom-up” 
strategy where smaller nanoscale or microscale tissue units are assembled to create 
a larger more complex engineered tissue construct with a more controlled 
architecture [20]. With regards to bottom-up approach, Livoti and Morgan et al. [21, 
22] reported on a tissue fusion technique, where a printing approach was used to 
produce complex shapes that were assembled using micro-tissues as building units 
on agarose moulds. Jakab et al. [23] demonstrated a system for the self-assembly of 
micro-tissues using a bio-printer with a device that cuts and extrudes cellular slurry 
into cylindrical aggregates and then delivers it into a printed hydrogel producing a 




assemble prefabricated tissue modules or units into a higher order tissue structure 
and this includes stacking of cell sheets [24], random packing of microgels [25], 
utilizing hydrophobic effect for assembling microgels [26], physical manipulation of 
individual cell-laden microgels [27] assembling micro-tissues into 3D plotted 
scaffolds [11], vacuum moulding [28, 29] or stacking rings on a tube [30]. 
 
Presently, bottom-up modular fabrication or tissue assembly technologies 
suffer from the inability to precisely place micro-tissues into a 3D plotted scaffold 
[31] and the manual assembly of micro-tissue spheroids has currently been limited 
to small, simple constructs. To our knowledge, there are currently no techniques 
available for the combination of automated top-down and bottom-up bioassembly 
approaches for hierarchical biofabrication and direct 3D bioassembly of micro-
tissues in complex, anatomically-shaped 3D scaffolds.  
 
The absence of a roadmap for scalable, reproducible, automated, large-scale 
biofabrication of tissue engineered products with a high level of cell-cell interaction, 
cellular self-assembly and co-location in combination with structurally reinforcing 
scaffolds offers opportunities to develop modular bioassembly technologies [32]. 
The requirements of such a system would include: (i) high degree of automation and 
scalability, (ii) ability to assemble micro-tissues of different cell types with 
controlled spatial resolution (e.g. osteochondral biphasic constructs [33]), (iii) 
ability to fabricate large, complex and high fidelity constructs of clinically relevant 
size. The system must also be able to promote rapid cell differentiation and ECM 
formation that mimics the complex 3D architecture of the native tissue as well as 
reduce overall construct fabrication time.  
 
For the advancement of biofabrication approaches, any 3D bioassembly 
technology should preferably offer flexibility and be highly capable of fabricating 
both simple and anatomically complex hybrid tissue constructs. We envisioned that 
the 3D Bioassembly process should be capable of two specific bioassembly 
strategies: (i) a simple or top-down bioassembly strategy which is a two-step 
process involving the fabrication of a 3D plotted scaffold and the assembly of specific 
tissue units into targeted locations in the fabricated 3D plotted scaffold allowing the 




which is a layer-by-layer multistep process involving the alternating 3D plotting of a 
scaffold layer and co-assembly of specific tissue units into targeted locations in the 
3D plotted scaffold layer enabling the fabrication of complex hybrid constructs. 
Figure 4-1. illustrates the opportunities offered by advanced modular tissue 

































































The specific aim of this study was therefore to develop an automated 
biofabrication strategy combining 3D micro-tissue bioassembly and 3D plotting of 
Micro-tissue injection heads 
Figure 4-1. Illustration of the envisioned automated 3D Bioassembly process. (a) A 
three dimensional design is translated from a computer aided model to a plotted 
construct. (b) Simple or top-down fabrication: two step simple assembly involving 
3D plotting a scaffold and subsequent spatial assembly of micro-tissues and (b) 
hybrid or bottom-up fabrication: multistep layer-by-layer assembly which involves 
in alternatively 3D plotting a layer and inserting micro-tissues to create a hybrid 
assembled construct.  
Singularise and inject micro-tissues Plot Simple construct 
(b) 
High-temperature print head Computer aided model of 
tissue construct 
(a) 
Plot first layer of Bioscaffold          Continue layer-by-layer assembly Hybrid construct 





























































thermoplastic polymer scaffolds. This involved the development of a system 
consisting of (i) a singularisation module that is able to separate large numbers of 
engineered spheroids or micro-tissues and then deliver them individually to an 
injection module, and (ii) an injection module which can assemble or seed the micro-
tissue at a pre-determined location within a defined scaffold architecture with the 
aid of a 3D positioning system. The ultimate goal of this technology was the 
development of an automated biofabrication system capable of assembling living 
constructs suitable for clinical translation, preliminarily targeting cartilage repair 
strategies. 
4.3 Methods 
4.3.1 Scaffold fabrication  
Biodegradable poly(ethylene glycol)-terephthalate-poly(butylene 
terephthalate) block copolymers (Polyactive 300PEGT55PBT45, PolyVation, The 
Netherlands) with  a PEG molecular weight (MW) of 300 g/mol and a PEGT:PBT 
weight percent (wt%) ratio of 55:45 were used to fabricate scaffolds with a specific 
pore size and architecture. PEGT/PBT copolymer composition was selected as a 
model scaffold based on previous studies demonstrating applicability across 
multiple processing techniques (e.g. melt extrusion), mechanical properties 
mimicking native tissue, as well as the capacity to modulate cell, adhesion, 
proliferation, differentiation and extra cellular matrix formation [8, 11, 34-38]. 
Porous scaffolds (15 × 15 × 3.52 mm), with accurately defined and controlled pore 
architecture for micro-tissue incorporation, were 3D plotted using a Bioscaffolder 
system (SYS ENG, Germany). Fibres were oriented in a repeating 0-90°-90°-0° 
pattern in order to provide porosity in both the x-y and x-z planes for assembly of 1 
mm diameter micro-tissues. During the melt dispensing process the following 3D 
plotting parameters were applied: (i) fibre spacing of 1 mm in both x and y-direction, 
(ii) fibre height offset of 0.22 mm, (iii) dispense head and plotting temperature of 
200° and 5 bar pressure, (iv) dispense head auger speed of 63 RPM and (v) 25 gauge 
dispense head nozzle moving at an x-y traverse speed of 500 mm/min.  
4.3.2 Scaffold characterisation  
3D plotted scaffold architectures designed for Bioassembly were gold sputter-




were taken using a Jeol 7000F FE-SEM with secondary electron detection used at an 
acceleration voltage of 15 kV. The interconnecting pore size of the 3D plotted 
scaffolds in the x-y plane and z plane and the fibre diameter was measured from 
calibrated SEM images. Rendered images illustrating the bioassembly scaffold 
design, interconnecting pore size and fibre diameter measurements are shown in 













The volume percentage porosity (Vol% porosityscaffold) of the 3D plotted scaffold 
was determined by mass-volume method using Equation 4-1 as described 
previously [8]. The length (lscaffold), breath (bscaffold), height (hscaffold) and the mass 
(mscaffold) of the 3D plotted scaffold was measured.   
 
𝑉𝑜𝑙% 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 = 1 −  
𝑚scaffold
𝑚solid material 
 𝑥 100 
 
Where msolid material was determined using equation 4-2 and 4-3 and the density 
of Polyactive 300PEGT55PBT45 (ρsolid material = 1.25 g/cm3) was based on the value 
previously reported and the theoretical value of porosity was also determined as 
described earlier [8].  
 
𝑚solid material =  𝑉scaffold × ρ solid material   
 
𝑉scaffold =  𝑙 scaffold × 𝑏 scaffold × ℎ scaffold   















Figure 4-2. Rendered images of the top view and sectional front view of the 3D 










The unconfined dynamic stiffness (compressive modulus) of the 3D plotted 
scaffolds was measured using an MTS Criterion® 42 mechanical test machine 
incorporating a 500N load cell. 3D plotted scaffolds with a dimension of 5 × 5 × 1.8 
mm were tested at room temperature under dry conditions. A preload of 0.1 N was 
applied to ensure that the machine crosshead was in contact with the sample. The 
dynamic stiffness was determined by applying a uniaxial unconfined cyclic 
compression between 1% and 5% strain (liner region of the stress-strain curve) at 
a frequency of 1 Hz. During cyclic compression, the equilibrium peak force was 
reached after approximately 70 cycles out of a total of 100 compression cycles. The 
dynamic stiffness was calculated by taking the average modulus for the last 10 
cycles. 
4.3.3 Cartilage excision and cell isolation  
Human chondrocytes were isolated, expanded and formed into micro-tissues 
as described previously [11]. Briefly, nasal or articular cartilage biopsies were 
obtained following ethics approval from consenting patients undergoing septoplasty 
surgery or cruciate ligament reconstruction respectively (n=2; 18, 25 years of age). 
The cartilage was diced into 1 mm cubes and digested overnight in basic 
chondrocyte media containing DMEM (high glucose, GlutaMAX Supplement, 
pyruvate; GIBCO, USA) with 10% fetal bovine serum (FBS; GIBCO, New Zealand), 0.1 
mM non-essential amino acids (NEAA; GIBCO, USA), 10 mM HEPES (GIBCO, Taiwan), 
0.2 mM L-ascorbic acid-2-phosphate (Sigma-Aldrich, USA), 0.4 mM L-proline 
(Sigma-Aldrich, USA), 100 units/mL penicillin (GIBCO, USA) and 100 μg/mL 
streptomycin (GIBCO, USA) containing 0.15% (w/v) collagenase type II 
(Worthington, USA). The suspension was then filtered through a 100 μm cell strainer 
(BD Biosciences, USA) and centrifuged at 700 g for 4 minutes.  
4.3.4 Cell expansion  
Freshly isolated human articular chondrocytes (HACs) or human nasal 
chondrocytes (HNCs) were seeded at a density of 3,000 cells/cm2 in tissue culture 
flasks (BD Biosciences, USA) in basic chondrocyte media. Cells were expanded at 
37°C in a humidified 5% CO2/95% air incubator and media changed twice a week. 




phosphate-buffered saline (PBS; GIBCO, USA), detached using 0.25% trypsin/EDTA 
(Gibco, Canada), counted by trypan blue exclusion in a haemocytometer and plated 
in a tissue culture flask at 3,000 cells/cm2. Passage 2 (P2) cells were harvested 
similarly and utilised to form micro-tissues. 
4.3.5 High-throughput micro-tissue fabrication  
Micro-tissues each consisting of 0.25 x 106 chondrocytes were formed in a 
high-throughput manner [11] and cultured in serum-free basic chondrocyte media 
supplemented with 1 % ITS+ (1 mg/ml insulin from bovine pancreas, 0.55 mg/ml 
human transferrin, 0.5 μg/ml sodium selenite, 50 mg/ml bovine serum albumin and 
470 μg/ml linoleic acid; Sigma), 0.1 x 10-6 M dexamethasone (Sigma, USA), 1.25 
mg/ml bovine serum albumin (GIBCO, New Zealand) and 10 ng/ml recombinant 
human transforming growth factor-β1 (TGF-β1; R&D systems, USA). Cell 
suspensions consisting of 0.25 x 106 chondrocytes in 290 μL media was pipetted into 
each well of a polypropylene 96-well V-bottom plate (Raylab, New Zealand), and 
centrifuged (Eppendorf 5810) at 200 g for 4 minutes and placed in an incubator at 
37°C, 5% CO2.  The following day, the newly formed micro-tissue was gently 
detached from the bottom of the V-plate by pipetting. During the micro-tissue 
culture period, the media was changed 3 times per week and samples harvested at 
day 7. 
4.3.6 Design of the Singularisation system  
The singularisation device is a subsystem of the integrated tissue assembly 
device that takes the pooled micro-tissues from the high-throughput fabrication 
process in a reservoir hopper and then delivers a single micro-tissue at a time when 
required. The singularisation system consisted of a fluidic block fabricated with 
polycarbonate. The fluidic block was designed so that the hydrodynamic forces in 
the block could be varied sequentially using hydraulic valves and a pinch valve to 
manipulate and trap the micro-tissues and to achieve singularisation.  
 
The block consisted of three small vertical pressure ports and a horizontal 
main chamber. The arrangement of chambers is illustrated in Figure 4-3. The vertical 
pressure ports – flush port 1, flush port 2 and capture port were connected to 




fluidic valves - hopper valve (H), flush valve 1 (F1), flush valve 2 (F2), capture port 
pressure valve (CP) and capture port vacuum valve (CV).  
 
In this study, the main fluidic chamber was designed with an internal diameter 
of 1.3 mm to accommodate micro-tissues (or any other spherical aggregate or 
bioassembly tissue unit) with a diameter of 1 mm [11] for initial proof of concept, 
and also prevented horizontal stacking of the micro-tissues. The pressure ports were 
designed with a reduced diameter of 0.7 mm, in order to restrict micro-tissue entry 
into the ports and to either capture or trap them in position. The distance between 
the pressure ports on the main chamber was designed to be minimal to reduce the 
presence of a dead volume where micro-tissues may become trapped. A pressure 
sensor at the capture port measured the pressure as a feedback-loop to identify 
successful micro-tissue capture or if blockages were present. Furthermore, a 
photomicrosensor downstream of the singularisation system was used to provide 
feedback if successful singularisation (i.e. the delivery of a single micro-tissue to the 























































Capture leading micro-tissue Agitation 
Clear leading micro-tissue Release leading micro-tissue 
(e) 
Figure 4-3. The singularisation concept. (a) agitation in the chamber to clear any 
blocks that might be present, (b) the capture port capturing the leading micro-tissue 
(c) flush back of the lagging micro-tissues and (d) the release and exit of the leading 
micro-tissue. The arrows show the direction of fluid and the dotted arrow indicates 
the direction of pressure. (H) hopper valve, (F1) flush valve 1, (F2) flush valve 2, (P) 
pinch valve, (CP) capture port pressure valve and (CV) capture port vacuum valve. 
Dotted boxes indicate that the valve is open and the solid boxes indicate that the 
valve is closed. (e) a photograph of the singularisation chamber, with the leading 





A summary of the singularisation process is illustrated Figure 4-3, and can 
primarily be broken down into 4 main steps - agitation, capture of leading micro-
tissue, clearing of micro-tissue and release of leading micro-tissue. Micro-tissues 
entered the horizontal main chamber from the hopper reservoir (micro-tissue were 
transferred into the hopper tank manually by the user utilising a Pasteur pipette) 
which had a pneumatic hopper valve (H) to let air in the tank. Expulsion of micro-
tissues from the singularisation device was controlled by a pinch valve (P). 
Pneumatic valves and pressure sensors were used to regulate the pressurised 
reservoirs containing media. Control software (LabVIEW, National Instruments, 
USA) and user interface was designed which took inputs from pressure sensors, the 
control system processes and feedback, user inputs as well as also sequentially 
controlling the valves and their timings. Preliminary tests using formalin fixed 
micro-tissues were used to determine the optimal valve timing and pressure settings 
for optimisation of the singularisation system. 
4.3.7 Design of the Injection system 
For the integrated tissue assembly device, a delivery subsystem was also 
required to automate the delivery of micro-tissues via two specific top-down and 
bottom-up fabrication strategies: (i) bioassembly of micro-tissues at target locations 
within a prefabricated scaffold with defined pore spacing (i.e. top-down), or (ii) 
bioassembly of micro-tissues at a target location via alternating layer-by-layer 
scaffold fabrication and assembly approach (i.e. bottom-up). To achieve this, an 
injection system was designed to successfully achieve both of these flexible 
bioassembly strategies and to minimise damage to the micro-tissues during the 
assembly process. 
 
Figure 4-4 describes the steps involved in the injection concept in detail and 
also demonstrates the process for successful injection of Ø1 mm micro-tissues into 
a pore of a 3D plotted scaffold. Briefly, the assembly process begins with accurate 
positioning of the injection nozzle over the centre of the scaffold pore using the 
Bioscaffolder tool path calculated via the programming code (g-code) used to 
fabricate the scaffold. A solenoid operated expanding rod located within the core of 
the injection nozzle was then retracted to make way for the micro-tissue. The 




controlled again by triggering the appropriate valves with specific control over valve 
timing via LabVIEW software interface (see Figure 4-7). Along with fluid flow of, the 
downward movement of the expanding rod (Figure 4-4 e) aided the delivery of the 
micro-tissue into the pore spacing. Apart from aiding the press-fit delivery of the 
micro-tissue into the pore, the expanding rod further helped to maintain a smooth 
profile for the nozzle so that the nozzle did not damage the scaffold fibres during the 
injection process and also protected the delicate nozzle during the placement of the 






























Figure 4-4. The Injection concept. (a) The injection system is positioned above the 
scaffold pore spacing where the micro-tissue is to be delivered, (b) it is then 
vertically lowered so that the expanding rod and nozzle sit on top of the upper fibres, 
(c) the expanding rod is retracted enabling (d) the delivery of the micro-tissue to the 
pore, (e) the expanding rod is lowered and pushes the micro-tissue in place if 
necessary and (f) the injection system is raised about the scaffold and is ready for 
the next insertion. The injection process. (a) Positioning the injection head, (b) 
micro-tissue singularisation and rod retraction and (c) micro-tissue insertion. Scale 


















4.3.8 The integrated tissue assembly system   
The integrated platform for the fabrication of 3D plotted scaffolds and 
automated assembly of micro-tissues consisted of the 3D Bioscaffolder and 
LabVIEW controlled singularisation and injection device. The 3D Bioscaffolder 
allowed scaffolds to be plotted via fibre deposition (Figure 4-5 a) and also served as 
a 3D positioning system for the micro-tissue injection head (Figure 4-5 b). The 
desired head could be mounted on the printer head with the use of a tool changer 
interface. The transport of single micro-tissues from the singularisation system to 



















For construct biofabrication, a scaffold layer (0º-90º-90º-0º fibre orientation 
with desired fibre spacing) was 3D plotted with the high-temperature thermoplastic 
polymer print head, after which a micro-tissue was singularised and precisely 
assembled into the desired location within the scaffold via the injection system. The 
multistep process was repeated to create a bioassembled hybrid construct.  
(a) (b) 
Figure 4-5. Illustration of (a) the high-temperature plotting head and the micro-
tissue injection head. Each head could be alternated or activated through the use of 
the tool changer mounting. 
 




4.3.9 Micro-tissue shape characterization before and after singularisation 
Micro-tissue (n=9) dimensions were analysed both before and after 
undergoing the singularisation process. Samples were fixed overnight with 4% 
neutral buffered formalin and imaged using a bright-field microscope. The major 
and minor diameters were measured using the image measurement function in the 
Micrometrics SE Premium 4 software. Following imaging and measurement, micro-
tissues were put through the singularisation device and then imaged and measured 
again as above, for comparison.  
4.3.10 Reliability and efficiency of the singularisation device 
Preliminary tests with the singularisation device demonstrated that micro-
tissues with a major diameter less than 0.82 ± 0.06 mm (n=3) became lodged into 
the pressure ports (diameter of 0.7 mm) of the fluidic chamber. The smaller micro-
tissues would be sucked into the negative pressure tank through the capture port, 
by increasing the pressure in the negative pressure tank. Whereas micro-tissues that 
had a major diameter greater than 1.26 ± 0.02 mm (n=3) did not enter the fluidic 
chamber (diameter of 1.3 mm). The larger micro-tissue were purged back into the 
hopper tank and would have to be manually removed by the user utilising a Pasteur 
pipette. The singularisation device could handle micro-tissues with a major 
diameter in between this range. To determine the optimal size range for reliable and 
efficient operation of the device and determine the efficiency of the singularisation 
device at the upper or lower limits of the micro-tissue diameter, the fabricated 
micro-tissues were fixed and sorted into two size ranges - group A and group B (see 






Group A 1.14 ± 0.12 mm  1.03 ± 0.18 mm 




Micro-tissues belonging to group A was then singularised in sets of 6 and 
repeated 17 times whereas micro-tissues belonging to group B were singularised in 
Table 4-1. Average major and minor diameter of micro-tissues.   
a Group A (n=6 microspheres)  






sets of 9 and repeated 12 times, with percentage success rate for singularisation 
recorded. The total number of successful singularisation cycles was used to 
determine the overall efficiency of the singularisation system (Equation 4-4). The 
number of successful detection of singularisation cycles was used to determine 




𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛 
𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛
            
 
𝑝ℎ𝑜𝑡𝑜𝑚𝑖𝑐𝑟𝑜𝑠𝑒𝑛𝑠𝑜𝑟 𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 
=
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑐𝑦𝑐𝑙𝑒𝑠
𝑡𝑜𝑡𝑎𝑙  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑐𝑦𝑐𝑙𝑒𝑠
 
 
Micro-tissues that were that were too small to be handled by the 
singularisation device (i.e. micro-tissues smaller than the diameter of the capture 
port (0.7 mm) would be), would pass through the capture port and end up in the 
negative pressure tank.  
4.3.11 Viability of the micro-tissue  
In order to determine if any of the automated fluidic-based steps for 
singularisation, transport and injection influenced cell viability, micro-tissues were 
divided into 4 groups, a control group (i.e. not put through the device), a singularised 
group (i.e. put through the singularisation device only), an injected group (i.e. put 
through the injection device only) and a singularised and injected group (i.e. put 
through both the singularisation and injection devices). The viability of the micro-
tissues was determined using the live/dead assay and the trypan blue exclusion 
assay.  
 
For the live/dead assay, samples were incubated at 37°C in 0.5 ml of Dulbecco’s 
phosphate-buffered saline (DPBS; Invitrogen, USA) with 1 μM Calcein AM (Molecular 
Probes, USA) for 15 minutes, then 1.5 μM Propidium Iodide (Molecular Probes, USA) 
was added and incubated for 10 further minutes. Samples were then washed twice 
with DPBS and a z-stack of the sample was imaged using a Zeiss Axioimager Z1 







For the trypan blue exclusion assay, micro-tissue samples were digested 
overnight with 0.15% (w/v) collagenase type II (Worthington, USA) in basic 
chondrocyte media as described previously [11]. The cells were then diluted in an 
equal amount of 0.04% trypan blue (GIBCO, USA) and the viability of the cells was 
quantified by imaging and counting of stained cells using a Zeiss Axioimager Z1 
microscope. 
4.3.12 Automated micro-tissue bioassembly 
To validate the process for automated bioassembly of a 3D construct, a 
bilayered scaffold was designed and 3D plotted to incorporate 16 micro-tissues in 
each layer adopting a layer-by-layer scaffold fabrication and micro-tissue 
bioassembly (bottom-up) approach. For the first layer of the construct, 8 fibre layers 
were plotted and subsequently, 16 viable HAC micro-tissues were singularised and 
inserted using the automated assembly system. This process was similarly repeated 
for the second layer.  
 
During the micro-tissue insertion process, the fluid flowing naturally through 
the nozzle was sufficient to keep the micro-tissues in the construct hydrated and the 
surface tension ensured that the fluid remained around the construct. For the 3D 
plotting of the subsequent layer of the scaffold, the fluid level around the construct 
was manually adjusted with a pipette so that the fluid level remained below the 
topmost scaffold fibre so that the micro-tissues were still hydrated and also allowed 
the adhesion of the fibre being 3D plotted onto the construct. Although we have 
presently controlled the fluid level manually, developing a fluid control system along 
with a chamber in which the media level can be controlled and the construct 
fabrication takes place would not be challenging.  
4.3.13 Efficiency of micro-tissue insertion 
A bilayered scaffold (n=6) was printed with 4 micro-tissues in each layer using 
the layer-by-layer approach described earlier. The efficiency of micro-tissue 
insertion into the scaffold was determined by the ratio of successful micro-tissues 
inserted into the target scaffold pore to the total attempted number of micro-tissues 





𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛
=  
𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛  
𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛 
          
 
4.3.14 Determination of viability of assembled construct 
The layer-by-layer approach based bilayered scaffold (n=3) with 4 viable 
micro-tissues per layer was assembled using the automated system. Furthermore, a 
manually assembled scaffold (n=3) was prepared as a control to compare against 
bioassembled constructs with the automated system.  In the latter case, the scaffold 
was 3D plotted and micro-tissues were inserted manually by hand into pre-
fabricated scaffold pores using a pipette fitted with a 1 mL pipette tip. 
 
Live/dead assay was performed on manual and automated assembled 
constructs as described for micro-tissues above. To quantify metabolic activity of 
bioassembled constructs, the AlamarBlue® assay was performed. AlamarBlue® 
(Invitrogen, USA) was added to the serum-free basic chondrocyte media so that the 
final concentration was 10% (v/v) and the samples were incubated at 37°C for 3.5 
hours.  The reduction in AlamarBlue® reagent was calculated colorimetrically using 
the equations provided by the manufacturer after measuring the absorbance at 570 
nm, using 600 nm as a reference wavelength (Fluostar Galaxy BMG Labtechnology, 
Germany). 
4.3.15 Statistical analysis 
Data was presented graphically as mean ± standard deviation. Data were 
analysed using GraphPad Prism v.6.0. Statistical analysis was performed using 1-way 
ANOVA or paired t-test, with p<0.05 set as criterion for statistical significance. 
4.4 Results 
4.4.1 Scaffold characterisation  
The SEM images (Figure 4-6) of the 3D plotted scaffold showed regular 
interconnecting pores in the in the x-y plane and z plane for the specific scaffold 



















The theoretical and measured values of interconnecting pore size in the x-y 
plane and z-plane, the volume percent (Vol% porosityscaffold) porosity and the fibre 
diameter for the 3D plotted scaffold are indicated in Table 4-2. The theoretical values 
for interconnecting pore size, Vol% porosityscaffold and fibre diameter were 
comparable with the measured values, where the average interconnecting pore size 
in the x-y plane was specifically designed at approximately 780 µm to allow a slight 
press-fit of the Ø1 mm micro-tissues. It was essential that the interconnecting pore 
size and Vol% porosityscaffold  were accurately designed and fabricated so that the 
micro-tissues could reliably be inserted into the pore by the automated bioassembly 
system, while at the same timing ensuring they remain in place and not dislodged 




Interconnecting pore size 
Vol% porosityscaffold Fibre diameter (µm) x-y plane (µm) z plane (µm) 
Theoretical   780 440 84.17 220 
Measured 767.02 ± 16.54 427.25 ± 9.78 78.17 ± 2.26 218.50 ± 7.94 
 
 
The mechanical properties of the 3D plotted scaffold can be influenced by the 
architecture of the scaffold [8, 39]. For the particular architecture used in this study 
a (n=4) 
 






Figure 4-6. Scanning electron microscopy (SEM) images (x50) of the top view and 
sectional front view of the 3D plotted scaffold. 




where the fibres were 3D plotted in a 0-90°-90°-0° pattern, the unconfined dynamic 
stiffness of the empty scaffold was determined to be 6.91 ± 0.62 MPa at 1 Hz. For 
articular cartilage, 1 Hz is in the range of physiological frequency representative of 
light to moderate activity [40]. In comparison, the dynamic stiffness of bovine 
cartilage under cyclic compression at 1 Hz has been reported to be approximately 
9.6 MPa [39], whereas for bovine carpometacarpal cartilage a dynamic stiffness of 
7.0 MPa at 1 Hz of cyclic compression has been reported [41]. The dynamic stiffness 
for human articular femoral cartilage at 1 Hz has been reported to be 4.5 MPa [42].  
Therefore our data suggest that the dynamic stiffness of the scaffold design adopted 
for bioassembly in this study are similar to that of articular cartilage.  














Initially, a prototype singularisation and injection system were designed and 
fabricated. After which, we examined and determined the most optimal valve and 
fluid flow timing sequences for the system to allow successful automated assembly. 
Figure 4-7 shows the timing diagram of the valve sequence for a single 
singularisation cycle. This particular valve sequence timing was specific for a 10 cm 
long fluidic tube connecting the singularisation chamber and the hopper tank, a 
positive pressure of 105.7 kPa in the positive pressure tank, a negative pressure of 
93.5 kPa in the negative pressure tank. A feedback control system that assumed 








Release leading micro-tissue 
Singularisation cycle 
Clear leading micro-tissue Agitation Capture leading micro-tissue 
Time 
Figure 4-7. Timing diagram of the valve sequence for a single cycle of 
singularisation. For valve positions see (H) hopper valve, (F1) flush valve 1, (CP) 
capture port pressure valve(CV), capture port vacuum valve, (F2) flush valve 2 and 




kPa, a micro-tissue had been captured at the port, signalling to the control system to 
change the valve sequence from capturing the leading micro-tissue to clearing 
lagging micro-tissues. Varying any of the above parameters would require a 
recalibration of the valve timing sequence. This sequence formed the initial 
framework for the operation of the device.  
4.4.3 Size comparison before and after singularisation 
To understand and scrutinize any physical deformation and mechanical impact 
on micro-tissues after being passed through the singularisation system, micro-
tissues were imaged and measured before and after singularisation. The average 
percentage change in the major and minor diameter of micro-tissues (n=9) 
measured before and after singularisation is listed in Table 4-3. The values 
demonstrated that there was no significant change in micro-tissue size and shape 




Average diameter Percentage change in 
diameter after 
singularisationa Before singularisation After singularisation 
Major diameter 1.04 ± 0.16 mm 1.03 ± 0.16 mm 2.2 ± 2.8% 
Minor diameter 0.99 ± 0.17 mm 0.98 ± 0.15 mm 2.7 ± 3.4% 
 
 
4.4.4 Reliability and efficiency of the singularisation device 
The reliability of the singularisation device was quantified by determining the 
successful singularisation of micro-tissues expressed in terms of efficiency. As 
demonstrated in Table 4-4, the singularisation efficiency for micro-tissues of larger 
sizes (group A) was 97.0 ± 6.6%, whereas it was 86.0 ± 13.8% for the smaller micro-
tissue group (group B). This result indicates that micro-tissues with a diameter 
closer to the upper limit of the device have better singularisation efficiency as long 
as they are not large enough to obstruct and cause a blockage in the singularisation 
chamber. Successful operation of the tissue bioassembly system, therefore, depends 
on the ability to fabricate tightly controlled regular-sized spherical micro-tissues 
a In paired samples.  
b Statistical analysis: paired t-test 
 
Table 4-3. Average diameter of the micro-tissues before and after singularisation 




and our group has previously described a high-throughput approach demonstrating 




Average diameter Singularisation 
 efficiency Major Minor 
Group A 1.14 ± 0.12 mm  1.03 ± 0.18 mm 97.0 ± 6.6%  
Group B 0.95 ± 0.07 mm  0.84 ± 0.06 mm 86.0 ± 13.8%  
 
 
During the experiment, the situations which resulted in singularisation 
failures included: (i) capture of 2 micro-tissue at a time, (ii) failure to trigger the 
capture pressure sensor even when a micro-tissue had been captured, (iii) 
accidental release of micro-tissue upstream rather than downstream, (iv) blocking 
of pressure ports by the micro-tissues, and (v) accidental dislodging of the captured 
micro-tissue. Nevertheless, the determined efficiency of approximately 97% for the 
targeted (group A) micro-tissues was deemed be acceptable for its application in 
tissue assembly. The singularisation failures that occurred were not critical and did 
not cause the failure of the device nor the inability to completely assemble all 
available micro-tissues. For example, in the event of a failure, the singularisation 
cycle could be repeated if the device had failed to release a micro-tissue, or in the 
case of a blockage, the device could be purged with fluid so as to dislodge the blocked 
micro-tissue and clear the bioassembly system after which normal operation was 
resumed. In the case of these failures, however, the overall bioassembly time for the 
entire construct would increase slightly. 
 
The photomicrosensor detection efficiency or the reliability of the 
photomicrosensor to detect a successfully singularised micro-tissue was based on 
the number of successfully detected singularised micro-tissues and this was 
determined to be 96.0 ± 5.2%.  
4.4.5 Viability of micro-tissues 
Significant attention was invested in designing the bioassembly system to 
ensure that the environment within the device was favourable for cell survival and 
 Table 4-4. Efficiency of singularisation.  





that, size or shape of the micro-tissues was not adversely affected. For that reason, a 
fully fluidic approach was adopted for singularisation and delivery of the micro-
tissues. To ascertain that the cells in the micro-tissues were not negatively affected 
during their passage through the device, a live/dead assay was carried out to inspect 
cell viability on the surface of micro-tissues.  In addition, a trypan blue exclusion 





















Fluorescence microscopy images (Figure 4-8) obtained from the live/dead 
assay of the micro-tissues indicated that the cells at the surface of micro-tissues that 
were most prone to mechanical or physical deformation were predominantly viable 
and unaffected by the singularisation and injection process. This was further 
Figure 4-8. Fluorescence microscopy images of (a) control (b) singularised (c) 
injected and (d) singularised and injected micro-tissues stained with Calcein AM 
(live cells, green) and Propidium Iodide (dead cells, red) on day 0. Scale bar = 0.2 mm 













validated by trypan blue exclusion assay (Figure 4-9) indicating no significant 
difference (p>0.05) in percentage of viable cells between the control (80.45 ± 4.77%; 
non-singularised/non-injected micro-tissue) and either singularised (83.45 ± 
3.43%) or injected (78.38 ± 2.37%) or both singularised and injected (83.55 ± 
5.53%) micro-tissues.  This data suggests that the automated bioassembly system 


















4.4.6 Automated tissue assembly 
The ability of the automated tissue bioassembly system to assemble a hybrid 
construct was demonstrated following the validation of the individual bioassembly 
device components. A scaffold consisting of 1 mm fibre spacing was 3D plotted with 
the high-temperature plotting head (see Figure 4-5 a) as described above, and fixed 
HAC micro-tissues stained with Safranin O were inserted into the pores using the 
micro-tissue injection head (Figure 4-5 b). The steps involved in the layer-by-layer 
3D plotting and micro-tissue assembly of a bilayered construct with the aid of the 























Figure 4-9. Percentage of viable cells determined using the Trypan blue exclusion 
assay for control, singulation, injected, and injected and singulated micro-tissues on 
day 0. The data is presented as mean ± SD (n=4). No significant difference (p>0.05). 
























4.4.7 Efficiency of micro-tissue insertion  
The efficiency of successful micro-tissue insertion into the scaffold was 
determined to be 79.2 ± 18.8%. Although there were micro-tissues that failed to be 
inserted into the scaffold, the scaffold was visually inspected by the user for errors 
at the end of assembling every layer and the micro-tissue insertion process was 
repeated for pores not containing a micro-tissue, thereby allowing the complete 
scaffold bioassembly as designed.  
4.4.8 Viability of bioassembled constructs         
After demonstrating that our fully fluidic approach did not damage the micro-
tissues, we had to ascertain that the micro-tissues were not affected by the 
Layer 1 
(a) (b) (c) (d) 













Figure 4-10. (a-h, Scale bar = 1 mm) Top view and sectional front view photographs 
of the steps involved in the layer-by-layer plotting and assembly of a bioassembled 
construct consisting of high-throughout fabricated HAC micro-tissues with the aid of 
the automated system. The construct contains 32 micro-tissues, arranged in 2 layers 
with 16 micro-tissues in each layer. (i) higher magnification image of the assembled 





automated system inserting the micro-tissues within the designated pores of the 
plotted scaffold. The dispensing temperature in the high-temperature print head 
was approximately 200°, although the extruded material rapidly solidifies and cools 
to ambient temperature. Therefore, during the layer-by-layer plotting process, we 
had to ensure that the molten polymer being plotted on the previous layer of 
assembled micro-tissues did not affect cell viability. 
 
The visual inspection of the live/dead fluorescence microscopy images of the 
manually assembled construct (i.e. micro-tissues were press-fit by hand into a 3D 
plotted scaffold) and the construct assembled using the bioassembly system showed 
no obvious differences (Figure 4-11). Furthermore, this observation was validated 
from the AlamarBlue® assay (Figure 4-12), which demonstrated no significant 
difference (p>0.05) in the percentage of AlamarBlue® reduced between the 
manually assembled construct (62.31 ± 4.12%) and construct assembled with the 
















Figure 4-11. Fluorescence microscopy images of (a) manually assembled construct 
and a (b) construct assembled using the bioassembly system stained with Calcein 
AM (live cells, green) and Propidium Iodide (dead cells, red) on day 0. Scale bar = 0.2 
mm for all images. 
(a) (b) 




























Typically, traditional tissue engineering strategies employ a “top-down” 
biofabrication approach, where cells are seeded into a pre-fabricated biomaterial 
scaffold to create an engineered tissue. However, “top-down” approaches with their 
inability to precisely control the spatial distribution of the cells and support material 
have difficulty recreating the intricate microstructural features of tissues [19]. On 
the other hand, “bottom-up” biofabrication approaches or modular tissue 
engineering focus on fabricating engineered tissue by the self-assembly or directed-
assembly of a tissue from smaller components or modules with specific micro-
architectural features [20, 43]. Furthermore, as many tissues are comprised of 
repeating functional units there is a strong biological basis for using bottom-up 
approaches [19] to biofabricate complex hierarchical and functional engineered 




























Figure 4-12. Percentage of AlamarBlue® reduced to determine the viability of the 
manually assembled construct and the construct assembled using the automated 
system on day 0. The data is presented as mean ± SD (n=3). No significant difference 




Modular tissue engineering aims to create biomimetic structures by designing 
modular tissues that can be used as building blocks to create larger tissues [19]. 
These modules can be created via a number of approaches, such as self-assembled 
aggregation [44], micro-fabrication of cell-laden hydrogels [45], creation of cell 
sheets [46], direct printing of cells [47] or via high-throughput pellet or micro-mass 
culture techniques [11] as described herein.  
 
The absence of an automated system that assembles micro-tissue “modules” 
into a bioscaffold to produce an assembled tissue and also the increasing focus on 
tissues engineered cartilage repair makes it essential and highly relevant to have an 
automated assembly system. By successfully testing and establishing a reliable and 
efficient blueprint for such a scheme, we have overcome a barrier to building large 
and complex high quality living constructs of clinically relevant sizes, with precision, 
in large numbers, and with a reduced construction time. 
 
Having an automated system means that tissues based on mathematical 
models or anatomical models generated through non-invasive imaging techniques 
such as computed tomography (CT) or magnetic resonance imaging (MRI) can easily 
be translated into a computer-aided design and computer aided manufacturing 
(CAD/CAM) file and inputted into a bio-plotter [48]. The application of computer-
aided technologies has led to the development of a new emerging field of computer-
aided tissue engineering (CATE) [49]. We believe that we have paved a path that 
employs computer-aided technology to create scaffolds with a wide array of 
properties and geometries, and the system described in this article can be thought 
of as a submodule of a computer-controlled tooling process for assembling tissue via 
computer-aided design models. 
 
The described fluidic based system offer advantages over other methods such 
as laser-based writing or jetting techniques where the cells experience an extreme 
kinematic profile during the cell transfer process [50-52]. Cell-based constructs 
fabricated using cell direct writing techniques also have a downfall in that they lack 
an initial support structure and the maturation of the bioactive tissue must be rapid 
so as to have the necessary structural support [51]. From our studies, the absence of 




through and assembled using our system reflects the gentle nature of the designed 
fluidic system. This gentle nature and the reduced human involvement which 
eliminates human error would encourage end-users to employ the system for their 
application.  
 
Although the described system works efficiently with micro-tissue sizes that 
are within the designed size range, the system has an innate shortcoming in that 
micro-tissues above or below the designed size range cannot be efficiently handled. 
By suitably modifying the size of the singularisation chamber and the injection 
nozzle and expanding rod, the tissue assembly system can be adopted for micro-
tissues of other desired sizes. Alternately, micro-tissue size can be optimised and 
adjusted to fit the device using strategies such as adjusting seeding densities during 
micro-tissue formation. 
 
With the use of parallel singularisation devices rigged up to an injection device, 
this system can potentially be used to assemble micro-tissues of different cell types 
in a specific order. The use of the technology in this fashion would have important 
implications in co-culture systems where two or more cell types are brought 
together in the same culture environment either to enhance tissue formation of a 
specific lineage and/or to form a multicellular tissue or organ replacement [33]. In 
cartilage engineering, this can be applied to chondrocytes and synovial fibroblasts 
[33], chondrocytes and osteoblasts [33], primary and passaged chondrocytes [53], 



























The automated bioassembly could be used to assemble a top-down based 
simple construct where a complete scaffold is prefabricated using 3D plotting, and 
micro-tissues are assembled into the scaffold or a more complex bottom-up or 
hybrid approach involving layer-by-layer fabrication where the scaffold is 3D plotted 
and micro-tissues are co-assembled alternatively to generate complex hierarchical 
constructs. The impact of this would be the ability to create anatomically shaped 
complex hybrid constructs (Figure 4-13).  
 
The bioassembly system can also be applied for micro-tissue based 
applications in other areas. Assembled cancer tissues might play a valuable role in 
translational research in cancer by potentially recreating the natural physical and 
structural environment of living tissues, and the use of a tissue assembly system is a 
natural choice [56]. However, cancer spheroids tend to have a large variation in 
aggregation pattern between different cell types and this would potentially require 
modification of the system to accommodate the assembly of certain types cancer 
spheroids [57].  
 
High-throughput screening (HTS) is another area where the system could be 
used to handle micro-tissues. In HTS, the use of micro-tissues as a 3D cell culture 
Figure 4-13. (a) Illustration of an assembled hemisphere. (b) a hemisphere 
assembled with coloured beads employing the automated tissue bioassembly 
system. This demonstrates possibility of bioassembling a biphasic osteochondral 





system is a better reflection of the in vivo behaviour of most cell types rather than 
monolayer or suspension cultures [58]. HTS in drug testing is frequently carried out 
on small spheroids of up to 200 µm, which is thought to be sufficient to reflect the 
3D cell-cell and cell-matrix interactions [59, 60]. 
 
To allow the efficient handling of the smaller sized micro-tissues in HTS, the 
developed tissue assembly system would have to be a modified for this application. 
However, with miniaturisation of the system, laminar flow, surface tension, diffusion 
and fluidic resistance begin to dominate the system [61] and the handling of micro-
tissues of very small sizes would require a miniaturized microfluidics-based system 
to handle the micro-tissues efficiently, making necessary further research on the 
design and development of a miniaturised system. 
4.6 Conclusions  
We have described here a novel integrated system applied to the automated 3D 
bio-assembly of micro-tissues in 3D plotted scaffolds. The singularisation system 
can effectively deliver a single micro-tissue to the injection system which with the 
aid of the 3D positioning system can deliver the micro-tissue to any desired point in 
the bioscaffold. Our results indicate that the system is efficient and that the micro-
tissues are unaffected by being handled through the singularisation and injection 
systems. No difference in viability was observed in a construct assembly manually 
and with the automated bioassembly system. With the automated bioassembly 
system, simple constructs could be either fabricated via a top-down approach 
involving 3D plotting of a complete scaffold and injection of micro-tissues or a 
flexible bottom-up approach combining layer-by-layer scaffold fabrication and 
micro-tissues co-assembly to generate complex hierarchical constructs. This 
technology paves the way to use an automated system to produce complex 
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Chapter 5 Automated 3D Bioassembly of cell-laden 






Encapsulating chondrocytes in hydrogels is an emerging tissue engineering 
strategy. Hydrogels are appealing as they can mimic the hydrated 3D environment 
in native cartilage. However, controlling the microarchitecture of a hydrogel 
construct is challenging and one of the strategies to overcome this is to exploit 
modular assembly based tissue engineering approaches to fabricate complex hybrid 
constructs. Not many technologies have been developed to automate the precise 
assembly of hydrogel modules into 3D plotted scaffolds. We fabricated GelMA 
microspheres and human articular chondrocyte (HAC)-laden 9.5% GelMA-0.5% 
HepMA hydrogel microspheres of Ø1 mm with a microfluidic device to be used as 
tissue units. Previously, we had developed a fluidic based 3D tissue bioassembly 
system that precisely assembles microspheres into 3D plotted scaffolds for 
fabricating large, complex tissue-engineered constructs. The fabricated 
microspheres were reliably and efficiently handled by the automated bioassembly 
system. Different arrangements of the various coloured (representing different 
microsphere types) microspheres were assembled into 3D plotted scaffolds to 
demonstrate the flexibility of the automated bioassembly system. Layer-by-layer 3D 
Bioassembly of 8 HAC-laden microspheres into a 3D plotted PEGT/PBT polymer 
scaffold with the automated tissue bioassembly system showed no significant 
difference in viability when compared with manually assembled bilayered 
constructs. Individual HAC-laden microspheres and assembled constructs were 
cultured for 5 weeks. Fixed frozen sections were stained for aggrecan and they 
revealed neocartilage formation. Higher aggrecan was visualized in the assembled 
construct compared to the individual microspheres. Furthermore, we demonstrated 
the fabrication of a graduated construct with Qtracker labelled HAC, co-culture (50% 
HAC and 50% mesenchymal stromal cells (MSC)) and MSC laden microspheres and 
the immunofluorescence staining for aggrecan revealed cartilage tissue formation. 
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This technology demonstrates the feasibility of bioassembling large complex 
constructs with hydrogel microspheres. 
5.2 Introduction 
The repair of injured or damaged cartilage is, unfortunately, challenging due to 
its limited ability to heal. It has been acknowledged by the research and medical 
community that tissue engineering and regenerative medicine (TERM) strategies 
could possibly be employed for clinical repair or regeneration of cartilage and 
hopefully be able to overcome the limitations of current repair strategies [1, 2]. The 
tissue engineering paradigm, the rational for tissue engineering of cartilage and the 
need for developing an automated system, has been discussed earlier (chapter 4), 
but an outline with respect to hydrogels is explained here.  
 
Biofabrication of a cartilage construct containing pre-formed high cell density 
micro-tissues has shown promising outcomes with respect to chondrogenic 
capacity, extracellular matrix (ECM) formation and tissue fusion during in vitro 
culture [3]. Creating a cartilage construct of clinically relevant size with micro-
tissues requires substantial cell expansion thereby making it expensive. Assuming a 
single 1 mm diameter micro-tissue contains 0.25 million cells, merely fabricating a 
clinically relevant sized construct of Ø25 mm and 2.4 mm thickness with micro-
tissues would require approximately 247 million cells [3-5]. Moreover, chondrocytes 
have a limited proliferative potential and when autologous cells are cultured in a 
monolayer, they dedifferentiate and lose their chondrogenic phenotype [6].  
 
An alternative route to fabricating micro-tissues would be to encapsulate 
chondrocytes or chondroprogenitor cells (mesenchymal stromal cells (MSCs)) 
within hydrogel microspheres. Hydrogels are appealing as fabricating a tissue 
construct with a hydrogel requires a lesser number of cells compared to a micro-
tissue based construct of the same size [3, 7, 8]. Moreover, hydrogels can promote 
cell survival and imitate the features of natural cartilage including providing a 
hydrated 3D environment [9]. A wide range of hydrogel systems such alginate [10], 
agarose [11], collagen [12], fibrin [13], poly(ethylene glycol) (PEG) [14], 
poly(ethylene oxide) (PEO)[15] and poly(vinyl alcohol) (PVA) [16] hydrogels have 
been researched for cartilage engineering. We chose gelatin-methacryloyl (GelMA) 
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which is a functionalised gelatin that allows for the irreversible covalent crosslinking 
as it has been shown to support cartilage formation and can be photocrosslinked 
with visible light making it less detrimental to cells [8, 17, 18]. GelMA is also 
appealing as it is inexpensive, is water soluble, contain cell binding motifs, can be 
derived from a wide variety of sources, is biocompatible, can be easily processed and 
its stiffness can be modulated [19, 20]. Moreover, GelMA based hydrogels can also 
be functionalised with cartilage specific matrix compounds like hyaluronic acid [8, 
21], chondroitin sulphate [21] and can also be incorporated with bioactive 
molecules like TGF-β1 [15, 22] to promote cartilage formation. 
 
Populating cells in a scaffold is the conventional tissue engineering paradigm 
for regenerative medicine strategies [23-26]. Hydrogel constructs are typically 
fabricated via casting approaches in a mould ultimately to be utilised for minimally 
invasive delivery of reparative cells [26]. A disadvantage of this approach is the 
limited ability to directly control the exact location or 3D spatial resolution of cells, 
multiple cell types and/or ECM components [27]. Current biofabrication or 3D 
Bioprinting strategies offer an alternative solution via top-down dispensing of  
multiple bioinks to fabricate complex layers of cell-laden hydrogel fibres, with each 
bioink comprising of multiple cell sources or combinations of ECM components, 
dispersed around 3D plotted structural thermoplastic biomaterial scaffolds to 
provide mechanical integrity to the hybrid construct [28, 29]. On the other hand, 
modular assembly based bottom-up approaches may allow the biofabrication of 
large constructs of complex geometry with specific cellular arrangement and 
microarchitectural features [23, 30]. In modular assembly based bottom-up 
strategies, larger macro-scale tissues are assembled using smaller tissue units [27]. 
A range of tissue module types can be fabricated for tissue assembly and these 
include cell sheets [31, 32], micro-tissues (which we have previously utilised for the 
demonstration of an assembled cartilage construct (Chapter 4)) or cellular 
aggregates [3, 33-36], cell-laden microgels [37, 38], tissue-rings [39] or cell-laden 
hydrogel microspheres [40]. A modular hydrogel system would enable the 
fabrication of large constructs of complex architecture. The approach would enable 
the assembly of zonal constructs with different zonal subpopulations thereby 
recreating the zonal arrangement of native articular cartilage [7, 35]. Bioassembly 
of an osteochondral construct assembled with chondrocytes and osteoprogenitor 
119 
 
cells would be possible [36]. This bioassembly technique could also be used to 
fabricate constructs with a gradient or different cell types, bioactive molecules, 
mechanical properties, hydrogel types or varying cell densities [7, 37]. The 
advantage of the bioassembly technique would be that it would allow the automated 
and controlled fabrication of functional engineered tissues which mimics the native 
tissue architecture and mechanical properties.   
 
Substantial work has been performed on the development of biofabrication 
techniques to control the architecture of an engineered construct. 3D plotting of cell-
laden photocurable bioinks for application in cartilage tissue engineering has been 
demonstrated by Costantini et al. and Lim et al. [18, 41]. Boere et al. engineered a 
hybrid 3D plotted cartilage constructs with improved mechanical properties by 
reinforcing the hydrogel with a 3D plotted thermoplastic [42]. Vissers et al. 
demonstrated the fabrication of a composite hydrogel construct mechanically 
reinforced with thermoplastic using melt electrospinning writing [43]. Specifically, 
with regards to bioassembly, the utilisation of hydrogel subunits or modules to 
assemble larger tissue structures have been demonstrated for cardiac tissue 
engineering [44], bone tissue engineering [45], vascularisation in a construct [46] 
and for general application in tissue engineering [37, 38]. Ozbolat et al. developed a 
system in which cell-laden alginate scaffold was 3D plotted with a co-axial nozzle 
and cell-laden alginate spheres that formed at the tip of the dispensing nozzle were 
deposited into the scaffold [47]. The arrangement of cell-laden microgels in specific 
configurations using a micromanipulator has also been shown [48]. As far as we 
know, there exists no fabrication technique or technology where cell-laden hydrogel 
microspheres can be assembled into a 3D plotted thermoplastic polymer scaffold to 
create a custom cartilage or musculoskeletal construct of complex architecture.  
 
We have previously developed a prototype automated tissue bioassembly 
system that can precisely assemble tissue units into a 3D plotted scaffold using a 
bottom-up approach based on the simultaneous layer-by-layer scaffold and micro-
tissue assembly strategy. The developed 3D Bioassembly system was capable of 
fabricating (i) simple constructs using top-down bioassembly strategy which is a 
two-step strategy involving the 3D plotting of a scaffold and the assembly of tissue 
units into the desired location in the scaffold, and (ii) hybrid constructs using a 
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bottom-up bioassembly strategy which is a multistep strategy involving the 
alternative 3D plotting and assembly of tissue units into the scaffold to generate the 
hybrid construct (see Chapter 4). The bioassembly of a hydrogel based construct 
requires the fabrication of hydrogel microsphere module or units. To fabricate the 
hydrogel microsphere modules or units, a diverse range of techniques including 
electrospraying [49], polyelectrolyte complexation [50], solvent evaporation [51], jet 
cutting [52], jet breakup [53], and electrostatic droplet generation [54] exist. We 
utilised a simple droplet microfluidic setup coupled with photopolymerisation [55]. 
This setup was adapted from Serra et al. as its ability to produce microspheres 
within a controlled size range with minimum variation was previously 
demonstrated [40, 55]. The commonly reported method of photopolymerising 
GelMA has been combining the photoinitiator, Irgacure 2959 with UV light 
irradiation [19, 56, 57]. However, UV light has been shown to be detrimental to cell 
cytocompatibility as it can cause chromosomal and genetic instability [20, 58]. Our 
group has previously developed a visible light based photopolymerisation system 
that showed an improved cytocompatibility and viability, which was adapted herein 
[18]. 
 
The specific objective of this study was the development and validation of an 
automated 3D Bioassembly of cell-laden hydrogel microspheres for biofabricating a 
tissue engineered cartilage construct. This involved (i) adopting a high-throughput 
microfluidic system to fabricate Ø1 mm cell-laden hydrogel microspheres that can 
be handled by the automated bioassembly system, (ii) validating the flexibility of the 
automated tissue bioassembly system by demonstrating different arrangements of 
the microspheres in a scaffold, (iii) demonstrating the ability to bioassemble cell-
laden hydrogel microspheres and fabricate a complex 3D construct utilising 
automated tissue bioassembly system without affecting the viability, (iv) assessing 
tissue formation in vitro in HAC-laden GelMA-HepMA hydrogels in individual 
microspheres and in 3D bioassembled constructs cultured in vitro (v) and 
demonstrating the fabrication of a complex 3D gradient construct containing HAC, 





5.3.1 Chondrocytes and mesenchymal stromal cells (MSCs) isolation  
Human articular chondrocytes (HACs) were isolated and expanded using the 
method described previously by Schon et al. [3]. Briefly, articular cartilage biopsies 
were obtained with ethics approval from consenting patients undergoing cruciate 
(knee) ligament reconstruction (n=2, 18, 25 years of age). The cartilage was diced 
into cubes sized around 1 mm and digested overnight in basic chondrocyte media 
containing DMEM (high glucose, GlutaMAX Supplement, pyruvate; GIBCO, USA) with 
10% foetal bovine serum (FBS; GIBCO, New Zealand), 0.1 mM non-essential amino 
acids (NEAA; GIBCO, USA), 10 mM HEPES (GIBCO, Taiwan), 0.2 mM L-ascorbic acid-
2-phosphate (Sigma-Aldrich, USA), 0.4 mM L-proline (Sigma-Aldrich, USA), 100 
units/mL penicillin (GIBCO, USA) and 100 μg/mL streptomycin (GIBCO, USA) and 
along with 0.15% (w/v) collagenase type II (Worthington, USA). The suspension was 
then filtered through a 100 μm pore cell strainer (Corning, USA) and centrifuged at 
700 g for 4 minutes.  
 
Human mesenchymal stromal cells (MSCs) were obtained from an iliac crest 
bone marrow aspirate. The aspirate was obtained from a healthy donor (n=1, 33 
years of age) undergoing upper limb procedure where an iliac crest bone graft was 
required. The MSCs were isolated from the bone marrow aspirate by plastic 
adhesion. The bone marrow aspirates were diluted 1:4 in basic MSC media 
containing MEM Alpha (GlutaMAX Supplement; GIBCO, USA) with 10% FBS, 100 
units/mL penicillin, 100 μg/mL streptomycin, and 1 ng/mL basic Fibroblast growth 
factor (bFGF; R&D systems, USA) and then plated into a tissue culture flask. The next 
day, the flasks were washed with PBS to remove any non-adherent cells and fresh 
basic MSC media was added. 
5.3.2 Cell expansion  
Freshly isolated HACs were seeded at a density of 3,000 cells/cm2 in tissue 
culture flasks (Falcon, USA) in basic chondrocyte media. Cells were expanded at 37°C 
in a humidified 5% CO2/95% air incubator and the media was changed twice a week. 
After approximately 7 days, subconfluent first passage cells (P1) were washed with 
phosphate-buffered saline (PBS; GIBCO, USA), detached using 0.25% trypsin/EDTA 
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(Gibco, Canada), counted by trypan blue exclusion (GIBCO, USA) in a 
haemocytometer and plated in a tissue culture flask at 3,000 cells/cm2. The third 
passage (P3) cells were harvested similarly, suspended in basic chondrocyte media 
and made ready to be encapsulated. 
 
The MSCs were seeded at a density of 5,000 cells/cm2 and expanded similarly 
to HACs but with basic MSC media.  
5.3.3 Cell labelling with Qtracker 
Qtracker cell labelling kit (Life technologies, USA) was used to track cells in a 
co-culture environment. HACs were labelled with Qtracker 655 and MSCs with 
Qtracker 800. To label the cells with Qtracker, cells were concentrated to 10 x 106 
cells/ml by centrifugation at 700 g for 5 minutes and resuspended in DMEM. A 10 
nM labelling solution was prepared by mixing 1 µL of the Qtracker Component A and 
1 µL of the Qtracker Component B in a 1.5 ml microcentrifuge tube and incubated at 
room temperature for 5 minutes. 0.2 ml of DMEM was added to the mixture and 
vortexed for 30 seconds. 106 cells were added to the labelling mixture and incubated 
for 60 minutes. The cells were subsequently washed twice with DMEM and re-
suspended in basic chondrocyte media for use.  
5.3.4 Synthesis of gelatin-methacryloyl (GelMA) and methacrylated 
heparin (HepMA) 
Gelatin (porcine skin, type A, 300g Bloom strength) (Sigma-Aldrich, USA) was 
dissolved in phosphate-buffered saline (PBS; GIBCO, USA) at a 10 wt% 
concentration. 0.6 g of methacrylic anhydride (Sigma-Aldrich, USA) per gram of 
gelatin was added to the gelatin solution, and left to react for 1 h at 50˚C under 
constant stirring [59], followed by dialysis against deionised water to remove 
unreacted methacrylic anhydride. The purified GelMA solution was filtered through 
a 0.2 µm sterile filter (Ahlstrom, Germany), then lyophilised under sterile conditions. 
The degree of methacryloyl substitution was quantified to be 60% (data not shown) 





Methacrylated heparin (HepMA) was synthesized based on methods described 
by Smeds et al. [60]. Heparin sodium salt (porcine intestinal mucosa, grade I-A) 
(Sigma-Aldrich, USA) was dissolved in PBS at a 1 wt% concentration. Methacrylate 
anhydride was added 10-fold molar excess over primary amine and hydroxyl groups. 
The reaction mixture was kept at 4˚C under constant stirring while repeatedly 
adjusting the pH to 8 for 24 hours. The remaining steps were carried out similar to 
GelMA.  
5.3.5 Micro-fluidic device  
Figure 5-1 shows the schematic of the microfluidic system. The system was 
adapted from the setup described by Serra et al. [55]. The micro-fluidic system 
consisted of fused silica capillary, T-junction and Tygon tubing. The T-junction was 
fabricated from Perspex using conventional machining techniques. A fused silica 
capillary (PostNova, Germany) with an ID x OD 530 x 660 μm was inserted into the 
T-junction along its horizontal axis. The tip of the fused silica capillary was 
positioned so that it exited from the T-junction at the centre of the outlet Tygon 
tubing ID x OD 1.6 x 3.2 mm. Two syringe pumps (New Era, USA) were used to deliver 
the continuous and dispersed phases at a specific flow rate. The dispersed phase was 
injected via the fused silica capillary while the continuous phase was injected 
through the horizontal port of the T-junction. Tygon tubing connected the syringes 
(BD Biosciences, USA) through a gauge-16 needle (BD Biosciences, USA) to the ports 
of the T-junction. The output port of the microfluidic system was connected to a long 
coil of transparent Tygon tubing which was positioned under the light source fitted 
with a collimator to crosslink the formed microspheres under the light. The length 
of the coil was so that each microsphere was exposed to the light source for 2 
minutes. The syringe containing the macromer (the pre-polymerised monomers) 
and the inlet tubing to the T-junction was wrapped in aluminium foil to prevent 






























Figure 5-1. (a) Schematic of the arrangement of the microfluidic system to form 
microspheres and (b) a magnified schematic of the T-junction, adapted from Serra 
et al.  [55]. 
 
5.3.6 Fabrication of cell-free GelMA hydrogel microspheres 
To fabricate the cell-free GelMA hydrogel microspheres, dried sterile GelMA (5 
wt% and 10 wt%) was dissolved in PBS at 37˚C and left to cool overnight at room 
temperature. A visible light system was chosen to crosslink the microspheres as UV 
light can be detrimental to the cells compared to visible light [18]. Prior to 
crosslinking, 0.2 mM tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate (Ru; 
Sigma-Aldrich, USA) and 2mM sodium persulfate (SPS; Sigma-Aldrich, USA) was 
added to the GelMA solution and the solution was loaded into the syringe. Food 
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grade sunflower oil was used as the continuous phase and the GelMA solution 
containing the photoinitiator made up the dispersed phase. For the continuous oil 
phase, the flow rate was set to 1 ml/minute and the dispersed gel phase it was set to 
40 μl/min to fabricate Ø1 mm microspheres, based on previous work by Young et al. 
[61] The formed microspheres were then irradiated with visible light (OmniCure® 
S1500, Excelitas Technologies). The light was irradiated through a light filter (Rosco 
IR/UV filter) where only light of 400 – 450 nm wavelength was allowed to pass 
through with a final intensity of 100 mW/cm2. The light intensity and exposure time 
were selected based on previous work by Lim et al. [18]. The formed microspheres 
were collected in polypropylene (Falcon, USA) centrifuge tubes containing PBS. To 
separate the oil from the microspheres, the centrifuge tube was centrifuged at 0.1 g 
for 5 minutes. The oil was then aspirated and the pellet of microspheres in PBS was 
collected using a Pasteur pipette. The microspheres were then resuspended in fresh 
PBS and the washing step was repeated.  
5.3.7 Cell encapsulation in GelMA-HepMA hydrogel microspheres 
The prepared chondrocyte suspension was added to the 9.5% wt GelMA-0.5% 
wt HepMA macromer solution containing sterile filtered initiators to give a final 
concentration of 15 x 106 HACs/ml. The cell encapsulated microspheres were then 
fabricated and visible light crosslinked as outlined previously. Each microsphere was 
transferred to well in a 96-well polystyrene plate (Falcon, USA). 150 μL of serum-
free basic chondrocyte media that was supplemented with 1% ITS+1 (1 mg/ml 
insulin from bovine pancreas, 0.55 mg/ml human transferrin, 0.5 μg/ml sodium 
selenite, 50 mg/ml bovine serum albumin and 470 μg/ml linoleic acid; Sigma-
Aldrich, USA), 0.1 x 10-6 M dexamethasone (Sigma-Aldrich, USA), 1.25 mg/ml bovine 
serum albumin (GIBCO, New Zealand) and 10 ng/ml recombinant human 
transforming growth factor-β1 (TGF-β1; R&D systems, USA) was then pipetted into 
the wells and placed in an incubator at 37°C, 5% of CO2. During the microsphere 
culture period, the media was changed 2 times per week.  
 
Cell-free 9.5% GelMA-0.5% HepMA and Qtracker labelled HAC, MSC and co-




5.3.8 Characterisation of microspheres  
The size distribution of the fabricated microspheres was determined by 
measuring the size of the microspheres for the cell-free 5% and 10% GelMA 
microspheres and the HAC-laden 9.5% GelMA-0.5% HepMA microspheres. 
Fabricated microspheres (n=50) were stained with Coomassie brilliant blue 
(Thermo Fisher Scientific, USA) for 15 minutes and were imaged using the Zeiss 
Axioimager Z1 microscope. The major and minor diameters were measured using 
the particle analysis function in ImageJ. The average of the major and minor 
diameter was calculated and normal distribution of the average diameter was 
plotted. The coefficient of variation was tabulated to gauge the microsphere size 
distribution.  
 
The DNA content of the HAC-laden 9.5% GelMA-0.5% HepMA microspheres 
(n=4, 8 microspheres/sample) were quantified using a CyQUANT kit (Molecular 
Probes, USA) on Day 0. The samples were first digested overnight at 56˚C in 500 µL 
of 1 mg/ml proteinase-K (Sigma-Aldrich, USA) solution. Post proteinase-K digestion, 
the cells in the sample were lysed and the RNA was degraded by using the provided 
lysis buffer with RNase A (1.35 KU/ml; Thermo Fisher Scientific, Lithuania) for an 
hour at room temperature. Samples were pipetted into  96-well white polypropylene 
plates (Nunc, Denmark) and GR-dye solution was added. The plate was then 
incubated at room temperature for 60 minutes in the dark and fluorescence was 
measured (Fluostar Galaxy BMG Labtechnology, Germany). A DNA standard curve 
was constructed using the λ-DNA provided in the kit and a cell standard curve was 
constructed using HACs to determine the cell number. 
 
The theoretical value (theoretical cell numbermicrosphere) of the number of cells 
encapsulated per microsphere for day 0 was calculated by calculating the volume 
(Vmicrosphere) of the microsphere (dmicrosphere) and then calculating the number of cells 
in that volume when the concentration of cells in the solution is 15 x 106 cells/mL 
(cell concentration). The theoretical cell numbermicrosphere was calculated using 











𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 = 𝑉𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒  𝑥 𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
5.3.9 Reliability and efficiency of the singularisation device with the 
microspheres 
To determine the reliability of the singularisation device with the 
microspheres, cell-free 5% and 10% GelMA microspheres and HAC-laden 9.5% 
GelMA-0.5% HepMA microspheres were put through the device. The microspheres 
were put into the singularisation device in sets of 10 and repeated 10 times, with the 
success or failure in singularisation being noted. The total number of successful 
singularisation was used to determine the overall efficiency of the singularisation 




𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛 
𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛
× 100 
 
5.3.10 Scaffold fabrication  
Biodegradable poly(ethylene glycol)-terephthalate-poly(butylene 
terephthalate) block copolymers (Polyactive 300PEGT55PBT45, PolyVation, The 
Netherlands) with  a PEG molecular weight (MW) of 300 g/mol and a PEGT:PBT 
weight percent (wt%) ratio of 55:45 were used to fabricate scaffolds with a specific 
pore size and architecture. PEGT/PBT copolymer composition was selected as a 
model scaffold based on previous studies demonstrating applicability across 
multiple processing techniques (e.g. melt extrusion), mechanical properties 
mimicking native tissue, as well as the capacity to modulate cell, adhesion, 
proliferation, differentiation and extracellular matrix formation [3, 62-67]. Porous 
scaffolds (25 × 25 × 2.64 mm), with accurately defined and controlled pore 
architecture for microsphere incorporation, were 3D plotted using a Bioscaffolder 
system (SYS ENG, Germany). Fibres were oriented in a repeating 0-90°-90°-0° 
pattern in order to provide porosity in both the x-y and x-z planes for assembly of 1 
mm diameter microspheres. During the melt dispensing process the following 3D 
plotting parameters were applied: (i) fibre spacing of 1 mm in both x and y-direction, 
(ii) fibre height offset of 0.22 mm, (iii) print head reservoir containing the polymer 







RPM and (v) print head fitted with a 25 gauge nozzle moving with a traverse speed 
of 500 mm/min.  
5.3.11 Automated tissue assembly with microspheres 
The automated assembly of a tissue construct with microspheres was 
demonstrated by 3D plotting a scaffold utilising a high-temperature print head 
containing Polyactive 300PEGT55PBT45 and then inserting microspheres using the 
microsphere injection head. To 3D plot the assembled construct a layer-by-layer 
approach was opted so as to not limit the height of the scaffold that can be 
constructed using the system. In this scheme, the first layer of the scaffold (8 layers 
of fibre strands) was 3D plotted (as described earlier) and then 16 (4 x 4 fashion) 
fixed microspheres were inserted into the pores of the 3D plotted scaffold. The 3D 
plotting was repeated on top of the first layer to generate the second layer of the 
scaffold (8 layers of fibre strands) and then 16 more microspheres were inserted 
into the second layer.  
 
Microspheres of different colours (which represented microspheres of 
different cell types, hydrogel types or microspheres containing different types of 
bioactive molecules), were inserted into specific locations in an alternating and 
concentric pattern in a single-layered scaffold similarly as described above. 
Microspheres of a particular colour were loaded into the microsphere injection 
head, the program containing the G code with the specific locations of where the 
microspheres were to be inserted was executed and the microspheres were inserted 
within the 3D plotted scaffold. Subsequently, the other coloured microspheres were 
similarly assembled.   
 
To validate the viability of the assembled constructs, HAC-laden 9.5% GelMA-
0.5% HepMA microspheres were assembled. Utilising a layer-by-layer approach as 
described above, the automated tissue assembly system was used to create a 2 
layered construct with 8 microspheres per layer (4 x 4 fashion). For the manually 
assembled scaffold, the whole scaffold was 3D plotted at once and the microspheres 
were inserted manually by hand into the pre-plotted scaffolds in a similar format to 
the ones assembled with the automated system. The constructs assembled with the 
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automated tissue assembly system and the manually assembled construct were 
compared with the live/dead assay and AlamarBlue® assay. 
 
For the live/dead assay, the samples were incubated at 37°C in 0.5 ml of PBS 
with 1 μM Calcein AM (Molecular Probes, USA) for 15 minutes. 1 μM Propidium 
Iodide (Molecular Probes, USA) was then added and the samples were incubated for 
10 more minutes. After this, the samples were washed twice with PBS and a z-stack 
of the sample was imaged using the Zeiss Axioimager Z1 microscope (FITC and Texas 
Red filter-set). 
 
For the AlamarBlue® assay, AlamarBlue® (Invitrogen, USA) was added to the 
media containing FBS so that the final concentration was 10% (v/v) and the samples 
were incubated at 37°C for 20 hours.  The reduction in AlamarBlue® reagent was 
calculated colorimetrically using the equations provided by the manufacturer after 
measuring the absorbance at 570 nm, using 600 nm as a reference wavelength 
(Fluostar Galaxy BMG Labtechnology, Germany). 
5.3.12 Efficiency of microsphere insertion 
A bilayered scaffold (n=8 scaffolds, n=64 microspheres) was assembled with 4 
microspheres in each layer using the layer-by-layer approach described earlier. The 
efficiency of microsphere insertion into the scaffold was determined by the number 
of successful microsphere insertion into the scaffold pore to the total attempted 
number of microsphere insertion with the automated system (equation 5-4). 
 
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛
=  
𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛  
𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛 
× 100 
 
5.3.13 Glycosaminoglycan (GAG) and DNA quantification 
After 1 day of fabricating the HAC-laden 9.5% GelMA-0.5% HepMA 
microspheres, the microspheres were assembled into a 3D plotted scaffold. The 
bilayered scaffold contained 8 microspheres in total with 4 microspheres in each 
layer in a 2 x 2 manner. The HAC-laden individual microspheres and assembled 




samples were sectioned for histology and immunofluorescence. Live/dead assay 
was also performed on the samples as described earlier after 1, 14 and 35 days of 
culture.  
 
The GAG and DNA content for individual HAC-laden 9.5% GelMA-0.5% HepMA 
microspheres (8 individually cultured microspheres were pooled together to make 
one sample) and HAC-laden 9.5% GelMA-0.5% HepMA assembled constructs (8 
microspheres per sample) were measured as described previously [3, 68] on day 0, 
14 and 35. The samples were digested overnight at 56˚C in 500 µL of 1 mg/ml 
proteinase-K solution to digest the cells, matrix and the hydrogel. The DNA in the 
samples were quantified as described earlier.  
 
To quantify the total GAG retained in the gel, the digested samples were reacted 
with dimethyl-methylene blue dye (DMMB; Sigma-Aldrich). The absorbance of the 
samples was then measured on a plate reader at 520 nm (Fluostar Galaxy BMG 
Labtechnology). GAG content was calculated from a standard curve constructed 
using known concentrations of chondroitin sulphate B (Sigma-Aldrich). The 
normalised GAG was calculated using (equation 5-5). 
 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐺𝐴𝐺 =  𝑠𝑎𝑚𝑝𝑙𝑒 𝐺𝐴𝐺 − 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑒𝑙𝑙𝑠 𝐺𝐴𝐺  
 
The GAG and DNA values for the assembled construct on day 0 was considered 
to be same as the individual microspheres. The normalised GAG, DNA and 
(normalised GAG)/DNA values were all calculated and plotted per microsphere so 
that the values of the individual microspheres could be compared with the 
assembled construct. 
5.3.14 Histology and immunofluorescence 
The cultured HAC-laden 9.5% GelMA-0.5% HepMA microspheres and HAC-
laden 9.5% GelMA-0.5% HepMA assembled constructs were washed in PBS, fixed in 
10% neutral buffered formalin for an hour, washed in PBS again and then immersed 
in OCT (Ted Pella, Inc. USA) overnight at 4˚C. The samples were then embedded in 





For safranin O staining, the slides were stained with Gill’s haematoxylin 
(Merck, Germany) and 0.001% (w/v) Fast Green solution (Sigma-Aldrich, USA) for 
cells and collagens respectively, and with 0.1% (w/v) safranin O (Sigma-Aldrich, 
USA), for sulphated glycosaminoglycans as described previously [3, 68]. The stained 
sections were imaged using a Zeiss Axioimager Z1 microscope. 
 
For immunofluorescence, the slides with the sections were rinsed with cold 
PBS thoroughly and were incubated in 0.1% (w/v) hyaluronidase (Sigma, USA) in 
PBS for 30 minutes for antigen retrieval. The sections were rinsed with cold PBS and 
were exposed to 2% (w/v) BSA in PBS at a pH 7.4 for 60 minutes at room 
temperature. They were then rinsed with cold PBS and incubated with rabbit 
polyclonal anti-collagen I antibody (1:150 dilution; ab34710, abcam, USA) and 
mouse monoclonal anti-chicken collagen II antibody (1:150 dilution; II-II6B3; DSHB, 
USA), and mouse monoclonal anti-human aggrecan (1:200 dilution; 969D4D11, 
Invitrogen, USA) anti-bodies at 4˚C overnight. The sections were washed in PBS and 
were incubated with secondary antibodies, goat Alexa Fluor 488 anti-mouse (1:400 
dilution; Thermo Fisher Scientific, USA) and goat Alexa Fluor 555 anti-rabbit (1:400 
dilution; abcam, USA) at 37˚C for an hour. Following further washing, the sections 
were counterstained with 4.5µM Hoechst 33342 (Invitrogen, USA) in PBS. Finally, 
the slides were washed with 0.05% Tween-20 (Sigma-Aldrich, USA) in cold PBS, 
rinsed in PBS and then coverslipped. The samples were imaged using a Zeiss 
Axioimager Z1 microscope (DAPI, FITC and Texas Red filter-set).  
5.3.15 Graduated construct assembly   
After 1 day of forming the Qtracker labelled HAC, MSC and co-culture (50:50 
HAC:MSC) 9.5% GelMA-0.5% HepMA microspheres, the microspheres were 
assembled into a 3D plotted scaffold. The bilayered co-culture graduated assembled 
construct contained 12 microspheres in each layer in a 4 x 3 manner with 4 
microspheres of each cell type. The samples were cultured up to 35 days and the 




5.3.16 Statistical analysis 
Data was presented graphically as mean ± standard deviation. Data were 
analysed using GraphPad Prism v.6.0. Statistical analysis was performed using 1-way 
ANOVA or 2-way ANOVA (if required Tukey's multiple comparisons test) or paired t-
test, with p<0.05 set as a criterion for statistical significance. 
5.4 Results 
5.4.1 Microsphere fabrication 
The reliable and efficient operation of the current automated bioassembly 
system requires microspheres of Ø1 mm as a model tissue unit of regular size and 
shape. This subsection describes the setup of the microfluidic system to fabricate Ø1 
mm sized microspheres with the desired requirements.  
5.4.1.1 Fabrication of GelMA microsphere hydrogels 
With the microfluidic system setup, and with the right flowrates for the 
continuous oil phase and the dispersed hydrogel phase, it was possible to generate 
GelMA based microspheres. A higher flow rate of the dispersed gel phase resulted in 
jetting of the dispersed phase. The droplet formation was characterised by the 
development of a droplet at the tip of the fused silica capillary (Figure 5-2 a), 
elongation of the neck to which the droplet is attached to the tip of the capillary 
(Figure 5-2 b) and the detachment of the droplet from the tip of the capillary (Figure 
5-2 c). The detached droplet then flows downstream through the coil where they are 
irradiated with light to be crosslinked and then collected. Cell-free 5% and 10% 
GelMA microspheres and cell-laden 9.5% GelMA-0.5% HepMA microspheres were 
fabricated using the system. Figure 5-2 (e and f) shows an image of the cell-free 10% 
GelMA microspheres and Figure 5-2 g shows an image of HAC-laden 9.5% GelMA-

































5.4.1.2 Characterisation of microspheres  
Cell-free 5% and 10% GelMA hydrogel microspheres and cell-laden 9.5% 
GelMA-0.5% HepMA microspheres were successfully fabricated with the micro-
fluidic system. The size distribution of the microspheres is plotted in Figure 5-3. 
There was a significant difference (p<0.05) in the average diameter (Table 5-1) 
between all conditions. The cell-free 10% (1.294 ± 0.052 mm) GelMA microspheres 
(a) t=0s (b) t=0.25s 
(c) t=0.5s (d) t=0.75s 
(e) (f) (g) 
Figure 5-2. Snapshots (a, b, c, and d, scale bar = 1 mm) of microsphere generation 
using sunflower oil which is the continuous oil phase flowing at a flow rate of 1 
ml/minute and 10% GelMA which is the dispersed gel phase flowing at flowrate of 
40 μl/min. The fused silica capillary (yellow) is upstream and the droplet exits 
downstream. Brightfield microscope image of (e and f) coloured cell-free 10% GelMA 
microspheres and (g) HAC-laden 9.5% GelMA-0.5% HepMA microspheres (stained 
with Coomassie brilliant blue). Microspheres can be seen to have a uniform size and 
a smooth and regular morphology. 
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had a larger average diameter than the cell-free 5% (1.193 ± 0.070 mm) 
microspheres and the HAC-laden 9.5% GelMA-0.5% HepMA microspheres (0.955 ± 
0.031 mm) had the smallest average diameter. For a constant flow rate of the 
dispersed phase and continues phase, the viscosity, surface tension and density of 
the dispersed phase could affect the size of the microsphere [69, 70]. The different 
macromer concentrations, the presence of HepMA, and the presence of cells could 
all contribute to the difference in viscosity, surface tension and density of the 
dispersed phase thereby affecting the size of the fabricated microspheres. The 
coefficient of variation (Table 5-1) tells us that the dispersion in microsphere size is 
quite low. This uniformity of the microsphere was critical and essential for the 
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Figure 5-3. Size (average diameter of the microspheres) distribution curves of 
(a) cell-free 5% GelMA, (b) cell-free 10% GelMA, and (c) HAC-laden 9.5% GelMA-







Cell-free   
5% GelMA 
Cell-free  
10% GelMA  
HAC-laden 
9.5% GelMA-0.5% HepMA 
Average diameter (mm) 1.193 ± 0.070   1.294 ± 0.052 
 
0.955 ± 0. 031 




After fabricating the HAC-laden 9.5% GelMA-0.5% HepMA microspheres, the 
number of cells per microsphere (Table 5-2) was determined. The determined value 
of cells per microsphere was significantly higher (p<0.05) compared to the expected 
or theoretical value. The coefficient of variation shows that the variation in the cells 






5.4.2 3D Bioassembly of microspheres 
In this subsection, the ability of the automated tissue assembly system to 
handle the microspheres was investigated. After which, the flexibility of the 
automated tissue assembly system was demonstrated by assembling microspheres 
of different colours (the different colours representing microspheres of different cell 
types, hydrogel types or microspheres containing different types of bioactive 
molecules) into a construct. Constructs were also assembled with cell-laden 
hydrogel microspheres to demonstrate that the automated bioassembly system does 
not affect the viability of the assembled construct.  
Cells 
HAC-laden  
9.5% GelMA-0.5% HepMA Theoretical 
Cells per microsphere 10337 ± 1019 7853.99 
Coefficient of variation 0.099 - 
a Distribution plotted in Figure 5-3. 
b n=50  




Table 5-1. Average diameter and coefficient of variation for microspheres 
fabricated with different conditions. 
a n=4 
b Significant difference (p<0.05) between HAC-laden 9.5% GelMA-0.5% HepMA microsphere and the 
theoretical value. 
c Theoretical value is the calculated number of cells for a microsphere of Ø1 mm formed with 








5.4.2.1 Reliability and efficiency of the singularisation device with the 
microspheres 
The efficiency of singularisation (n=100) determined for microspheres is listed 
in Table 5-3. The HAC-laden 9.5% GelMA-0.5% HepMA microspheres had a 
significantly higher (p<0.05) singularisation efficiency compared to the cell-free 5% 
GelMA microspheres. However, there was no significant difference (p>0.05) in 
singularisation efficiency between the cell-free 5% and 10% GelMA microspheres or 
the cell-free 10% GelMA microspheres and the HAC-laden 9.5% GelMA-0.5 HepMA 
microspheres. The higher efficiency of the HAC-laden 9.5% GelMA-0.5 HepMA 
microspheres compared to the cell-free 5% GelMA microspheres could possibly be 
due to two reasons. Firstly, the higher stiffness of the HAC-laden 9.5% GelMA-0.5% 
HepMA microspheres caused by a higher macromer concentration could have 
resulted in the better handling of the microspheres by the automated tissue 
assembly system. Secondly, as the average diameter of HAC-laden 9.5% GelMA-0.5% 
HepMA microspheres was closer to 1 mm (the diameter for which the automated 
tissue assembly system was designed for) compared to the cell-free 5% GelMA 
microspheres, this could also have contributed to the better handling of the 
microspheres.  
 






10% GelMA  
HAC-laden  
9.5% GelMA-0.5% HepMA 
Singularisation 
efficiency  82 ± 11.35% 89 ± 7.38%   




 During the experiment, the reasons for singularisation failures were due to, 
either, the release of 2 microspheres at a time, or due to the microsphere being 
sucked into the vacuum pressure port. In the event of a singularisation failure, the 
singularisation cycle could be repeated to release a microsphere. If the microsphere 
has blocked the ports of the singularisation device, the device can be purged with 
fluid to dislodge the microsphere after which normal operation of the device can be 
resumed. The singularisation failures that occurred were not critical and did not 
a n=100. 
b Significant difference (p<0.05) only between 5% cell laden microspheres and HAC-laden 9.5% GelMA-







cause the failure of the device. The photomicrosensor that was fitted to detect 
singularised micro-tissues could not detect the microspheres as they were not 
opaque to light and did not trigger the photomicrosensor. The successful 
singularisation was visually inspected by the user.  
5.4.2.2 Automated tissue assembly with microspheres 
Layer-by-layer assembly (Figure 5-4) of a construct was successfully 
demonstrated with cell-free 10% GelMA microspheres. The 10% GelMA macromer 
concentration was chosen based on previous studies on cartilage engineering [71]. 
2 layers with 16 (4 x 4 fashion) microspheres per layer was assembled. Microsphere 
of different colours were inserted into specific location (which includes a checked 
and concentric pattern) in a single layer scaffold (Figure 5-5) to demonstrate the 
























(a) (b) (c) (d) 






Layer 1 Layer 2 
Figure 5-4. Top-view and cross sectional-view photographs of the steps involved in 
the layer-by-layer printing and assembly of a microsphere assembled construct with 
the aid of the automated assembly system. Contains 32 microspheres, arranged in 2 

















5.4.2.3 Efficiency of microsphere insertion  
The efficiency of successful microsphere insertion into the scaffold was 
determined to be 90.6 ± 11.0% (n=8 scaffolds, n=64 microspheres) for the cell-free 
10% GelMA microspheres. Although there were microspheres that failed being 
inserted into the scaffold, the scaffold was inspected for the missed microsphere 
insertions and the microsphere insertion process was repeated for the failed pores 
and the scaffold was completely filled as planned.  
5.4.2.4 Viability of assembled construct      
The print head containing the thermoplastic material is heated to 
approximately 200°C and during the 3D plotting process, the extruded fibre rapidly 
cools. However, it was essential to ascertain that the extruded molten polymer 
coming in contact with microspheres during the layer-by-layer assembly process 
and the handling of the microspheres by the automated bioassembly system did not 
affect the viability of encapsulated cells. HAC-laden 9.5% GelMA-0.5% HepMA 
microspheres were assembled manually and using the automated tissue assembly 
system. The visual inspection of the live/dead fluorescence microscopy images 
(a) 
(a) (b) (c) 
 Figure 5-5. Top-view of a microsphere assembled construct with the aid of the 
automated assembly device to demonstrate the flexibility of the system. Different 
coloured microspheres were inserted into specific 3D locations, (a-b) contains 16 
microspheres arranged in a single layer and (c) contains 36 microspheres arranged 
in a single layer. Scale bar = 1 mm for all images. 
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(Figure 5-6) of the manually assembled scaffold and the construct assembled using 
the assembly system showed no obvious differences and this was validated with the 
AlamarBlue® assay (Figure 5-7). There was no significant difference (p>0.05) in the 
percentage of AlamarBlue® reduced by the manually assembled scaffold (55.12 ± 
4.51%) and the construct assembled using the automated bioassembly system 
(52.82 ± 6.89%). 
 
 
                                                                                                                                                                                                                                                                                               
              














Automated assembly Manual assembly 
Live/Dead 
Figure 5-6. Fluorescence microscopy images of (a) manually assembled construct 
and a (b) construct assembled using the assembly system assembled with HAC-laden 
9.5% GelMA-0.5% HepMA microspheres stained with Calcein AM (live cells, green) 









The live/dead images of HAC-laden 9.5% GelMA-0.5% HepMA microspheres 
and manually assembled construct cultured over time (day 0, 14 and 35) is shown 
in Figure 5-8 . Visual inspection did not reveal a significant population of dead cells 






































Figure 5-7. Percentage of AlamarBlue® reduced to determine the viability of the 
manually assembled construct and the construct assembled using the automated 
system with HAC-laden 9.5% GelMA-0.5% HepMA microspheres on day 0. The data 

















5.4.3 Assessment of cartilage tissue formation  
In this subsection, cartilage tissue formation in vitro in the HAC-laden 9.5% 
GelMA-0.5% HepMA hydrogel microspheres and assembled constructs were 
assessed.  
5.4.3.1 GAG and DNA quantification 
The DMMB assay was utilised to quantify the glycosaminoglycan (GAG) 
produced. However, the DMMB assay quantifies not only the GAG produced by the 
chondrocytes but also the heparin that is present in the HepMA hydrogel that was 
incorporated during the microsphere fabrication. Therefore, interpreting the data 
with high basal GAG values caused by the presence of HepMA was challenging [72]. 
To try and overcome this and to measure the quantity of GAG produced over time by 
the chondrocytes, the GAG values of the cell-laden 9.5% GelMA-0.5% HepMA 
samples (individual microspheres and assembled constructs) were normalised by 
subtracting the GAG values from cell-free 9.5% GelMA-0.5% HepMA hydrogel 
microspheres. The normalised GAG per microsphere for the individual microspheres 
and the assembled construct is plotted in Figure 5-9 a. A decrease in normalised GAG 
Figure 5-8. Fluorescence microscopy images HAC-laden 9.5% GelMA-0.5% HepMA 
microspheres and assembled constructs on day 0, 14 and 35 stained with Calcein AM 
(live cells, green) and Propidium Iodide (dead cells, red). Scale bar = 400 µm for all 
images. 






















(a) (b) (c) 




(p<0.05) was observed in the individual microspheres between day 0 (0.31 ± 0.05 
µg/microsphere) and 14 (0.12 ± 0.07 µg/microsphere). This decrease could be due 
to the leaching out of the HepMA from the microspheres and the remodelling of the 
HepMA by the cells [72]. The decrease from day 0 (0.31 ± 0.05 µg/microsphere) to 
14 (0.20 ± 0.08 µg/microsphere) was possibly less pronounced in the assembled 
construct due to higher production of GAG compared to the individual microspheres. 
In the assembled construct, the normalised GAG increased (p<0.05) from day 14 
(0.20 ± 0.08 µg/microsphere) to 35 (0.42 ± 0.09 µg/microsphere). Higher 
normalised GAG (p<0.05) was observed in the assembled construct (0.42 ± 0.09 
µg/microsphere) compared to the individual microspheres (0.25 ± 0.10 
µg/microsphere) after 35 days in culture. 
 
The DNA content per microsphere for the individual microspheres and 
assembled constructs is plotted in Figure 5-9 b. The DNA content observed in the 
individual microspheres decreased (p<0.05) between day 0 (80.20 ± 8.15 
ng/microsphere) and 14 (63.62 ± 5.85 ng/microsphere). In the assembled 
construct, the DNA content significantly increased (p<0.05) from day 14 (67.03 ± 
10.97 ng/microsphere) to 35 (98.72 ± 10.27 ng/microsphere). A higher (p<0.05) 
DNA content was observed between the assembled construct (98.72 ± 10.27 
ng/microsphere) compared to the individual microspheres (72.91 ± 4.46 
ng/microsphere) on day 35. With the normalised GAG per DNA (Figure 5-9 c), a 
significant change (p<0.05) was observed only in the individual microspheres where 












































































































Figure 5-9. (a) normalised GAG per microsphere, (b) DNA per microsphere and (c) 
(normalised GAG)/DNA for HAC-laden 9.5% GelMA-0.5% HepMA microspheres and 
assembled construct at day 0, 14 and 35. The data is presented as mean ± SD (n=4). 
*Significant differences between columns below each end of lines (p<0.05). Statistical 







5.4.3.2 Histology and immunofluorescence  
The cryosections were stained with safranin O (Figure 5-10) to visually 
investigate GAG production in microspheres and assembled constructs. GAG is one 
of the major components of articular cartilage and is responsible for the elasticity 
and resilience of cartilage [73]. However, the presence of HepMA incorporated 
during the microsphere fabrication process caused high background staining for 
GAG. The background staining can be seen in the control microspheres without cells 


























Figure 5-10. Histological staining (safranin O/haematoxylin/fast green) for cell-free 
9.5% GelMA-0.5% HepMA individual microspheres, HAC-laden 9.5% GelMA-0.5% 
HepMA individual microspheres and assembled constructs on day 14 and 35. For 
lower magnification images see Figure 5.A-v, Appendix 5.A. Scale bar = 100 µm for all 
images. 
Safranin O/haematoxylin/fast green 









































Immunofluorescence staining on cryosections for aggrecan is shown in Figure 
5-11 for HAC-laden 9.5% GelMA-0.5% HepMA individual microspheres and 
assembled constructs. Aggrecan is a large proteoglycan present in the extracellular 
matrix and aids cartilage in withstanding compressive loads [74]. Visual inspection 
for aggrecan suggest that higher aggrecan can be observed on day 35 (Figure 5.A-vi.  
b and d) compared to day 14 (Figure 5-11 a and c) for both individual microspheres 
and assembled construct. The assembled construct (Figure 5-11 a and b) was 
observed to have produced higher aggrecan compared to the individual 
















5.4.4 Graduated construct assembly 
As chondrocytes have limited source and in vitro proliferative potential, MSCs 
can potentially serve an alternative cell source for cartilage engineering [6, 75-77]. 
In this subsection, the fabrication of a graduated construct with HAC, MSC and co-
culture microspheres was demonstrated.  
 
1 mm 
Figure 5-11. Immunofluorescence staining for Aggrecan and Hoechst 33342(Cell 
Nuclei) imaged using a fluorescence microscopy for HAC-laden 9.5% GelMA-0.5% 
HepMA individual microspheres and assembled constructs on day 14 and 35. For 
lower magnification images see Figure 5.A-vi, Appendix 5.A. Scale bar = 100 µm for 
all images. 
Day 14 Day 35 



























The cells in the graduated assembled construct were labelled with Qtracker to 
track the rearrangement and self-assembly of the cells in the construct. See Figure 
5.A-xv, Appendix 5.A for the confocal microscopy images of the cryosectioned 
graduated assembled construct. The visual inspection revealed that the intensity of 
the Qtracker was very low to track the rearrangement and self-assembly of the cells 
and no conclusion could be deduced.  
 
The cryosections of the graduated assembled construct were stained with 
safranin O (Figure 5-12) to visually investigate GAG production. As seen previously, 
the incorporation of HepMA during the microsphere fabrication resulted in a high 
background staining for GAG. The background staining of HepMA made it 

















































Immunofluorescence staining on cryosections for aggrecan for the whole 
graduated assembled construct is shown in Figure 5-13 and the higher 
magnification images are shown in Figure 5-14. On day 1, the observed aggrecan 
staining appeared to be pericellular and was observed only in the HAC microspheres 
(Figure 5-14 a) and the co-culture microspheres (Figure 5-14 d). No noticeable 
pericellular aggrecan staining could be visualised in the MSC microspheres (Figure 
5-14 g) on day 1. With the day 14 images (Figure 5-14 b and e), higher aggrecan was 
observed in the HAC and co-culture microspheres compared to the day 1 images 
suggesting aggrecan production. The visualisation of aggrecan observed in day 14 
MSC microspheres (Figure 5-14 h) was higher than the day 1 MSC microspheres 
Safranin O/haematoxylin/fast green 


















Figure 5-12. Histological staining (safranin O/haematoxylin/fast green) for HAC, 
co-culture (50% HAC and 50% MSC) and MSC laden 9.5% GelMA-0.5% HepMA 
microspheres that were assembled as a construct on day 1, 14 and 35. For lower 
magnification images see Figure 5.A-x, Appendix 5.A. Scale bar = 100 µm for all 
images. 
(a) (b) (c) 
(d) (e) (f) 
(g) (h) (i) 
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(Figure 5-14 g) however the expression seemed comparatively lower than in the day 
14 HAC (Figure 5-14 b) and co-culture (Figure 5-14 e) microspheres. The aggrecan 
staining in the day 35 images (Figure 5-14 c and f, and Figure 5-13 b) appeared to 
be slightly higher compared to the day 14 images (Figure 5-14 b and e, and Figure 
5-13 a) in the HAC and co-culture microspheres. Similar to the day 14 data, the 
aggrecan staining in MSC microspheres at day 35 was visualised to be lower than the 
HAC and co-culture microspheres (Figure 5-14 I and Figure 5-13 b). The increased 
aggrecan staining observed by the visual inspection of the graduated assembled 




 On day 35 (Figure 5-14 b), higher aggrecan can be visualised in the HAC and 
co-culture microspheres compared to day 14 and the presence of aggrecan can be 
















































Figure 5-13. Immunofluorescence staining for Aggrecan and Hoechst 33342 (cell 
nuclei) imaged using a confocal fluorescence microscopy for a graduated assembled 
construct (HAC, co-culture (50% HAC and 50% MSC) and MSC-laden 9.5% GelMA-
0.5% HepMA microspheres) on day 14 and 35. The dotted lines shows the division 









































5.5 Discussion  
We have demonstrated the automated 3D Bioassembly of cell-laden hydrogel 
microspheres for biofabricating a tissue engineered cartilage construct via a bottom-
up tissue engineering strategy. Bottom-up modular tissue engineering approaches 
are attractive alternatives given that larger tissue engineered constructs can be 
biofabricated from smaller tissue modules or subunits with specific micro-
architectural features [78, 79]. The advantage of bottom-up strategies over top-
down strategies is that the precise control of the spatial distribution of the cells and 
support material to recreate the microstructural features of tissues is possible [23]. 





















Figure 5-14. Immunofluorescence staining for Aggrecan and Hoechst 33342 (cell 
nuclei) imaged using a fluorescence microscopy for HAC, co-culture (50% HAC and 
50% MSC) and MSC laden 9.5% GelMA-0.5% HepMA microspheres that were 
assembled as a construct on day 1, 14 and 35. Scale bar = 100 µm for all images. 
 
(a) (b) (c) 
(d) (e) (f) 
(g) (h) (i) 
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As many native tissues are composed of repeating functional units, there is a strong 
biological reasoning for employing bottom-up strategies [23]. Utilising the layer-by-
layer strategy, we demonstrated the use of a prototype automated biofabrication 
system to bioassemble cartilage constructs without affecting the viability of the 
individual tissue subunits. By successfully validating the automated bioassembly 
system with microspheres, we have opened a pathway to precisely build large and 
complex constructs of clinically relevant sizes in large numbers with a reduced 
construction time. Mathematical models or anatomical models generated via 
imaging techniques such as computed tomography (CT) or magnetic resonance 
imaging (MRI) can be inputted into a bio-plotter and easily translated to create an 
assembled construct [80].  
 
Encapsulating cells in hydrogels is an attractive strategy to engineer multiple 
tissue modules in a short amount of time. In particular, GelMA based hydrogels do 
not only provide a hydrated 3D environment similar to native cartilage, but also 
enable the incorporation of bioactive molecules or compounds to further promote 
cartilage formation. Besides that, by tuning the stiffness of the GelMA hydrogels, 
encapsulated cells can be forced to maintain a rounded morphology to promote or 
direct a pro-chondrogenic phenotype [8, 9, 15, 19, 22, 81]. Encapsulating cells would 
be beneficial in a single surgery strategy, where, following harvesting of the tissue, 
chondrocytes could be isolated, encapsulated, bioassembled into a scaffold quickly 
and then the construct could be immediately transplanted into the patient. 
Moreover, one of the criteria for the cell scaffolds used in tissue engineering is that 
the scaffold should be completely degraded and replaced over time by the ECM 
produced by the cells [82]. As GelMA is prone to enzymatic degradation (GelMA 
contains MMP degradable motifs), the cartilage construct implanted in situ over time 
would eventually be degraded to be completely replaced by neocartilage [83, 84].  
 
The major advantage of utilising cell-laden hydrogel microspheres over micro-
tissues is the number of cells required. Fabricating an individual cell-laden Ø1 mm 
microsphere required approximately 8,000 cells at a concentration of 15 million 
cells/ml. In comparison, fabricating a Ø1 mm micro-tissue required 250,000 cells 
which is approximately 31-folds higher [3]. Based on these numbers, fabricating a 
construct of Ø25 mm and 2.4 mm thickness with microspheres would require only 
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8 million cells in comparison to fabricating a construct with micro-tissues which 
would require 247 million cells as mentioned earlier [3, 4]. Moreover, microspheres 
do not require the rate-limiting step of culturing the cell pellet for 7 days to form the 
micro-tissues before they can be bioassembled. These advantages with the 
microsphere based construct would aid in saving time, resources and man-power. 
With the microfluidic system that we have adopted, a large number of uniformly 
sized microspheres with a narrow size distribution of about Ø1 mm could be 
fabricated in a convenient and high-throughput manner. In an emulsion (macromer 
solution and oil), the surface tension causes the droplets to contract into a sphere to 
minimise the surface energy and this leads to the formation of microspheres at the 
edge of the fused capillary in the microfluidic system [40, 85]. The microspheres 
fabricated in this manner has been previously shown to be smooth and spherical 
[40].   
 
A difference in average diameter was observed in the microspheres fabricated 
with different conditions. The average diameter of the cell-free 10% GelMA 
microspheres (1.294 ± 0.052 mm) was larger than the cell-free 5% GelMA 
microspheres (1.193 ± 0.070 mm) and the HAC-laden 9.5% GelMA-0.5% HepMA 
microspheres (0.955 ± 0.031 mm) had the smallest average diameter of all the 
conditions. The macromer concentrations and the addition of HepMA and cells could 
all possibly cause a change in viscosity, surface tension or density of the dispersed 
phase causing the variation in the size of the fabricated microspheres among 
different conditions [69, 70]. A significantly higher (p<0.05) singularisation 
efficiency was observed in the HAC-laden 9.5% GelMA-0.5% HepMA microspheres 
(94 ± 9.66%) compared to the cell-free 5% GelMA microspheres (82 ± 11.35%). It is 
likely that the higher macromer concentration increases the stiffness of the HAC-
laden 9.5% GelMA-0.5% HepMA microspheres which improves the singularisation 
efficiency as microspheres of higher stiffness are trapped more effectively than 
softer microspheres which tend to get deformed or become lodged in the pressure 
ports of the singularisation chamber (see Chapter 4). The average diameter of the 
HAC-laden 9.5% GelMA-0.5% HepMA microspheres was closer to 1 mm (the 
diameter the tissue assembly system was designed to handle) compared to the cell-





The incorporation of heparin in a hydrogel scaffold has previously been shown 
to stimulate the redifferentiation of dedifferentiated chondrocytes [86]. The 
increase neocartilage synthesis in the presence of HepMA has been observed by our 
group [87]. Heparin and heparan sulphate is part of the GAG family and HepMA has 
been shown to exhibit a similar anticoagulant and growth factor signalling 
properties to heparin [72]. It has been suggested that the role of heparin could be to 
capture endogenous and exogenous growth factors produced by the cells when 
added into the media [86, 88]. These growth factors could signal the 
redifferentiation of the cells back into a more chondrogenic like phenotype [86]. The 
presence of heparin has also been shown to improve expression of chondrogenic 
markers [86, 88]. Due to the above potential of heparin for cartilage engineering, 
HepMA was incorporated into the cell-laden GelMA microspheres. 
 
The individual microspheres and assembled constructs were cultured for 35 
days to evaluate neocartilage formation. The presence of HepMA in the 
microspheres interfered with GAG quantification as the DMMB assay quantifies the 
heparin present in the HepMA microspheres. Likewise, the visual inspection for the 
presence of synthesised GAG was challenging with the safranin O stained sections as 
the presence of HepMA in the microspheres resulted in a high background staining 
[72]. To overcome this, the total GAG in the samples were normalised by subtracting 
the GAG values of the cell-free microspheres from the GAG values of the samples to 
evaluate the GAG production in the microspheres with the assumption that the 
HepMA content in the cell-free and cell-laden microspheres are similar over time. 
The decrease in normalised GAG per microsphere from day 0 (0.31 ± 0.05 
µg/microsphere) to day 14 (0.12 ± 0.07 µg/microsphere) observed in the individual 
microspheres could possibly be due to HepMA leaching of the out of the hydrogel 
and the remodelling of the hydrogel by the chondrocytes [72]. However, the decrease 
in normalised GAG per microsphere from day 0 (0.31 ± 0.05 µg/microsphere) to 14 
(0.20 ± 0.08 µg/microsphere) is less pronounced in assembled constructs and could 
possibly be due to higher GAG production by the cells in the assembled construct. 
Likewise, an increase in normalised GAG was seen in the assembled construct from 
day 14 (0.20 ± 0.08 µg/microsphere) to 35 (0.42 ± 0.09 µg/microsphere) but the 
increase was not significant in the individual microsphere possibly due to lower GAG 
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synthesis and retention. It has been previously shown that the GAG incorporated in 
an assembled micro-tissue construct is higher than that in individual micro-tissues 
[89]. This difference seen in the study was attributed to the reduced surface area to 
volume resulting in improved retention of GAG in the assembled construct [89]. It is 
also known that a hypoxic environment stimulates chondrocyte redifferentiation 
and extracellular matrix production in vitro and the assembled construct being 
larger could be more hypoxic compared to the individual microspheres resulting in 
the higher extracellular matrix production [90, 91]. The staining for aggrecan 
revealed neocartilage formation [92]. Higher aggrecan staining was visualised in the 
assembled construct compared the individual microspheres on day 35 and this is in 
line with the trend observed with the normalised GAG.  
 
Although a higher normalised GAG per microsphere (Figure 5-9 a) was 
observed in the assembled construct (0.42 ± 0.09 µg/microsphere) compared to the 
individual microspheres (0.25 ± 0.10 µg/microsphere) on day 35, a higher 
normalised GAG per DNA was not observed in the assembled construct compared to 
the individual microspheres. This could be due to the higher DNA content (Figure 
5-9 b) in the assembled construct (98.72 ± 10.27 ng/microsphere) compared to the 
individual microspheres (72.91 ± 4.46 ng/microsphere) due to the proliferation of 
cells on the fibres of the scaffold. The live/dead images on day 35 confirm the 
presence of cells on the scaffold fibres (Figure 5-8 f). Significant chondrocyte 
proliferation on Polyactive 300PEGT55PBT45 has previously been reported [62, 93]. 
It is known that the production of GAG by chondrocytes is lower in a 2D environment 
compared to cells in 3D [94]. Therefore, even though there was an increase in cell 
number on the surface of the scaffold fibres they might not be producing sufficient 
GAG comparable to the cells encapsulated within the hydrogel. As mentioned earlier, 
we are also of the opinion that we might be underestimating the production of GAG 
as the cells might be remodelling the incorporated HepMA and the quantity of 
HepMA leaching out in the cell-free microspheres might be different from the cell-
laden microspheres. As the presence of HepMA incorporated in the hydrogel 
interfered with quantification and histology of GAG, other approaches to quantify 
neocartilage tissue formation is required. Further studies investigating the gene 
expression of collagen type I and II and aggrecan could potentially be more 
informative [17]. While there was no significant difference observed in normalised 
154 
 
GAG/DNA in the individual microspheres compared to the assembled construct, the 
normalised GAG per microsphere values and aggrecan staining observed in the 
assembled construct compared to the individual microspheres are encouraging as it 
suggests improved production of neocartilage in the assembled construct compared 
to the individual microspheres.  
 
MSCs are considered as a relevant alternative source to chondrocytes for 
cartilage engineering as they can be easily isolated, expanded and differentiated into 
chondrocytes [75]. We have demonstrated the assembly of a graduated cartilage 
construct with HAC, co-culture and MSC laden 9.5% GelMA-0.5% HepMA 
microspheres. The cells in the graduated assembled construct were labelled with 
Qtracker (photostable fluorophores) to investigate any rearrangement and self-
assembly of the cells. As Qtracker has previously been shown to not affect the 
viability of the cells and as it photo-bleaches very little over time, it was employed 
to track the cells [95, 96]. However, the faint signal of the Qtracker labelled cells (see 
Figure 5.A-xv, Appendix 5.A) made it challenging to precisely track the cells and the 
rearrangement and self-assembly of cells in the graduated assembled construct 
could not be concluded. Future experiments to track the rearrangement and self-
assembly of the cells could potentially be carried out by labelling the cells with green 
fluorescent protein (GFP) and red fluorescent protein (RFP) [95].  
 
With regards to tissue formation, higher aggrecan staining (Figure 5-13 and 
Figure 5-14) was visualised in the graduated assembled construct over time 
suggesting neocartilage formation. The production of aggrecan was however not 
uniform in the graduated assembled construct. The visualisation of aggrecan in the 
MSC microspheres (Figure 5-14 h and i and Figure 5-13) was comparatively lower 
to the HAC (Figure 5-14 b and c and Figure 5-13) and co-culture (Figure 5-14 e and 
f and Figure 5-13) microspheres in the construct on day 14 and 35 suggesting that 
MSC-laden microspheres had a lower matrix production, and is comparable to 
previous similar studies. For example, it has been shown that chondrogenesis does 
occur in MSC-laden agarose hydrogels, however, the quantity of matrix formed was 
lower than that produced by chondrocytes [81]. Furthermore, studies have shown 
that the expression of aggrecan and collagen type II is higher in MSC and HAC co-
culture hydrogels compared to MSC only laden hydrogels [76]. This study also 
155 
 
suggests that a close proximity is required between MSCs and HACs for the 
promotion of chondrogenesis in MSCs [76] and can be related to cell-cell signalling 
via the establishment of gap junctions and also paracrine signalling mechanisms 
between cells and respective endogenous secretion of growth factors. This could 
possibly be the reason why the aggrecan staining was higher in the co-culture 
microspheres compared to the MSC only microspheres (Figure 5-14 and Figure 
5-13). It has also been shown that the co-culture of MSCs with HACs reduced 
hypertrophy in MSCs [76, 77]. Moreover, the inhibition of chondrogenesis in MSCs 
could be due to the presence of RGD sequences in GelMA. It has been reported that 
RGD sequences can inhibit chondrogenesis of MSCs within alginate hydrogels and a 
similar behaviour might be occurring in our microspheres [97, 98].  
 
We have demonstrated the flexibility of the system by assembling 
microspheres of different colours representing microspheres consisting of either 
different cell types or hydrogel compositions. Although this was performed with just 
one singularisation device rigged up to an injection device, potentially, parallel 
singularisation devices containing different types of microspheres can be rigged to 
an injection device to assemble microspheres of different cell types in a specific 
order. In cartilage engineering, assembling microspheres in a particular 
organisation can be of significant importance. Zonal constructs with different zonal 
subpopulations of cells could be assembled to recreate the arrangement in native 
articular cartilage [9, 99, 100]. A biphasic osteochondral construct with 
chondrocytes and osteoblasts/osteocytes could be assembled, with the potential 
advantage that an osteochondral construct would allow for fixation of the construct 
in the bony section of the defect and better integration of the cartilage with the bone 
[5, 101] compared to a single-phase chondral construct. Assembling vascularised 
bone modules for the bony region of the construct would allow diffusion of 
nutrients, gases and waste products and aid in avoiding necrosis in an osteochondral 
construct [27, 57]. Constructs with a gradient of cell types or different cell types (e.g. 
chondrocytes, MSCs or osteoblasts) could be fabricated to recapitulate a specific 
desired tissue structure [9, 76]. Furthermore, hydrogels of different mechanical 
properties could be assembled to induce chondrocytes to behave like cells from 
different zones [9, 102]. The cell density varies in different zones of cartilage, with 
higher cell density in the superficial zone compared to the middle and deep zones 
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[4]. The variation in cell density could be recapitulated in the assembled construct 
by assembling microspheres of different cell density [4]. Bioactive molecules such as 
basic fibroblast growth factor (bFGF) [103], TGF-β1 [15, 22] or insulin-like growth 
factor I (IGF-I) [15] could be incorporated into a microsphere with different 
concentrations and a construct with a gradient in bioactive molecules could be 
fabricated, this would be beneficial in zonal chondrogenesis of MSCs and 
chondrocytes [9]. Furthermore, even a micro-tissue and microsphere hybrid 
construct could potentially be assembled. For example, chondrogenic differentiation 
of MSCs in a micromass culture was demonstrated in the presence of hyaluronic acid 
microspheres which behaved as a growth factor delivery system delivering bone 
morphogenetic protein 2 (BMP-2) in a controlled manner and similarly a hybrid 
construct with micro-tissues and microspheres delivering growth factors could be 
fabricated [104].  
 
Hydrogels possess limited mechanical strength and for application in cartilage 
tissue engineering, they need mechanical reinforcement to enhance their load-
bearing ability [8, 42, 43]. The reinforcement of the hydrogel with thermoplastics to 
create a composite construct has previously been demonstrated, but the respective 
fabrication technique did not allow control over the microarchitecture [42, 43]. In 
the previous chapter we have shown that the stiffness of the fabricated scaffold is 
comparable to native cartilage and by assembling cell-laden microspheres into 
thermoplastic scaffold not only provide mechanical reinforcement for the hydrogels 
but also allowed spatial control over the construct’s microarchitecture [8, 42, 43]. 
The reinforced hydrogel constructs would allow the implantation of a construct 
consisting of relatively immature neo-cartilage matrix thereby reducing in vitro 
culture time [5]. Previous studies have suggested that integration of engineered 
cartilage with host cartilage is improved when a more immature construct is 
implanted as opposed to a more mature in vitro cultured construct [105, 106].  
Moreover, a study has also reported a higher chondrogenic expression in 
mechanically reinforced hydrogels compared to non-reinforced hydrogels when 
mechanically stimulated [43]. Apart from the mechanical reinforcement of the 
hydrogel, the pores present in between the microspheres after bioassembly could 
potentially also allow for easier diffusion of nutrients during early stages of tissue 




Previous studies have shown that physiological mechanical stimuli which 
include cyclic dynamic compression, fluid-induced shear, and hydrostatic pressure 
can positively influence cartilage ECM production [108-110]. Likewise, a low oxygen 
environment has been demonstrated to stimulate chondrocyte redifferentiation in 
vitro [90]. Further studies on the assembled construct in a hypoxic environment or 
with mechanical stimuli for optimal neocartilage synthesis would be beneficial in 
producing cartilage of higher quality [91, 108]. 
 
The fabrication of microspheres for a wide range of microsphere sizes (50-
3000 µm) has previously been demonstrated [40, 49, 115, 116]. Presently, we have 
only validated the automated bioassembly system with microspheres of 
approximately 1 mm diameter and to be able to accommodate and handle 
microspheres outside this range, the physical components and the soft parameters 
of the automated tissue assembly system would have to be suitably modified. The 
miniaturisation of the system could unavoidably cause additional problems due to 
the nature of physics. Laminar flow, surface tension, diffusion and fluidic resistance 
start influencing the system as the design of the system approaches the microscale 
range, requiring further research or redesign of the system [117].  
5.6 Conclusions  
We demonstrated here the automated 3D Bioassembly of cell-laden hydrogel 
microspheres into a 3D plotted scaffold for biofabricating a tissue engineered 
cartilage construct. Microspheres of Ø1 mm that could be reliability handled by the 
automated bioassembly system were fabricated with a microfluidic system. The 
bioassembly system could effectively handle the fabricated microspheres and with 
the aid of the 3D positioning system could deliver the microspheres to any desired 
point in the 3D plotted scaffold. The flexibility of the automated tissue assembly 
system was demonstrated by assembling constructs with different arrangements of 
the various coloured microspheres into a 3D plotted scaffold. The layer-by-layer 
assembly of a cartilage construct with human articular chondrocyte (HAC)-laden 
hydrogel microspheres utilising the automated bioassembly system was 
demonstrated. No significant difference in viability was observed between manually 
assembled constructs and constructs assembled with the automated bioassembly 
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system. HAC-laden 9.5% GelMA-0.5% HepMA hydrogel microspheres were 
assembled and cultured up to 35 days. Immunofluorescence staining for aggrecan 
revealed cartilage tissue formation with a higher amount of aggrecan visualised in 
the assembled constructs compared to the individual microspheres. Furthermore, 
we demonstrated the fabrication of a graduated construct consisting of HAC, co-
culture (50% HAC and 50% MSC) and MSC laden microspheres and the 
immunofluorescence staining for aggrecan revealed cartilage tissue formation over 
time. With this technology, large complex constructs of clinically relevant sizes can 
be fabricated.  
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Chapter 6 Automated 3D Bioassembly of micro-tissues 
for biofabrication of an in vitro 3D cancer model and its 





6.1 Abstract  
3D in vitro cancer models have an invaluable role in cancer research and drug 
discovery. Presently, high-throughput fabrication of complex 3D cancer constructs 
with the precise arrangement of micro-tissues in 3D plotted scaffolds has been 
limited. We aimed at the automated 3D Bioassembly of micro-tissues for 
biofabricating a modular assembly based cancer construct for application as an in 
vitro 3D cancer model. Compact and spherical Ø1 mm cancer micro-tissues that can 
be handled by the automated bioassembly system were fabricated by co-culturing 
SKOV3 (human ovarian adenocarcinoma cell-line) with human foreskin fibroblasts 
(HFF) using liquid overlay technique and were characterised. Qtracker labelled 
micro-tissues showed that the cells self-segregated to form a fibroblastic core 
enveloped by SKOV3s. A bilayered cancer construct containing 4 micro-tissues per 
layer was fabricated via a layer-by-layer approach by alternately 3D plotting a 
PEGT/PBT polymer scaffold and inserting the cancer micro-tissues using a 
prototype automated bioassembly system. No significant difference in viability 
between the construct assembled using the automated system and the manually 
assembled construct was observed. For the chemosensitivity test, cells cultured in 
2D, micro-tissues and assembled cancer constructs were exposed to doxorubicin for 
4 days and the metabolic activity was measured using the AlamarBlue® assay. The 
chemosensitivity test revealed a cell-dependent chemoresistance and higher 
chemoresistance in 3D models compared to cells in 2D. Fixed frozen sections were 
stained for Ki67 and γ-H2AX. A cell-dependent Ki67 expression was visualised. 
Higher γ-H2AX was visualized at higher drug concentrations demonstrating double-
stranded DNA breakage caused by the drug. This model and technology opens the 
path for the automated bioassembly of large modular assembly based cancer 





With cancer becoming a major cause of morbidity and mortality, research in 
cancer is highly imperative [1]. Understanding cancer progression in situ can be very 
long and impractical. Also, clinical trials of probable anticancer drugs tend to have 
risks associated with it, are expensive and need ethical approval [2]. Thus there is 
an indispensable need to develop cancer models that can be employed to provide 
some very important insights into the process of tumorigenesis, to help in 
accelerating translational research in cancer and also facilitate the development and 
screening of novel tumour-specific drugs [2]. 
 
Two-dimensional (2D) monolayer culture systems and animal models have 
long been relied upon by researchers as cancer models to conduct cancer research. 
2D culture systems are too simplistic and primitive and do not recapitulate the 
anatomy or physiology of a tissue [3]. When cells are grown as a monolayer on a 
plastic or glass substrate, the tissue-specific architecture, metabolic gradient, 
cellular differentiation, cell cycle control, mechanical cues, biochemical cues, three-
dimensional (3D) cell–cell and cell–matrix interactions are lost [4, 5]. Furthermore, 
cells cultured in 2D have a lower resistance to chemotherapy compared to cells 
cultured in a 3D environment, resulting in poor negative screening power during 
drug screening [6].  
 
With regards to animal models, the transplantable tumour model in rodents 
was developed as early as the start of the 20th century, which allowed for the testing 
of anticancer drugs [7]. Animal models are currently the gold standard in cancer 
research and are critical in drug testing. However, they tend to be expensive, require 
ethical approval, and are complex and containing many multivariable uncontrollable 
factors, such as, the presence of the host immune response, differences in liver 
toxicity, differences in telomerase regulation, contain non-human host cells, 
differences in haemodynamics, and production of endogenous growth factors [2, 8-
10].  
 
The high cost of drug research and development means there is a need for 
selecting the most promising candidates in the earlier stages of screening rather 




and ethical issues associated with animal models, there is a need for in vitro 3D 
models with increased predictive power that can more accurately anticipate the 
outcome of a candidate drug in tumours in vivo before animal testing and clinical 
trials [4, 12].  
 
Multicellular spheroids (micro-tissues) [13, 14] along with gel systems which 
allow cell encapsulation in 3D hydrogels [15, 16] make up the two major frequently 
used in vitro 3D cancer platforms. Micro-tissues are an aggregation of cells used in a 
wide range of research fields including drug screening, research in drug transport 
and binding, cancer research, tissue morphogenesis, differentiation, tissue 
engineering, regenerative medicine and stem cell research [17-22]. Although the 
drug response of tumours in vivo is more similar to micro-tissues in comparison to 
cells in 2D, micro-tissues are comparatively smaller and the drug response is altered 
compared to larger tumour tissues [23, 24]. In general, cancer micro-tissues of 
approximately Ø70 µm up to Ø1 mm have been fabricated, where the micro-tissue 
size is dependent on the cell type, seeding density and culture time [22, 25, 26]. 
However, these sizes are not necessarily clinically relevant as most tumours in vivo 
are much larger in size [27]. For example for stage 2 breast cancer, the tumour size 
varies from 2 to 5 cm [28]. Similarly, with regards to ovarian cancer, the average 
cancer tumour size varies from 4.6 to 11.8 cm depending on the stage [29]. 
Moreover, the tissue architecture in micro-tissues is less complex than actual 
tumours that are found in vivo [22, 30, 31]. Therefore, there is a need for an improved 
fabrication approach that can tailor make large 3D cancer models to recreate tumour 
niches of complex architecture and is also adaptable with high-throughput analysis 
systems.  
 
Research in tissue engineering and regenerative medicine (TERM) has led to 
advances in biofabrication enabling the control of macro and microscale structure 
and architecture of an engineered construct. These TERM concepts can potentially 
be translated for application in cancer research. Advances in biofabrication relating 
to the bioassembly of micro-tissues for application in tissue engineering such as 
vascular tissue engineering [32] and cartilage engineering [33, 34] have been 
reported. Nevertheless, little focus has been given to bioassembly of micro-tissues 




fabrication of co-culture micro-tissues with rat hepatoma cells and human 
fibroblasts and assembled the micro-tissues into a larger complex structure by 
seeding the micro-tissues into micromoulds [35]. However, this model was used to 
demonstrate tissue fusion and cell sorting and not for application as a tumour model.  
 
To our knowledge, there exists no system - either manual or automated, to 
tailor make a well-defined and reproducible complex tumour model based on 
modular assembly. By applying the principles of bioassembly, a target oncological 
model could be stripped down to its basic elements and different types of 
prefabricated modules or subunits can be potentially assembled into one complex 
biologically relevant assembled cancer construct via a modular assembly based 
bottom-up approach. As many tissues are composed of repeating functional units, 
there is a biological basis for using the modular assembly approach [36]. The 
fabrication of such cancer models may allow higher spatial control of the 
arrangement of cells/prefabricated modules to be possible. The developed model 
and complementary automated bioassembly system would be highly beneficial for 
fabricating large-scale cancer constructs in a high-throughput fashion for cancer 
research and drug discovery.  
 
The specific aims of this study were to validate the process for automated 3D 
bioassembly of micro-tissues for biofabrication of an in vitro 3D cancer construct 
and to evaluate the performance of this 3D tumour model compared to existing 2D 
and 3D drug screening models. This study involved: (i) the fabrication of compact 
and spherical Ø1 mm cancer micro-tissues that could be handled by the automated 
bioassembly system, (ii) demonstrating the fabrication of cancer constructs with 
micro-tissues using the automated tissue bioassembly system without affecting cell 
viability, (iii) and the investigation and characterization of the response of the 
engineered cancer construct to an anticancer drug – doxorubicin, compared to 





6.3.1 Cell expansion  
Experiments were carried out with human breast adenocarcinoma cell lines 
MCF-7 and MDA-MB-231, human ovarian adenocarcinoma cell-line SKOV3 and 
normal human foreskin fibroblasts (HFF). SKOV3 and HFF were cultured in media 
containing DMEM (high glucose, GlutaMAX Supplement, pyruvate) (GIBCO, USA) 
with 5% foetal bovine serum (FBS; GIBCO, New Zealand), 100 units/mL penicillin 
(GIBCO, USA) and 100 μg/mL streptomycin (GIBCO, USA). MCF-7 and MDA-MB-231 
cells lines were cultured with the above media composition but with 10% foetal 
bovine serum. The cells were seeded at a density of 3,000 cells/cm2 in tissue culture 
flasks (BD Biosciences). Cells were expanded at 37°C in a humidified 5% CO2/95% 
air incubator and media changed twice a week.  
 
After approximately 7 days, subconfluent passage cells were washed with 
phosphate-buffered saline (PBS; GIBCO, USA), detached using 0.25% trypsin/EDTA 
(Gibco, Canada), counted by trypan blue exclusion in a haemocytometer and plated 
in a tissue culture flask at 3,000 cells/cm2. The cells were passaged until there were 
a sufficient number of cells, after which the cells harvested to form micro-tissues. 
6.3.2 Preliminary experiment – high-throughput micro-tissue fabrication 
Preliminary experiments to form spherical micro-tissues were conducted. 
Micro-tissues were cultured using a liquid-overlay technique [37]. SKOV3, MDA-MB-
231 and MCF-7 cells lines were seeded at 80,000 cells/well in a 2% agarose 
(Invitrogen, USA) coated 48-well plate and placed in an incubator at 37°C, 5% of CO2. 
During the micro-tissue culture period, the media was changed twice a week and 
culture until day 7. 
 
None of the different cells types formed satisfactory spherical micro-tissues. 
Further preliminary experiments were performed with SKOV3s as it formed the 
most regular compact circular flat spheroid (discoid). SKOV3s were seeded at 
80,000 cells/well in a 2% agarose coated 48-well plate with DMEM, 10 ng/ml EGF, 
10 ng/ml bFGF, 5 μg/ml Insulin and 0.4% BSA and DMEM and 5% FBS and placed in 




cultured until day 7. The addition of supplement did not result in satisfactory 
spherical micro-tissues either.  
 
Finally SKOV3s and HFFs at different percentage co-culture ratios of 100:0, 
99:1, 95:5, 90:10, 75:25, 50:50, 25:75 and 0:100 were suspended at 80,000 cells in 
500 μL of DMEM with 5% FBS and were pipetted into a 2% agarose coated 48-well 
plate and placed in an incubator at 37°C, 5% of CO2. This gave us successful results 
in forming compact non-discoid spherical micro-tissues. 
 
6.3.3 Cell labelling with fluorescent nanoparticle 
A Qtracker cell labelling kit (Life technologies, USA) was used to track cells in 
a co-culture environment. HFFs were labelled with Qtracker 655 and the SKOV3s 
with Qtracker 800. To label the cells with Qtracker, cells were concentrated to 107 
cells/ml by centrifugation at 700g for 5 minutes and resuspended in DMEM. A 10 
nM labelling solution was prepared by mixing 1 µL of the Qtracker Component A and 
1 µL of the Qtracker Component B in a 1.5 ml microcentrifuge tube and incubated at 
room temperature for 5 minutes. 0.2 ml of DMEM was added to the mixture and 
vortexed for 30 seconds. 106 cells at a concentration of 10 x 106 cells/ml were added 
to the labelling mixture and incubated for 60 minutes. The cells were subsequently 
washed twice with media and resuspended in media for use.  
6.3.4 Percent co-culture ratio versus sphericity  
To determine how spherical micro-tissues of different co-culture ratios of 
SKOV3 to HFF were, the sphericity of the micro-tissues was determined. The 
sphericity is a measure of how spherical an object is [38].  Labelled SKOV3 and HFF 
at different percentage ratio of 100:0, 99:1, 95:5, 90:10, 75:25, 50:50, 25:75 and 
0:100 were cultured as described earlier at a seeding density of 80,000 cells/well 
for 7 days. The micro-tissues were fixed overnight in 10% neutral buffered formalin 
and imaged using the Zeiss Axioimager Z1 microscope. The major and minor 
diameters were measured using the image measurement function in ImageJ. The 
axial measurement function in the microscope was used to measure the height 
between the centre to the periphery. The micro-tissue was then flipped and the 




two measured heights was taken to be the diameter of the micro-tissue in the z-axis. 
Using the approximated equation for sphericity as given by Krumbein [39], the 










In the equation a>b>c, where a was assigned to the major diameter of the 
micro-tissue, b was the minor diameter and c was the diameter of the micro-tissue 
in the z-axis. A sphericity value of 1 indicated that theoretically the micro-tissue was 
a perfect sphere and a value of 0 indicated that the micro-tissue was least spherical.  
 
The Qtracker labelled whole micro-tissues and cryosections were imaged 
using a Leica TCS SP5 confocal microscope to investigate the distribution of different 
cell types in the micro-tissues. 
6.3.5 Seeding density per well versus micro-tissue size 
To determine the relationship between the cell seeding density per well versus 
the size of the micro-tissue 60,000, 80,000, 100,000, 120,000, 140,000 and 160,000 
cells in the chosen percent ratio of 75% SKOV3 and 25% HFF were seeded in a 2% 
agarose coated 48-well plate. They were cultured for 7 days and the micro-tissues 
were fixed overnight in 10% neutral buffered formalin and imaged using the Zeiss 
Axioimager Z1 microscope. The average diameter of each micro-tissue was obtained 
by taking the average of the measured major and minor diameter using the image 
measurement function in ImageJ. 
6.3.6 Scaffold fabrication  
Biodegradable poly(ethylene glycol)-terephthalate-poly(butylene 
terephthalate) block copolymers (Polyactive 300PEGT55PBT45, PolyVation, The 
Netherlands) with  a PEG molecular weight (MW) of 300 g/mol and a PEGT:PBT 
weight percent (wt%) ratio of 55:45 were used to fabricate scaffolds with a specific 
pore size and architecture. The material and composition were selected based on 
previous studies demonstrating its applicability for 3D plotting and biofabrication 







Porous scaffolds (15 × 15 × 1.8 mm), with accurately defined and controlled 
pore architecture for micro-tissue incorporation, were 3D plotted using a 
Bioscaffolder system (SYS ENG, Germany). Fibres were oriented in a repeating 0-
90°-90°-0° pattern in order to provide porosity in both the x-y and x-z planes for 
assembly of 1 mm diameter micro-tissues. During the melt dispensing process the 
following 3D plotting parameters were applied: (i) fibre spacing of 0.7, 0.8 and 0.9 
mm in both x and y-direction, (ii) fibre height offset of 0.22 mm, (iii) dispense head 
and plotting temperature of 200° and 5 bar pressure, (iv) dispense head auger speed 
of 63 RPM and (v) 25 gauge dispense head nozzle moving at an x-y traverse speed of 
500 mm/min. 
6.3.7 Assembled cancer construct – fibre spacing 
Co-culture micro-tissues seeded at a density of 120,000 cells per well with a 
percent ratio of 75:25 of SKOV3s and HFFs were cultured for 7 days and then 
inserted into the pores of a sterile 3D plotted scaffold. 8 micro-tissues were 
assembled into the scaffold with 4 micro-tissues in each layer of the bilayered 
scaffold. Constructs with fibre spacing of 0.7, 0.8 and 0.9 mm were assembled. The 
cancer constructs were cultured for 5 days after assembly. The samples were imaged 
using the Zeiss Axioimager Z1 microscope and the DNA content was quantified using 
a CyQUANT kit (Molecular Probes, USA). For the CyQUANT assay, the samples were 
first digested overnight at 56 ˚C in 500 µL of 1 mg/ml proteinase-K (Sigma-Aldrich, 
USA) solution. Post proteinase-K digestion, the cells in the sample were lysed and 
the RNA was degraded by using the provided lysis buffer with RNase A (1.35 KU/ml; 
Thermofisher, Lithuania) added for an hour at room temperature. Samples were 
pipetted into 96-well white polypropylene plates (Nunc, Denmark) and GR-dye 
solution was added. The plate was then incubated at room temperature for 60 
minutes and fluorescence was measured (Fluostar Galaxy BMG Labtechnology, 
Germany). A standard curve was constructed using the λ-DNA provided in the kit. 
6.3.8 Reliability of the singularisation device with cancer micro-tissues 
To determine the reliability of the singularisation device (see Chapter 4, Figure 
4-3) with cancer micro-tissues, cancer micro-tissues formed with a co-culture of 
75% SKOV3 and 25% HFF at a seeding density of 80,000 and 120,000 cells per well 




with a seeding density of 80,000 could not be handled by the device. So only micro-
tissues formed at a seeding density of 120,000 cells per well was selected. The 
micro-tissues were put into the singularisation device in sets of 10 and repeated 10 
times, with the success or failure in singularisation being noted. The total number of 
successful singularisation cycles was used to determine the overall efficiency of the 
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6.3.9 Automated bioassembly with cancer micro-tissues 
The automated assembly of a construct with cancer micro-tissues was 
demonstrated by printing a scaffold using the high-temperature print head 
containing Polyactive 300PEGT55PBT45 and then inserting the co-culture micro-
tissues (75% SKOV3s and 25% HFFs) using the micro-tissue injection head. To 
fabricate our assembled construct a layer-by-layer approach was opted so as to not 
limit the height of the scaffold that can be constructed using the system. In this 
scheme, the first layer of the scaffold (6 layers of fibre strands) was 3D plotted (as 
described earlier) and then 4 micro-tissues were inserted into the pores of the 3D 
plotted scaffold. The 3D plotting was repeated on top of the first layer to generate 
the second layer of the scaffold (2 layers of fibre strands) and then 4 more micro-
tissues were inserted into the second layer.  
 
The layer-by-layer approach based bilayered scaffold (n=3) with 4 live micro-
tissues per layer was assembled using our automated tissue assembly system. For 
the manually assembled scaffold (n=3), the whole scaffold was 3D plotted at once 
and the micro-tissues were inserted manually by hand into pre-plotted scaffolds. 
The manually assembled constructs were assembled in a similar format to the 
constructs assembled with the automated system. The manual insertion of the 
micro-tissues into the pore involved in placing the micro-tissues on top of the 
scaffold pore with a Pasteur pipette and press-fitting the micro-tissues into the 
scaffold pore with a spatula. There is a possibility that the shear force experienced 
during the manual press-fitting process could damage the micro-tissues, however, 







For the live/dead assay, the samples were incubated at 37°C in 0.5 ml of PBS 
with 1 μM Calcein AM (Molecular Probes, USA) for 15 minutes, then 1 μM Propidium 
Iodide (Molecular Probes, USA) was added and incubated for 10 more minutes. After 
this, the samples were washed twice with PBS and a z-stack of the sample was 
imaged using the Zeiss Axioimager Z1 microscope (FITC and Texas Red filter-set). 
 
For the AlamarBlue® assay, AlamarBlue® (Invitrogen, USA) was added to the 
media containing FBS so that the final concentration was 10% (v/v) and the samples 
were incubated at 37°C for 24 hours. The reduction in AlamarBlue® reagent was 
calculated colourimetrically using the equations provided by the manufacturer after 
measuring the absorbance at 570 nm, using 600 nm as a reference wavelength 
(Fluostar Galaxy BMG Labtechnology, Germany). 
6.3.10 Efficiency of cancer micro-tissue insertion 
A bilayered scaffold (n=6) was 3D plotted with 4 micro-tissues in each layer 
using the layer-by-layer approach described earlier. The efficiency of micro-tissue 
insertion (see Chapter 4, Figure 4-4) into the scaffold was determined (Equation 
6-3) by the number of successful micro-tissue insertion into the scaffold pore to the 
total attempted number of micro-tissue insertion with the automated system. 
 
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛
=  
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𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛 
          
 
6.3.11 Chemosensitivity test 
To evaluate the tumour models, cells in 2D, micro-tissues and assembled 
tumour constructs were exposed to varying concentrations of doxorubicin (see 
Figure 6-1). Doxorubicin was dissolved in DMSO so that the maximum final 
concentration of DMSO in the media did not exceed 0.5% v/v of DMSO. On day 7 of 
forming the micro-tissues, cancer constructs were manually assembled and 
transferred to a 2% agarose coated 24-well plate with 1.2 ml of media per well. 
SKOV3, HFF and co-culture micro-tissues were transferred to a 2% agarose coated 






in the 2D model, SKOV3s, HFFs and co-culture (SKOV3:HFF 75:25) cells were seeded 
onto a 48-well plate at 30,000 cells and 200 µl of media per well. The next day, the 
samples were treated with different concentrations of doxorubicin – no drug control, 
0.001 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM. Media with 5% FBS containing the specific 
concentration of drug was changed every 2 days. After 4 days of exposure to the 
drug, AlamarBlue® assay was conducted to measure metabolic activity of the 
samples. For the AlamarBlue® assay, AlamarBlue® (Invitrogen, USA) was added to 
the media containing FBS so that the final concentration was 10% (v/v). After which 
the micro-tissues and assembled constructs was incubated for 20 hours and the cells 
in 2D were incubated for 3.5 hours at 37°C. Fluorometric measurements were made 
at an excitation wavelength of 545 nm and an emission wavelength of 590 nm and 
these values were curve fitted to estimate the half maximal inhibitory concentration 
(IC50) using GraphPad Prism v.6.0. The samples from the chemosensitivity test were 
also quantified for DNA content. The DNA was purified by ethanol precipitation as 
described earlier [42] for the assembled constructs but not for the micro-tissues. 
The purification was performed as the AlamarBlue® used to measure the metabolic 
activity stained the scaffold fibres, leached out during the DNA isolation process and 






6.3.12 Histology and immunofluorescence 
After the AlamarBlue® assay, the micro-tissues and cancer constructs from the 
chemosensitivity tests were fixed in 10% neutral buffered formalin for an hour, 
washed in PBS, immersed for an hour in 15% (w/v) sucrose in PBS and then 
immersed overnight in 30% (w/v) sucrose in PBS at 4˚C. The samples were then 
embedded in OCT and were cryo-sectioned (15 µm thick sections). The slides with 
the sections were rinsed in cold PBS thoroughly and were permeabilized with 0.25% 
(v/v) Triton X-100 in PBS for 30 minutes. The sections were rinsed in cold PBS and 
were exposed to 5% (w/v) BSA in PBS at pH 7.4 for 60 minutes at room temperature. 




They were then rinsed with cold PBS and incubated with monoclonal anti-Ki67 
(1:100 dilution: abcam, USA) and polyclonal anti-gamma H2AX (1:5,000 dilution: 
abcam, USA) anti-bodies at 4˚C overnight. The sections were washed in PBS and 
were incubated with secondary antibodies, goat Alexa Fluor 488 anti-mouse (1:500 
dilution: Thermofisher, USA) and goat Alexa Fluor 555 anti-rabbit (1:500 dilution: 
abcam, USA) at 37˚C for an hour. Following further washing, the sections were 
counterstained with 4.5 µM Hoechst 33342 in PBS. Finally, the slides were washed 
with 0.05% (v/v) Tween-20 in cold PBS, rinsed in PBS and then coverslipped. The 
samples were imaged using a Leica TCS SP5 confocal microscope.  
6.3.13 Statistical analysis 
Data was presented graphically as mean ± standard deviation. Data were 
analysed using GraphPad Prism v.6.0. Statistical analysis was performed using 1-way 
ANOVA or 2-way ANOVA (if required Tukey's multiple comparisons test) or paired t-
test, with p<0.05 set as a criterion for statistical significance. 
6.4 Results 
6.4.1 High-throughput fabrication of compact micro-tissues of regular 
spherical size and shape 
The efficient and reliable working of the automated bioassembly system as 
discussed and shown in Chapter 4 requires compact spherical micro-tissues with a 
diameter of 1 mm. This subsection describes the results to fabricate cancer micro-
tissues with the desired requirements.   
6.4.1.1 Preliminary experiment – effect of single cell source on micro-
tissue spheroid fabrication  
MCF-7, MDA-MB-231 and SKOV3 cell-lines were cultured for 7 days in our 
attempt to form compact spherical micro-tissues. These cell-lines were selected 
based on the prior experience we have of working with them, their availability in our 
laboratory and our intention of engineering a tumour construct. MCF-7 formed a 
delicate loose aggregate (Figure 6-2 a), MDA-MB-231 formed a slightly denser 
irregular micro-tissue of no particular shape (Figure 6-2 b) and SKOV3 formed a 














As the discoid shaped SKOV3 spheroids were not spherical and compact, it 
would not be able to be handled by the automated tissue assembly system.  So 
further attempts were made to form spherical micro-tissues by culturing SKOV3s in 
media supplemented with EGF, bFGF, Insulin and BSA for 7 days (Figure 6-3 b) which 










Cadherins play an important role in micro-tissues formation and fibroblasts 
are known to express multiple types of cadherin [21, 43].  Moreover, fibroblasts are 
known to produce and maintain extracellular matrix (ECM) by which they are 
interconnected [44]. Therefore, we investigated the co-culture of SKOV3s with 
human foreskin fibroblasts (HFFs) and this led to the successful formation of a more 
spherical shaped compact micro-tissue (Figure 6-4 c) compared to a discoid shaped 
micro-tissues formed from the SKOV3 monoculture. Apart from aiding the formation 
of compact spherical micro-tissues, the addition of fibroblasts to the 3D model is 
Figure 6-3. Darkfield images of (d) SKOV3 without supplements (e) SKOV3 
supplemented with EGF, bFGF, Insulin and BSA on day 7 at 80,000 cells/well. Scale 
bar = 500 µm for all images. 
 




Figure 6-2. Brightfield images of (a) MDA-MB-231, (b) MCF-7 and (c) SKOV3 micro-











valuable. Fibroblasts are one of the cellular components that make up tumours. They 
are known to have an important role in the progression, growth and spread of 
cancers and are associated with cancer cells in all stages of progression [45, 46]. The 
co-culture micro-tissue was investigated further for application with the automated 









6.4.1.2 Effect of cell co-culture ratio on micro-tissue sphericity 
The sphericity of the micro-tissue is important for the reliable functioning of 
the automated tissue bioassembly system. A spherical-shaped micro-tissue can 
easily move and be fluidically manipulated through the cylindrically shaped ports 
and tubes of the automated bioassembly system compared to a non-spherical 
shaped micro-tissue. Moreover, it was essential that the micro-tissues are compact 
so that they can withstand the fluidic forces while being handed by the fluidic tissue 
bioassembly system and that the micro-tissues do not end up falling apart or being 
dispersed. For the sphericity, a value closer to 1 indicates that theoretically, the 
micro-tissue is more spherical. Micro-tissues formed with percentage ratios of 100:0 
(0.47 ± 0.01), 99:1 (0.49 ± 0.02), 95:5 (0.49 ± 0.02), 90:10 (0.55 ± 0.08) of SKOV3 to 
HFF were more disc-shaped and there was no significant difference (p>0.05) (Figure 
6-5) in sphericity between them. However, with the percentage of HFF equal to 25% 
or more, the micro-tissues were more spherical in shape. The sphericity was 
significantly different (p<0.05) between micro-tissue ratios of 90:10 (0.55 ± 0.08) 
and 75:25 (0.71 ± 0.02), and 75:25 (0.71 ± 0.02) and 50:50 (0.82 ± 0.05). There was 
no significant difference (p>0.05) in sphericity between micro-tissues with a 
percentage ratios of 50:50 (0.82 ± 0.05), 25:75 (0.78± 0.01) and 100:0 (0.80 ± 0.06) 
of SKOV3 to HFFs. A ratio of 75:25 of SKOV3 to HFF was selected for the remaining 
experiments as it was the ratio that contained the lowest proportion of HFFs that 
Figure 6-4. Darkfield images of (a) SKOV3 (b) HFF and (c) co-culture (SKOV3:HFF 










resulted in micro-tissues spherical enough to be handled by the automated tissue 






6.4.1.3 Effect of cell seeding density on micro-tissue spheroid size 
The automated bioassembly system was designed for the reliable handling of 
micro-tissues with a diameter of 1 mm (deviation from the designed size could cause 
blockage or improper functioning of the system). Therefore, it was necessary that 
the fabricated micro-tissues have a diameter around 1 mm. Increasing the cell 
seeding density increased the average diameter of the co-culture micro-tissues. 
There was no significant difference (p>0.05) (Figure 6-6) in average diameter for 
micro-tissues formed with a seeding density of 100,000 (0.97 ± 0.03 mm) and 
120,000 (0.99 ± 0.02 mm), 120,000 and 140,000 (1.04 ± 0.02 mm), and 140,000 and 
160,000 (1.06 ± 0.04 mm) cells per well. All other conditions were significantly 
different (p<0.05). A cell seeding density of 120,000 (0.99 ± 0.02 mm) cells per well 
was chosen for the remaining experiments as it produced micro-tissues with an 















Percentage ratio of SKOV3 to HFF
* 
* 
Sphericity of micro-tissue 
Figure 6-5. Sphericity of micro-tissues for different percentage ratios of SKOV3 to 
HFF (n=4). *Significant difference (p<0.05) between neighbouring values. Statistical 








6.4.1.4 Cell distribution in co-cultured micro-tissues 
The SKOV3 and HFF cells were labelled with Qtracker 800 and 655 respectively 
and micro-tissue were fabricated with the labelled cells. Figure 6-7 displays the 
whole and sectioned fluorescence microscope images of the monoculture and co-
culture (SKOV3:HFF 75:25) micro-tissues cultured for 7 days. The distribution of the 
two cell types in the co-culture micro-tissues are not homogenous and there is a 
clear rearrangement of cells that can be visualized (Figure 6-7 g). The micro-tissue 
contains a core predominantly containing HFFs and a periphery predominately with 
SKOV3s. Although the cell seeding density in all the micro-tissues were the same, the 
monoculture SKOV3 micro-tissue (Figure 6-7 a, b, c and d) formed a discoid with a 
larger diameter, the monoculture HFF micro-tissue (Figure 6-7 i, j, k and l) was 
compact and spherical with a smaller diameter and the co-culture micro-tissue was 



















Seeding density versus micro-tissue size 
# # 
# 
Figure 6-6. Cell seeding density versus micro-tissues size on Day 7 for co-culture 
micro-tissues (SKOV3:HFF 75:25). # No significant difference (p>0.05) between 























6.4.2 Cancer construct bioassembly 
After successful fabrication of the desired compact spherical micro-tissue of 1 
mm diameter, we scrutinized the ability of the prototype automated bioassembly 
system to handle the cancer micro-tissues and validated the bioassembly of a cancer 
construct with the automated tissue bioassembly system. 
6.4.2.1 Assembled cancer construct – effect of fibre spacing 
A perfect fit of the micro-tissue within the scaffold pore was required so that 
the micro-tissues were not displaced out of the scaffold or that there were no gaps 
in the assembled construct when cultured over time. Therefore, the optimal fibre 
spacing for the 3D plotted scaffold for a Ø1 mm cancer micro-tissue was determined. 
After 5 days of culture of the assembled cancer construct, the darkfield images 
(Figure 6-8) showed that the assembled construct with a fibre spacing of 0.7 mm 

















Figure 6-7. Fluorescence microscope images of whole micro-tissues and micro-
tissue sections with SKOV3 (Qtracker 800, red) and HFF (Qtracker 655, green), and 
Hoechst 33342 (cell, nuclei blue). The ratio of SKOV3 to HFF are in rows. See Figure 
























(Figure 6-8 a) was substantially full and intact but the 0.8 (Figure 6-8 b) and 0.9 mm 
(Figure 6-8 c) constructs had pockets of space. The quantified DNA (Figure 6-9) did 
not show any significant difference (p>0.05) between constructs of different fibre 
spacing (0.7 mm - 12.27 ± 0.48 µg, 0.8 mm - 13.82 ± 2.41 µg, 0.9 mm - 13.16 ± 0.51 
µg). This suggests that the proliferation and attrition rate was constant across all 
fibre spacing. Based on these observations, scaffolds with a fibre spacing of 0.7 mm 






































Figure 6-9. DNA content (each scaffold containing 8 micro-tissues) after 5 days of 
culture for assembled cancer constructs with fibre spacing of (a) 0.7, (b) 0.8 and (c) 
0.9 mm. No significant difference (p>0.05). Statistical analysis: 1-way ANOVA. 
 
 
DNA conte t 
0.8 mm 0.9 mm 0.7 mm 
(a) (b) (c) 
Figure 6-8. Darkfield images imaged after 5 days of culture of assembled cancer 













6.4.2.2 Reliability and efficiency of the singularisation device with cancer 
micro-tissues 
The efficiency of singularisation for the co-culture cancer micro-tissues was 
determined to be 97 ± 4.83%. During the experiment, the reasons for singularisation 
failures included either the release of 2 micro-tissues at a time or due to the micro-
tissues being sucked into the vacuum pressure port. The singularisation failures that 
occurred were not critical and did not cause the failure of the device. In the event of 
a failure, either the singularisation cycle can be repeated if the device has failed to 
release a micro-tissue or in the case of a blockage the device can be purged with fluid 
so as to dislodge the blocking micro-tissue and clear the bioassembly system after 
which normal working can be resumed.  
6.4.2.3 Efficiency of cancer micro-tissue insertion  
The efficiency of successful micro-tissue insertion into the scaffold for the first 
layer (bottom) was 87.5 ± 13.69% and for the second layer (top) was 33.33 ± 
25.81%. The total efficiency was found to be 60.42 ± 12.29% (n=6 scaffolds, 8 micro-
tissues per scaffold). The smaller fibre spacing (0.7 mm) together with fewer fibre 
layers could have made it harder for the automated system to insert the second layer 
of cancer micro-tissues into the scaffold. Nevertheless, the scaffolds were visually 
examined by the user for missed micro-tissues insertions at the end of the assembly 
process for each layer, and the micro-tissue insertion process was repeated for pores 
without micro-tissues and the scaffold was completely assembled as intended.  
6.4.2.4 Cell viability of bioassembled cancer constructs  
During the 3D plotting process, the temperature in the high-temperature print 
head was approximately 200°C. Although the extruded material cools down rapidly 
during the layer-by-layer plotting, we had to ascertain that the molten polymer being 
plotted on the micro-tissues did not affect the viability of the micro-tissues and also 
that the handling of the micro-tissues by the automated bioassembly system did not 
affect the viability of the micro-tissues.  
 
To ascertain that the micro-tissues were not affected by the automated 
bioassembly process, cancer constructs were assembled automatically using the 




tissues were press-fitted by hand into a 3D plotted scaffold). The visual inspection 
of the live/dead fluorescence microscopy images (Figure 6-10) of the manually 
assembled scaffold and the construct assembled using the assembly system showed 
no obvious differences. This result was further validated with the AlamarBlue® assay 
(Figure 6-11). There was no significant difference (p>0.05) in the percentage of 
AlamarBlue® reduced by the manually assembled construct (92.75 ± 6.89%) and the 
construct assembled using the automated assembly system (82.08 ± 3.78%). 






















Figure 6-10. Fluorescence microscopy images of a manually assembled construct 
(a) top view  and (b) bottom view and (c) top view and (d) bottom view of a construct 
assembled using the automated assembly system assembled with cancer micro-
tissues stained with Calcein AM (live cells, green) and Propidium Iodide (dead cells, 
red). Scale bar = 0.2 mm for all images. 
(a) (b) 
(c) (d) 



































6.4.3 Drug response 
After successful fabrication of the desired micro-tissue and bioassembly of 
the tumour construct, the response of the engineered cancer constructs was further 
assessed with a chemotherapeutic drug - doxorubicin. Doxorubicin is a clinically 
relevant anticancer drug often used in combination chemotherapy to treat a range 
of tumours including ovarian cancer [47-49]. Therefore, doxorubicin was adopted as 
a model anticancer drug for evaluating the chemosensitivity in the 2D and 3D cancer 
models. Doxorubicin works by preferentially killing dividing or cycling cells [50]. 
The drug response was evaluated only for the co-culture assembled constructs as 
(described earlier) it was not possible to form compact and spherical SKOV3 micro-
tissues for assembly into a construct.  
6.4.3.1 Chemosensitivity test 
Chemosensitivity to doxorubicin was determined in vitro for cells in 2D, 



























Figure 6-11. Percentage of AlamarBlue® reduced to determine the viability of the 
manually assembled construct and the construct assembled using the automated 
system with cancer micro-tissues. The data is presented as mean ± SD (n=3). No 





exposure, and their dose-response curves were plotted in Figure 6-12. The accurate 
IC50 estimation requires a sufficient number of values in the upper and lower plateau 
regions of the dose-response curves [51]. A maximum drug concentration value of 
10 µM was selected for the experiment based on the previously reported value of 
3.75 µM for the peak concentration of free doxorubicin available to act on the cells 
in clinical chemotherapy [52]. However, the dose-response curves (Figure 6-12 b) of 
the micro-tissues (especially the HFF micro-tissues) and assembled constructs did 
not achieve a lower plateau region unlike the cells in 2D (Figure 6-12 a) making the 
IC50 estimates less accurate. Nevertheless, the IC50 estimates based on the available 
dose-response curves were used to evaluate the models. A significant increase 
(p<0.05) in the percentage of cell viability was observed in the HFF micro-tissues 
with increasing drug concentration from 0.1 µM (106.04 ± 14.82%) to 1 µM (126.30 
± 12.90%). It has been previously shown that the treatment of fibroblasts with 
doxorubicin can cause a decrease in the production of procollagen which is a 
precursor of the extracellular matrix protein collagen [53]. The decreased 
production of procollagen with increasing drug concentration could potentially 
result in better diffusion of nutrients, drug, and also AlamarBlue® which was used to 
measure the metabolic activity. This increased diffusion could have resulted in the 
observed higher percentage of growth control from 0.1 to 1 µM concentration of 
drug seen in the HFF micro-tissues [54, 55].  
 
The estimated IC50 values were higher for the individual 3D micro-tissue 
(SKOV3 - 0.17 µM, HFF - 7.05 µM, co-culture - 0.33 µM) and assembled 3D tumour 
construct (co-culture - 1.19 µM) respectively compared to cells in 2D (SKOV3 - 0.05 
µM, HFF - 0.05 µM, co-culture - 0.08 µM) (Figure 6-12 and Table 6-1). The differences 
in the IC50 values observed in cells in 2D versus 3D micro-tissues depended on the 
cell type. For the SKOV3s and the co-culture there was a 3-4 fold increase, but for the 
HFFs there was a 45 fold increase in IC50 values between cells in 2D and 3D micro-
tissues. The higher drug resistance of the individual 3D micro-tissue models 
compared to the cells in 2D shows the need for testing candidate drugs on 3D models 
which are more analogous to tissues in vivo. Moreover, the cell-dependent response 
emphasizes the importance of complex co-culture 3D models. A 15 fold increase 
between cells in 2D and the assembled construct and a 4 fold increase in IC50 value 




observed. This higher drug resistance of the assembled constructs compared to co-
culture micro-tissues highlights the significance of a larger more complex assembled 
construct model compared to a smaller micro-tissue model. It also suggests that the 





































































Cells in 2D 
 
Figure 6-12. Dose-response curves for doxorubicin for (a) cells in a 2D (b) micro-
tissues and assembled construct. The response of SKOV3s, HFF, and co-culture cells 


















SKOV3 0.05 0.17   3.48     
HFF 0.16 7.05   45.05     
Co-culture 0.08 0.33 1.19 4.17 3.59 14.97 
 
 
The DNA content expressed in percentage of control against drug 
concentration for the micro-tissues and assembled construct is shown in Figure 
6-13. The DNA content of SKOV3 and co-culture micro-tissues reflected their dose-
response curve (Figure 6-12 b) and showed a similar trend of decrease in DNA 
content with increasing concentration of the drug. The normalised DNA content in 
the SKOV3 micro-tissues decreased significantly (p<0.05) from 0.01 (107.89 ± 
0.57%) to 0.1 µM (74.84 ± 0.57%) and from 0.1 (74.84 ± 0.57%) to 1 µM (19.88 ± 
23.74%). In the co-culture micro-tissues, a significant decrease (p<0.05) in 
normalised DNA content was observed from 0.1 (81.77 ± 1.92%) to 1 (43.24 ± 
1.15%) µM and from 1 (43.24 ± 1.15%) to 10 µM (0.00 ± 0.45%). In the HFF micro-
tissues the significant decrease (p<0.05) in normalised DNA content was only 
observed from 1 (83.81 ± 4.94%) to 10 µM (0.00 ± 2.19%) of drug concentration. 
Whereas the dose-response (Figure 6-12 b) of HFF micro-tissues increased with 
increasing drug concentration, peaked at 1 µM of drug and steeply fell at 10 µM. The 
significant decrease in normalised DNA content was observed at lower drug 
concentrations in the SKOV3 micro-tissues (0.01 – 0.1 µM) compared to the co-
culture micro-tissues (0.1 - 1 µM) and at a higher drug concentration in the HFF 
micro-tissues (1 µM). The normalised DNA content for the assembled construct 
decreased from 0.01 (118.31 ± 9.35%) to 0.1 µM (77.59 ± 26.48%) and from 1 (55.08 
± 9.93%) to 10 µM (0.00 ± 2.22%). This decrease in normalised DNA content is 
consistent with the darkfield microscopy images (Figure 6-14) of the assembled 
construct which revealed that at higher concentration of drug there was an atrophy 
of the tissue present in the construct. The tissue atrophy was especially noticeable 
at 1 µM concentration (Figure 6-14 e) of the drug and at 10 µM (Figure 6-14 f) there 
was almost no tissue present within the construct. The larger error bars observed in 
Table 6-1. Chemosensitivity of doxorubicin. 
 




the assembled construct could be due to the ethanol precipitation method used to 
purify DNA in which the yield of purified DNA can vary resulting variability in among 
the samples. At 1 µM of drug concentration, there was a significant difference 
(p<0.05) in normalised DNA content between all the 3D models apart from the 
difference between the 3D assembled constructs and co-culture 3D microspheres 
(SKOV3 – 19.88 ± 23.74%, HFF – 83.81 ± 4.94%, co-culture – 43.24 ± 1.15%, and 



























Figure 6-13. Doxorubicin dose dependent DNA content normalised to control and 
expressed in percentage of control for SKOV3, HFF and co-culture micro-tissues and 
assembled construct with co-culture micro-tissues measured after 4 days of 
exposure to the drug. The data is presented as mean ± SD (n=4). *Significant 
differences between columns are below the ends of each line (p<0.05). Statistical 



























































































6.4.3.2 Histology and immunofluorescence 
Immunofluorescence staining for Ki67, γ-H2AX and Hoechst 33342 on 
cryosections of SKOV3, HFF, co-culture micro-tissues is shown in Figure 6-15 and for 
assembled cancer constructs in Figure 6-17 respectively. Ki67 protein is a 
proliferation nuclear marker that is required for maintaining cell proliferation and 
is present in all active phases of the cell cycle apart from G0 phase or the quiescent 
state [56, 57]. In SKOV3 micro-tissues, the expression of Ki67 was observed mostly 
at the periphery of the micro-tissues (Figure 6-15 f-j). In the co-cultured micro-
tissues (Figure 6-15 aj-an), Ki67 expression was also observed mostly at the 
periphery. The fluorescence staining observed in the core (Figure 6-15 aj-an and 
Figure 6-17 c and d) was due to autofluorescence of the HFF core and disappears at 
a higher magnification (see Figure 6-16 f and h). However, limited Ki67 expression 
was observed in HFFs (Figure 6-15 u-y). The cells in the cancer constructs (Figure 
6-17 c and d) expressed Ki67 suggesting the presence of proliferating cells and – as 
in the case of the co-culture micro-tissues – the fluorescence staining observed in 




0.001 µM 0.01 µM 
(b) (c) 
0.1 µM 1 µM 10 µM 
(d) (e) (f) 
Figure 6-14. Darkfield images of the assembled cancer construct imaged after 4 days 
of exposure to anticancer drug. (a) control, (b) 0.001, (c) 0.01, (d) 0.1, (e) 1 and (f) 




Doxorubicin causes double-strand breaks in DNA which correlates with the 
cytotoxicity of the drug [58]. Double-strand breaks in DNA can be visualised by the 
formation of γ-H2AX which is a precise and a highly amplified response [59, 60]. In 
SKOV3 micro-tissues, the expression of γ-H2AX observed in control (Figure 6-15 k) 
and 0.001 µM (Figure 6-15 l) concentration of the doxorubicin was very low but 
present. At 0.01 µM (Figure 6-15 m) concentration of the drug, the expression of γ-
H2AX observed was high and towards the periphery of the micro-tissue. At 0.1 
(Figure 6-15 n) and 1 µM (Figure 6-15 o) concentration of the drug, lower expression 
of γ-H2AX compared to 0.01 µM (Figure 6-15 m) was observed. This reduction in γ-
H2AX visualisation at 0.1 and 1 µM compared to 0.01 µM drug concentration in the 
SKOV3 micro-tissues could be due to the lower cell number and density as seen from 
the Hoechst staining (Figure 6-15 c, d and e). The higher expression of DNA damage 
marker that we observed in the SKOV3 micro-tissues correlated with the higher 
proportion of proliferating cells, earlier significant decrease (at 0.01 µM) in 
normalised DNA content and lowest IC50 value (0.17 µM) among the 3D models. In 
HFF micro-tissues, expression of γ-H2AX was only observed at 1 µM (Figure 6-15 
ad) concentration of the drug and the expression of γ-H2AX observed was very low. 
The lower DNA damage observed in the HFF micro-tissues correlated with a lower 
proportion of proliferating cells, a later significant decrease (at 1 µM) in normalized 
DNA content and the highest IC50 value (7.05 µM) among the 3D models. In the co-
culture micro-tissues, expression of γ-H2AX was low in the control (Figure 6-15 ao), 
0.001 (Figure 6-15 ap) and 0.01 µM (Figure 6-15 aq) concentration of doxorubicin. 
The expression of γ-H2AX observed (Figure 6-15 ao-as) was more toward the 
periphery of the micro-tissue where the distribution of SKOV3 cells are higher (from 
the Qtracker labelling of the cells – Figure 6-15 at-ax). At 0.1 µM (Figure 6-15 ar) 
concentration of the drug, the expression of γ-H2AX observed was higher, and the 
expression of γ-H2AX was highest at 1 µM (Figure 6-15 as). Even at 1 µM of 
doxorubicin, the expression of γ-H2AX observed was more toward the periphery of 
the micro-tissue (Figure 6-16 k) whereas in the SKOV3 (Figure 6-16 o) micro-tissue 
it was distributed throughout. In the assembled cancer construct, the γ-H2AX 
expression observed at 1 µM (Figure 6-17 f) concentration of drug was higher than 
the control (Figure 6-17 e) and the expression was higher at the periphery of the 
assembled construct itself. The co-culture micro-tissues and assembled constructs 




this correlated with the median level in the proportion of proliferating cells and IC50 
values (co-culture micro-tissues - 0.33 µM and assembled construct - 1.19 µM). The 
increased drug resistance of the assembled construct compared to the co-culture 
micro-tissues could be due to the larger size of the construct resulting in the reduced 
drug, oxygen and nutrient concentration [23, 61].  
 
It has been suggested that the uptake of doxorubicin is significantly reduced in 
larger micro-tissues [23]. The decreased penetration of the drug along with the 
higher nutrient constraint and lower proliferation would have a protective effect on 
the cancer construct from the drug. This situation is comparable to an in vivo 
environment where due to deficient or abnormal vascularisation in a tumour, there 














































































































































Figure 6-15. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), Hoechst 
33342 (cell nuclei, blue), and SKOV3 (Qtracker 800, red) and HFF (Qtracker 655, green) 
imaged using a confocal microscope for SKOV3, HFF and co-culture micro-tissues for no 
drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM concentration of doxorubicin. Scale bar = 



















































































Control  1 µM 
Periphery Core Periphery Core 
Figure 6-16. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), 
Hoechst 33342 (cell nuclei, blue), and SKOV3 (Qtracker 800, red) and HFF 
(Qtracker 655, green) imaged using a confocal microscope for co-culture micro-
tissues at the periphery and core for no drug control and 1 µM concentration of 


















































Control  1 µM 
Figure 6-17. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), 
Hoechst 33342 (blue), and SKOV3 (Qtracker 800, red) and HFF (Qtracker 655, 
green) imaged using a confocal microscope for assembled cancer constructs for 























































In this study, a modular bioassembly based approach was employed for 
biofabrication of an in vitro 3D cancer model. The cancer model was developed by 
adopting a “bottom-up” or modular assembly strategy currently being developed for 
tissue engineering applications [36, 62]. Modular tissue engineering aims at the 
development of complex, multi-cellular tissue constructs with hierarchical cell 
organization, through the use of smaller self-assembled or direct-assembled tissue 
modules or building blocks [62]. Modular tissue engineering approaches offer 
potential in recreating the intricate microstructural features of native tissues [36]. 
As many tissues are composed of repeating functional units, there exists a rational 
for using modular tissue engineering approaches to fabricate larger tissues from 
smaller tissue units [36].  
 
We have developed a prototype automated bioassembly system that can 
assemble smaller tissue units (i.e. micro-tissues) into a 3D plotted scaffold. Our data 
demonstrated the reliable and efficient handling of cancer micro-tissues by the 
automated bioassembly system. The prototype fluidic-based automated 
bioassembly system was developed to provide a flow path and micro-tissue handling 
solution that did not damage the micro-tissues and no significant effect on cell 
viability were observed in constructs assembled with the automated bioassembly 
system (Figure 6-10 and Figure 6-11). This platform thereby provided a pathway for 
investigating automated modular assembly of 3D cancer micro-tissues for in vitro 
drug screening. With the automated bioassembly system, mathematical models or 
anatomical models can be easily translated into a computer aided manufacturing 
(CAD/CAM) file and inputted into a bio-plotter [63]. This, along with the layer-by-
layer strategy, would enable the fabrication of complex constructs, or constructs 
with an array of desired combinations of micro-tissues assembled with the required 
geometry in precision and in large numbers.  
 
For the purpose of initial validation, the automated tissue assembly system 
was designed for optimal handling of spherical Ø1 mm sized tissue units, therefore, 
it was essential that the fabricated micro-tissues were compact, spherical and of Ø1 
mm in size. Many cancer cell lines form only loose aggregates or association of cells 




lines  [31]. Previous studies have reported scales such as a “compactness index” to 
quantify compactness of micro-tissues [21, 64]. Unfortunately, much of the 
compactness of micro-tissues reported in the literature for a particular cell-line type 
tend to be descriptive and not quantitative, making it challenging to select a compact 
micro-tissue forming cell-line. MCF-7 (a non-invasive cell-line [65]) has been 
reported to form compact micro-tissues, SKOV3 (invasive cell-line [66]) an aggregate 
and MDA-MB-231 (invasive cell-line [65]) a loose aggregate after 24 hours of culture 
on poly-HEMA coated plates [31, 67, 68]. On the contrary, it has also been suggested 
that the ability to form compact spheroids in cancer cell-lines is associated with an 
invasive phenotype [67, 69]. However, from our preliminary experiments, we were 
only able to form discoid (flat and circular) SKOV3 micro-tissues after 7 days of 
culture using a liquid overlay technique. The discrepancy in the ability to form 
compact micro-tissues across different studies reported and our experiment could 
be due to the cells, culture techniques or even the targeted micro-tissue size. The 
formation of micro-tissues has been associated with the expression of integrins and 
cadherins [21]. The major adhesion molecule that maintains tight cell-cell 
interaction has reported to be E-cadherin and has been correlated to the formation 
of compact micro-tissues [67]. The reduction or the loss of expression of adhesion 
molecules can alter the ability of the cells to aggregate into a compact micro-tissue 
[67]. The loss of E-cadherin expression in MDA-MB-231 could be the possible reason 
that they do not form compact micro-tissues [67]. With MCF-7s, they have been 
reported to express E-cadherin and form compact micro-tissues, but their inability 
to form compact micro-tissues in this study was unexpected [31, 67]. One possible 
explanation could be the difference in the technique used for the micro-tissue 
fabrication which caused an altered E-cadherin expression. In studies reported by 
Ivascu et al. micro-tissues were fabricated by seeding 5000 cells per well in a poly-
HEMA coated 96-well plate with centrifugation after seeding the cells which resulted 
in compact micro-tissues after culture for 24 hours [31, 67]. However, we seeded 
80,000 cells per well in an agarose coated 48-well plate without centrifugation 
which did not result in the formation of compact micro-tissues after 7 days of 
culture. Genotypic and phenotypic drifts can occur in cell lines and biological 
differences have been observed in MCF-7s obtained from different laboratories and 
this could also possibly contribute to the difference in the ability to form compact 




(HFFs) with SKOV3 yielded a compact spherical micro-tissue of 1 mm diameter that 
could successfully be handled by the tissue assembly system for assembling cancer 
constructs.  
 
With respect to the self-assembly and arrangement of co-cultured HFFs and 
SKOV3s in micro-tissues, Qtracker labelling (Figure 6-7) revealed an 
inhomogeneous cell distribution, with the cells self-segregating to form a 
predominantly HFF core surrounded by SKOV3s in the periphery. When the micro-
tissues were assembled in a scaffold, the cells did not rearrange again and 
maintained their original arrangement they had as an individual micro-tissue. A 
similar rearrangement of cells has been reported by Rago et al. with normal human 
fibroblasts and rat hepatoma cells [35]. The self-segregation of cells in a micro-tissue 
can be explained based on the differential adhesion hypothesis (DAH). According to 
the DAH, cellular aggregates form a spherical structure to maximize intercellular 
adhesion and to minimize free energy, and cells in the micro-tissue self-segregate 
due to differences in cell-cell adhesion or apparent surface tension [72]. Cells with a 
higher cohesion are located on the inside and cells with a lower cohesion are located 
on the outside [72]. It has been reported that in a co-culture system, cells that 
produced similar levels of N-cadherin did not segregate, but when the levels were 
moderately different they segregated with the cells with a higher N-cadherin 
expression on the inside and the cells with a lower N-cadherin expression on the 
outside [73]. Cancer cells with a more fibroblastic phenotype and reduced E-
cadherin expression have been suggested to be more invasive [74]. SKOV3 is an 
invasive cancer cell-line in which the E-cadherin DNA is highly methylated and also 
it has been reported that hypoxia reduces E-cadherin expression in SKOV3 cells [75, 
76]. The reduced cadherin expression in SKOV3 cell-line could explain the formation 
of a less compact discoid in SKOV3 only micro-tissues and the formation of a more 
compact spherical micro-tissue that self-segregate when SKOV3 is co-cultured with 
fibroblasts which express multiple types of cadherin [43]. Fibroblasts and 
myofibroblasts represent the majority of the cells in a tumour stroma, and tumour 
stroma plays an important role in the support and progression of epithelial cancer 
cells [77, 78]. The observed rearrangement of fibroblasts and SKOV3s could 
potentially partly simulate the tumour cell-stroma interactions in tumours in vivo, 




could potentially be investigated for chemotherapy targeting tumour-associated 
stroma [78].  
 
Fibroblasts are known to play an important role in the progression, growth and 
spread of cancers and are associated with cancer cells at all stages of progression 
[45, 46]. Activated fibroblasts associated with malignant tumours – called cancer-
associated fibroblasts (CAFs) – are known to enhance tumour progression [45, 79, 
80]. Co-culture cancer models with normal (non-cancer-associated) fibroblasts are 
thought to envisage early stages of tumour development and dissemination 
compared to co-culture with cancer-associated fibroblasts which reflect later stages 
[68]. This could mean that our model could potentially be made to resemble an early 
or late stage tumour based on whether the model is composed of normal or cancer-
associated fibroblast.  
 
The efficacy of the drug on cells in 2D, individual micro-tissues and assembled 
constructs were evaluated by exposing the models to varying concentrations of 
doxorubicin. An enhanced chemoresistance indicated by the higher IC50 values 
(Table 6-1) was observed in the 3D models compared to cells in 2D, which is in 
agreement with other studies [5, 81-84]. There are many possible reasons for the 
higher chemoresistance of doxorubicin in 3D models compared to the cells in 2D. 
Micro-tissues have a larger number of non-proliferating cells especially in the core 
compared to cells in 2D where most cells are proliferating. The toxicity of 
doxorubicin is dependent on the proliferating rate of cells and a lower proliferation 
rate in 3D models results in a lower number of doxorubicin induced DNA strand 
breaks [84]. This is in agreement with our Ki67 (marker for proliferation) and γ-
H2AX (marker for double-strand breaks in DNA) immunofluorescence staining 
(Figure 6-15 and Figure 6-16) which were expressed at a greater intensity at the 
periphery of the micro-tissue than in the core. Other possible reasons for the higher 
chemoresistance in 3D models could be attributed due to the reduced drug 
penetration, hypoxia, cell-cell interaction, gene and protein expression, and 
increased extracellular matrix components [24, 85-88]. The proliferating cells at the 
periphery of the micro-tissues observed predominantly in the SKOV3 micro-tissues 




and has been attributed to the inefficient mass transport towards the core of the 
micro-tissue [84, 89]. 
 
From the dose-response curves (Figure 6-12) and IC50 values (Table 6-1), a cell 
type-dependent response to the drug was observed. Co-cultured micro-tissues (0.33 
µM) containing SKOV3 and HFF had a higher IC50 value compared to SKOV3 only 
monoculture micro-tissues (0.17 µM). HFF micro-tissues (7.05 µM) were the most 
chemoresistant and had the highest IC50 value. The higher chemoresistance of 
fibroblasts to tumour cells and increased chemoresistance of tumour cells in the 
presence of fibroblasts has been previously been reported [90, 91]. The higher 
resistance of fibroblasts and co-culture micro-tissues could be caused by a 
physiological resistance due to the extracellular matrix secreted resulting in the 
reduced penetration of anticancer drug [45, 92]. Moreover, in the HFF micro-tissues, 
low Ki67 expression (Figure 6-15 u-y) was observed suggesting a low proliferation 
rate resulting in a low number of doxorubicin-induced DNA strand breaks observed 
by the low γ-H2AX expression (Figure 6-15 z-ad). This observation is consistent with 
the high IC50 value (7.05 µM) as well as the observed significant decrease in 
normalised DNA content (1 - 10 µM) at a higher drug concentration (Figure 6-13). 
The lower γ-H2AX expression in the HFF micro-tissues could also be attributed to 
the ability of non-proliferating cells to repair damaged DNA caused by the drug [93]. 
With the SKOV3 micro-tissues, the higher proliferation rate as seen from the Ki67 
expression (Figure 6-15 f-j) leaves the SKOV3 micro-tissues at a higher susceptibility 
to the number of doxorubicin-induced DNA strand breaks. This observation is in line 
with the lower IC50 value (0.17 µM), the higher levels of γ-H2AX visualised for a 
particular concentration of drug compared to the co-culture and HFF micro-tissues 
and also the observed significant decrease in normalised DNA content (0.01 – 0.1 
µM) at a lower drug concentration (Figure 6-13). With the co-culture micro-tissues 
(Figure 6-15 aj-an), the fraction of proliferating cells was observed to be lower 
compared to the SKOV3 micro-tissues but higher compared to the HFF micro-tissues 
and can be confirmed by the Ki67 staining (Figure 6-15). This Ki67 expression 
correlated with the median level in the expression of γ-H2AX estimated IC50 values 
(0.33 µM) and also the observed significant decrease in normalised DNA content (0.1 
- 1 µM) all of which was in-between the response for the SKOV3 and HFF micro-




Figure 6-16) observed with increasing drug concentration was more toward the 
periphery of the micro-tissue where the distribution of SKOV3 is higher and a higher 
proportion of proliferating cells are located. Micro-tissues that are more compact 
have also been correlated to have a higher drug resistance and the difference we 
observed in the chemoresistance could be due to the difference in the micro-tissue 
compaction between micro-tissues of different cell types [94]. The increased micro-
tissue compaction is associated with increased intercellular adhesion which causes 
a lower fraction of proliferating cells thereby possibly resulting in higher 
chemoresistance [94].  
 
A higher background levels of γ-H2AX was visualised in the control SKOV3 
micro-tissue (Figure 6-15 k). Similarly in the control co-culture micro-tissues, a 
higher background level of γ-H2AX expression (Figure 6-15 ao) was visualised in the 
periphery of the micro-tissues where the SKOV3s are located (Figure 6-15 at) 
compared to the HFF core where no noticeable expression of γ-H2AX was observed. 
However, in the control HFF micro-tissues, no noticeable expression of γ-H2AX 
(Figure 6-15 z) was observed. The higher background levels of γ-H2AX visualised in 
the SKOV3 micro-tissues and in the SKOV3s in the co-culture micro-tissues (inferred 
from the Qtracker labelling and γ-H2AX expression) without drug treatment, could 
be due to the presence of double-stranded breaks caused by the higher rate of 
mutations in genes involved in DNA repair and unregulated cell cycle checkpoints in 
cancer cells as reported previously [59, 95-97]. 
 
The 3D assembled co-culture construct had a higher chemoresistance 
compared to individual 3D co-culture micro-tissue. A 4-fold increase in IC50 values 
between co-culture micro-tissues (0.33 µM) and the co-culture assembled 
constructs (1.19 µM) was observed. As in the case of ECM in tumours in vivo the ECM 
in the 3D models can slow down the diffusion of nutrients, drugs and oxygen 
resulting in a concentration gradient of these molecules and these gradients could 
be greater in the larger assembled construct compared to the smaller micro-tissues 
[23, 24, 85]. The lower diffusion of nutrients and oxygen in the larger assembled 
construct compared to the micro-tissues would result in the lower proliferation rate 
in the assembled construct and lower efficacy of the drug as doxorubicin 




uptake of doxorubicin is significantly reduced in larger micro-tissues [23]. The 
reduced diffusion and increased concentration gradient of doxorubicin towards the 
core in the larger assembled construct compared to the smaller micro-tissues would 
result in the drug being less effective on the cells distal to the periphery of the 
assembled construct, consequently causing an increased chemoresistance of the 
assembled construct compared to the micro-tissues [24, 85]. As the treatment of 
tumours becomes more challenging with increasing tumour size, the size-dependent 
response highly is relevant for the treatment of tumours in vivo (as mentioned 
earlier, the average ovarian cancer tumour size can range from 4.6 to 11.8 cm) [27, 
29]. Despite the fact that small (<200 µm) micro-tissues are commonly used in high-
throughput screening models to reproduce cell-cell and cell-matrix interactions, the 
observed size depended on the response of the 3D models to the drug also need to 
be factored in during the screening of candidate anticancer drugs. Therefore, larger 
(>1.6 mm which is the size we used in the study here) assembled constructs as an in 
vitro 3D model would be more relevant compared to 2D models or individual micro-
tissues for predicting promising drug candidates for larger in situ tumours. 
 
The 3D models investigated in this study consisted only of ovarian cancer 
cells and fibroblasts, however, native in vivo tumour tissues are composed of 
heterotypic cell types which includes cancer stem cells [98], primary stem cells, 
fibroblasts [45], endothelial [99] and immune cells [100], where modelling a more 
clinically relevant in vivo like a tumour would require the incorporation of these cells 
into the model [101]. Even though there exists abundant literature on the co-culture 
of 2 different cell types, little research has focused on the development of in vitro 
models with 3 or more cell types [101, 102]. Further development of the 3D 
bioassembly model to incorporate other cell types found in tumours would be the 
next step. For example, the stroma consists of connective tissues, blood vessels, and 
inflammatory cells and plays an essential role in the progress or inhibition of cancer 
[46, 103]. To potentially recapitulate the tumour-stroma interaction in vivo, a 
biphasic construct with a phase containing tumour micro-tissues and the other 
containing micro-tissues fabricated with elements of the stroma could be assembled 
to fabricate a 3D model. The drug and toxin metabolism in vivo by the liver could be 
simulated by assembling a tumour construct with tumour micro-tissues along with 




assembled with bone micro-tissues to simulate a metastatic model to investigate 
bone invasion and osteolysis [106]. The automated tissue assembly system could be 
used to assemble mono-culture or co-culture micro-tissue modules of healthy or 
tumour origin cells into a 3D plotted scaffold in a predetermined desired 
arrangement. The construct can be assembled in a high-throughput format and 
interaction between different types of micro-tissues and the cells targeted by the 
drug can be investigated and analysed [101]. An alternative approach to 
investigating complex tumours would be a modular assembly based deconstruction-
reconstruction approach. Here, complex tumours are deconstructed to its individual 
basic cell type after which the deconstructed component is added to the model to 
vary the complexity of the cancer model. This would enable understanding both the 
individual components and collective components of the tumour as a whole [101].  
 
The application of Biofabrication and 3D plotted models for drug 
development has grown rapidly from an abstract concept and has received 
considerable recent attention from researchers and commercial entities alike. 
Organovo, an early-stage medical laboratory and research company has even begun 
offering services to evaluate drug exposure on a bioprinted human liver model [107]. 
Developing a new drug by the pharmaceutical industry is a billion dollar process of 
which a major portion is spent on research [108]. Screening new drugs with 3D 
tissue culture models have an increasingly important role to play before clinical 
trials on humans [109, 110]. For a model to be efficient and effectively suited for 
preclinical testing especially in an industrial environment it is essential to be able to 
scale it for medium or high-throughput screening (HTS) [4]. The prototype, fluidic 
based automated assembly system developed in this study could serve as a template 
for developing an industry standard system that can be integrated with commercial 
liquid handling systems currently being used. The potential to transform the 
prototype technology into an industrial system would make the technology 
attractive to pharmaceutical researchers and companies which in turn would attract 
investment. Given our oncological model can be fabricated in a high-throughput 
fashion, a large number of complex tumour constructs can be potentially fabricated 





In the near future, we could see our organotypic in vitro 3D cancer model 
adapted to generate a personalised patient-specific model for screening cancer 
drugs from a repertoire and select a patient-specific drug [98]. The model could 
contain cells of both normal and tumour phenotype and the impact of different 
anticancer drugs could be examined to predict and foresee the benefits of treatment 
and the impact on quality of life of the patient. 
  
The primary drawback of the micro-tissue based system is that only cells that 
can form or induce the formation of compact spheroids can currently be used with 
our automated tissue assembly system. One alternative approach would be to 
forcefully encapsulate the cells in a 3D matrix - an approach to be described and 
tackled in the next chapter [31, 111].  Encapsulation of cells would also cut short the 
rate-limiting step of the long culture time required before a robust compact micro-
tissue can be formed.  
 
Currently, the tissue assembly system has an innate shortcoming in that micro-
tissues need to be of a fairly uniform size and micro-tissues above or below the 
designed size range of 1 mm diameter cannot be efficiently handled. Though 
spheroids can be formed over a wide range of sizes, quite often micro-tissues of up 
to 200 µm in diameter are used for high-throughput screening, which is thought to 
be sufficient to reflect the 3D cell-cell and cell-matrix interactions [22, 31]. For the 
automated bioassembly system to be capable of handling micro-tissues smaller or 
larger than the designed range, the physical components (i.e. tubing singularisation 
chamber and injection nozzle, see chapter 3 and 4) and the soft parameters (i.e. valve 
timing, fluid pressure) of the automated bioassembly system would have to be 
modified to accommodate the new desired size. Therefore, as we approach smaller 
sizes the system might become strongly influenced by laminar flow, surface tension, 
diffusion and fluidic resistance making the development of a new system inevitable 
[112].  
 
We forecast that our developed model and tissue assembly system can cater to 




6.6 Conclusions  
We have reported the 3D Bioassembly of micro-tissues for biofabricating cancer 
constructs for application as an in vitro 3D cancer model. The co-culture of ovarian 
cancer cells with fibroblasts was necessary to form compact and spherical Ø1 mm 
cancer micro-tissues that can be handled by the automated bioassembly system. The 
cells in the micro-tissue self-segregated to form a predominantly fibroblast core 
surrounded by SKOV3 in the periphery and this arrangement was maintained when 
the micro-tissues were assembled into a scaffold. Using our prototype automated 
tissue bioassembly system, we successfully demonstrated the fabrication of a cancer 
construct. Our results indicate that the bioassembly system efficiently handles the 
cancer micro-tissues and that the cancer micro-tissues are unaffected by being 
handled by the automated tissue bioassembly system. We then characterised and 
studied the response of the micro-tissues and the cancer construct to an anticancer 
drug - doxorubicin. The results show an obvious difference between the response of 
the cells in the 2D model and the 3D model, and micro-tissues of different cell types 
and the co-culture assembled construct. With its flexibility, the technology and the 
cancer model would have a broad utility and could be used for a wide range of 
applications including as 3D model for investigation cancer and for anticancer drug 
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Chapter 7 Automated 3D Bioassembly of cell-laden 
microspheres for biofabrication of an in vitro 3D cancer 
model and its evaluation compared to existing 2D and 3D 





Oncological models are imperative for investigating cancer and for the 
development of therapeutics. 2D cultures are primitive and animal models are 
expensive, complex and need ethical approval. 3D models provide a more attractive 
intermediate solution. However, methods describing the high-throughput 
fabrication of large 3D cancer constructs with complex architecture have been 
limited. We aimed at the automated 3D Bioassembly of cell-laden microspheres for 
biofabricating modular assembly based cancer constructs for application as in vitro 
3D cancer models. SKOV3, human foreskin fibroblast (HFF) and co-culture cell-laden 
GelMA microspheres of Ø1 mm were fabricated with a microfluidic device and 
characterised. The microspheres were reliably and efficiently handled by the 
automated bioassembly system. Layer-by-layer assembly of 8 microspheres into a 
3D plotted PEGT/PBT polymer scaffold utilising the automated tissue bioassembly 
system showed no significant difference in viability when compared with manually 
assembled bilayered constructs. For evaluating the chemosensitivity, cells in 2D, 
microspheres and assembled cancer constructs were exposed to doxorubicin for 4 
days and the metabolic activity was measured using AlamarBlue® assay. Fixed frozen 
sections were stained for Ki67 and γ-H2AX. Chemosensitivity testing demonstrated 
that the 3D assembled constructs had the highest chemoresistance, the cells in 2D 
were the most vulnerable to the drug, whereas 3D microspheres showed an 
intermediate chemoresistance. The chemoresistance to the drug was also cell 
dependent. This model and technology demonstrated the feasibility of 







It is generally recognised that 3D in vitro models are able to more accurately 
mimic tissues in vivo than 2D models as they are a more physiologically relevant 
model system [1, 2]. 2D culture systems differ considerably in the proliferation, 
apoptosis, differentiation, and gene expression and do not recapitulate the 3D 
anatomy or physiology of native tissue [3, 4]. Furthermore, cells cultured in 2D have 
an altered drug response and sensitivity compared to cells in a 3D environment, 
resulting in the poor negative screening of candidate antitumour drugs [5]. Animal 
models, on the other hand, are complex, expensive and require ethical approval [4]. 
With the drawbacks of 2D monolayer systems and animal models, there is a need for 
3D models that can bridge the gap between 2D drug screening models and animal 
models, to improve the reliability of current drug screening protocols before 
implementation in clinical trials [1, 6]. 
 
In the previous chapters, we described the development of an automated 3D 
tissue bioassembly system and forged an in vitro 3D cancer model that was 
populated with micro-tissues. Unfortunately, the formation of compact micro-
tissues is only limited to a small subset of cancer cells and is highly dependent on 
the cell phenotype [7-10]. For example, we showed that breast cancer cell lines such 
as MCF-7 and MDA-MB-231 could not be fabricated into compact spherical micro-
tissues, whereas the ovarian cancer cell line (SKOV3) required to be co-cultured with 
fibroblasts to form compact spherical micro-tissues that could be handled and 
assembled by the automated bioassembly system. This drawback of not being able 
to form compact spherical micro-tissues would seriously hinder the application of 
the developed model for a wider range of cell types. The alternative path to conquer 
this issue would be to encapsulate the cells in a 3D hydrated polymeric network, i.e. 
hydrogel microspheres that can be handled by the automated bioassembly system.  
 
Encapsulating cells in a hydrogel is appealing as it provides a hydrated tissue-
like environment which is structurally similar to the native extracellular matrix 
(ECM) of many tissues [11, 12]. A wide range of 3D hydrogel-based matrices for 
cancer models have been described, such as reconstituted basement membrane 





[5] and silk fibroin [15]. However, gelatine-methacryloyl (GelMA) hydrogels are an 
appealing alternative given that it is inexpensive, water soluble, can be derived from 
a wide variety of natural sources, biocompatible, and can be photocrosslinked with 
tailorable physicomechanical properties [16, 17]. In the literature, various 
techniques have been employed to fabricate hydrogel microspheres, such as 
electrospraying [18], polyelectrolyte complexation [19], solvent evaporation [20], jet 
cutting [21], jet breakup [22], and electrostatic droplet generation [23]. In this 
chapter, we adapted a simple droplet microfluidic setup coupled with 
photopolymerisation from Serra et al. [24] to produce microspheres of a uniform 
size range [25]. The setup was presented earlier (Chapter 5, Figure 5-1) to form 
GelMA microspheres encapsulated with chondrocytes.  We adopted the technique to 
fabricate cancer cell encapsulated GelMA microspheres as described herein.  
 
By employing bottom-up tissue engineering strategies, smaller subunits or 
building blocks such as microspheres can be assembled to generate large constructs 
of complex and precise architecture [26]. Clinically relevant tumours in vivo are often 
quite large. Rosen et al. reported that tumour sizes in stage II breast cancer varied 
from 2.1 to 5 cm and Horvath et al. reported that average ovarian cancer tumours 
range from 4.6 to 11.8 cm respectively [27-29]. The ability to generate larger cancer 
constructs that mimic in vivo tumours would be advantageous for high-throughput 
drug screening given that larger 3D models potentially provide a more realistic drug 
response compared to a smaller 3D model [30, 31]. Essentially, there exists a need 
for a state-of-the-art fabrication technique that can custom-make cancer models to 
recreate tumour niches of complex architecture and is also adaptable with 
commonly adopted high-throughput approaches. 
 
Biofabrication techniques have been developed for tissue engineering and 
regenerative medicine (TERM) to allow the control of macro and micro scale 
structure, as well as the architecture of an engineered construct. These techniques 
can be potentially adapted for application in cancer research. Recent progress in 
hydrogel-based fabrication of 3D cancer models includes a temperature controlled 
cell printing system to print hepatocellular carcinoma and epithelial cell-laden 
Matrigel for application as a disease model [32]. 3D in vitro cervical [33] and liver 





of cells, gelatin, alginate and fibrinogen. Specifically, advances in biofabrication 
involving the bioassembly of hydrogel subunits have been demonstrated for cardiac 
tissue engineering [35], vascularisation [36] and for general applications in tissue 
engineering [37, 38]. With tumour cells, Bruzewicz et al. assembled liver 
hepatocellular carcinoma and fibroblast cell-laden collagen gel modules in a micro-
channel to demonstrate the ability to assemble constructs of multiple cell types with 
spatial organisation [39]. Apart from these few studies, little progress has been 
made in the bioassembly of hydrogel subunits or modules for tumour engineering.   
 
To our knowledge, there are no studies which have described a system where 
prefabricated cell encapsulated microspheres can be precisely inserted into a 3D 
plotted scaffold in a layer-by-layer approach to custom-make large well-defined and 
reproducible complex-tumour models (see Chapter 4, Figure 4-1).  Fundamentally 
to fabricate the model, we have employed a modular assembly based bottom-up 
strategy. Here, a hydrogel is used to encapsulate cells to form modular cell-laden 
hydrogel microspheres which would make up prefabricated subunits or building 
blocks. These prefabricated subunits can be potentially assembled into a 3D plotted 
scaffold to create a more complex biologically relevant tumour construct. By using 
this biofabrication approach, tumour models with a higher control of the spatial 
position of prefabricated modules would be possible. The biological rationale for 
adopting a modular assembly strategy to construct tissues of higher order is related 
to the ability to mimic the in vivo tissue structure using repeating functional units 
[40]. Furthermore, the technique would allow the fabrication of larger and more 
clinically relevant models in an automated and repeatable manner. The novel model 
would be a relevant research tool in cancer biology for translational research and 
drug discovery [4]. 
 
Therefore, the specific aim of this study was to develop an automated process 
for 3D Bioassembly of cell-laden hydrogel (GelMA) microspheres and biofabrication 
of complex cancer constructs for application as an in vitro 3D cancer model. This 
study involved (i) the fabrication of Ø1 mm cell-laden GelMA microspheres using a 
simple microfluidic setup that can be integrated with the automated bioassembly 





microsphere bioassembly without affecting cell viability, (iii) and to investigate and 
characterise the response of the engineered cancer construct to a clinically relevant 
anticancer drug – doxorubicin compared to existing 2D and 3D drug screening 
models. 
7.3 Methods 
7.3.1 Cell expansion 
Experiments were carried out with human ovarian adenocarcinoma cell line 
(SKOV3) and normal human foreskin fibroblasts (HFF). SKOV3 and HFF were 
cultured in media containing DMEM (high glucose, GlutaMAX Supplement, pyruvate) 
(GIBCO, USA) with 5% foetal bovine serum (FBS; GIBCO, New Zealand), 100 
units/mL penicillin (GIBCO, USA) and 100 μg/mL streptomycin (GIBCO, USA). The 
cells were seeded at a density of 3,000 cells/cm2 in tissue culture flasks (Corning, 
USA). Cells were expanded at 37°C in a humidified 5% CO2/95% air incubator and 
media was changed twice a week. After approximately 4-7 days, subconfluent 
passage cells were washed with phosphate-buffered saline (PBS; GIBCO, USA), 
detached using 0.25% trypsin/EDTA (Gibco, Canada), counted by trypan blue 
exclusion in a haemocytometer and plated in a tissue culture flask at 3,000 cells/cm2. 
The cells were passaged until there was a sufficient number of cells, after which the 
cells were harvested to form cell encapsulated microspheres. All HFFs used for this 
study were between passages 24 and 28 and SKOV3 were between passage 44 and 
48. 
7.3.2 Cell labelling with fluorescent nanoparticle 
A Qtracker cell labelling kit (Life technologies, USA) was used to track cells in 
a co-culture environment. HFFs were labelled with Qtracker 655 and the SKOV3s 
with Qtracker 800. To label the cells with Qtracker, cells were concentrated to 10 x 
106 cells/ml by centrifugation at 700 g for 5 minutes and resuspended in media. A 
10 nM labelling solution was prepared by mixing 1 µL of the Qtracker Component A 
and 1 µL of the Qtracker Component B in a 1.5 ml microcentrifuge tube and 
incubated at room temperature for 5 minutes. 0.2 ml of DMEM was added to the 





and incubated for 60 minutes. The cells were subsequently washed twice with media 
and resuspended in media for use.  
7.3.3 Synthesis of gelatine-methacryloyl (GelMA) 
Gelatine (porcine skin, type A, 300g Bloom strength) (Sigma-Aldrich, USA) was 
dissolved in phosphate-buffered saline (PBS; GIBCO, USA) at a 10 wt% 
concentration. 0.6 g of methacrylic anhydride (Sigma-Aldrich, USA) per gram of 
gelatine was added to the gelatine solution and left to react for 1 hour at 50˚C under 
constant stirring [41], followed by dialysis against deionised water to remove 
unreacted methacrylic anhydride. The purified GelMA solution was filtered through 
a 0.22 µm sterile filter, then lyophilised under sterile conditions. The degree of 
methacryloyl substitution was quantified to be 60% (data not shown) using 1H-
proton nuclear magnetic resonance spectroscopy (Bruker Avance 400 MHz).  
7.3.4 Cancer cell encapsulation in GelMA hydrogel microspheres  
Non-labelled cells were used to form SKOV3 microspheres and HFF 
microspheres. Labelled SKOV3 and HFF were mixed so that the ratio of SKOV3 to 
HFF in the mixture was 75:25 and was used to form the co-culture microspheres. 
The microspheres were formed as outlined previously in Chapter 5, Briefly, dried 
sterile 10% (w/v) GelMA was dissolved in PBS at 37˚C and left to cool overnight at 
room temperature. A cell pellet was formed by centrifuging the cells at 700 g and the 
supernatant was discarded. The cell pellet was then resuspended in 10% wt GelMA 
(preliminary experiments showed that SKOV3 degraded the 5% (w/v) GelMA when 
culture for 7 days) macromer solution containing sterile filtered initiators (0.2 mM 
tris(2,2-bipyridyl)dichlororuthenium(II) hexahydrate (Ru; Sigma-Aldrich, USA) and 
2 mM sodium persulfate (SPS; Sigma-Aldrich, USA)) to give a final concentration of 
10 x 106 cells/ml. The solution containing the cells was loaded into a syringe. Food 
grade sunflower oil was used as the continuous phase and the GelMA solution 
containing the photoinitiator and cells made up the dispersed phase. For the 
continuous oil phase the flow rate was set to 1 ml/minute and the dispersed gel 
phase it was set to 40 μl/min, this was based on studies by Young et al. [42]. The 
formed microspheres were then irradiated with visible light (OmniCure® S1500, 
Excelitas Technologies). The light was irradiated through a light filter (Rosco IR/UV 





through and had a final intensity of 100 mW/cm2. The light intensity and exposure 
time were selected based on previous work by Lim et al. [43]. The formed 
microspheres were collected in polypropylene (Falcon, USA) centrifuge tubes 
containing PBS. To separate the oil from the microspheres, the centrifuge tube was 
centrifuged at 0.1 g for 5 minutes. The oil was then aspirated and the pellet of 
microspheres in PBS was collected using a Pasteur pipette. The microspheres were 
then suspended in fresh PBS and the washing step was repeated. Each cell 
encapsulated microspheres was then transferred into a well in a 96-well polystyrene 
plate (Falcon, USA). 150 µL of cell culture media was then pipetted into the wells and 
placed in the incubator. The media was changed twice a week. 
7.3.5 Size distribution of cell encapsulated microspheres  
The size distribution of the fabricated microspheres was determined by 
measuring the size of the SKOV3, HFF and co-culture encapsulated microspheres. 
Fabricated microspheres (n=50) were stained with Coomassie brilliant blue 
(Thermo Fisher Scientific, USA) for 15 minutes and were imaged using the Zeiss 
Axioimager Z1 microscope. The major and minor diameters were measured using 
the particle analysis function in ImageJ. The average of the major and minor 
diameter was calculated and normal distribution of the average was plotted. The 
coefficient of variation was tabulated to gauge the microsphere size distribution.  
7.3.6 DNA content – microspheres 
The DNA content of the fabricated cell-laden microspheres was measured to 
quantify if a consistent number of cells were encapsulated in the microspheres as 
well as to investigate cell proliferation during culture. The DNA content of the 
microspheres (n=3, 4 microspheres/sample) was quantified using a CyQUANT kit 
(Molecular Probes, USA) on Day 0, 7 and 12. The samples were first digested 
overnight at 56 ˚C in 400 µL of 1 mg/ml proteinase-K (Sigma-Aldrich, USA) solution. 
Post proteinase-K digestion, the cells in the sample were lysed and the RNA was 
degraded by adding the provided lysis buffer with RNase A (1.35 KU/ml; 
Thermofisher, Lithuania) and incubating for an hour at room temperature. Samples 
were pipetted into 96-well white polypropylene plates (Nunc, Denmark) and GR-dye 
solution was added. The plate was then incubated at room temperature for 60 





Labtechnology, Germany). A DNA standard curve was constructed using the λ-DNA 
provided in the kit to determine the DNA quantity and a cell standard curve was 
constructed using SKOV3, HFF, and 75% SKOV3 and 25% HFF to determine the cell 
number.  
7.3.7 Reliability and efficiency of microsphere singularisation  
To determine the reliability of the singularisation device (see Chapter 4, Figure 
4-3) to successfully assemble individual cancer microspheres, (SKOV3, HFF and co-
culture) cell encapsulated microspheres were put through the device. The 
microspheres were put into the singularisation device in sets of 10 and repeated 10 
times, with the success or failure in singularisation being noted. The total number of 
successful singularisation events was used to determine the overall efficiency of the 




𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛 
𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜­𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑖𝑛𝑔𝑢𝑙𝑎𝑟𝑖𝑠𝑎𝑡𝑖𝑜𝑛
            
 
7.3.8 Scaffold fabrication  
Biodegradable poly(ethylene glycol)-terephthalate-poly(butylene 
terephthalate) block copolymers (Polyactive 300PEGT55PBT45, PolyVation, The 
Netherlands) with  a PEG molecular weight (MW) of 300 g/mol and a PEGT:PBT 
weight percent (wt%) ratio of 55:45 were used to fabricate scaffolds with a specific 
pore size and architecture. The material and composition were selected based on 
previous studies demonstrating its applicability for 3D plotting of extruded fibre 
scaffolds with controlled properties and stability both in vitro and in vivo [44, 45].  
 
Porous scaffolds (25×25×2.64 mm), with accurately defined and controlled 
pore architecture for microsphere incorporation, were 3D plotted using a 
Bioscaffolder system (SYS ENG, Germany). Fibres were oriented in a repeating 0-
90°-90°-0° pattern in order to provide porosity in both the x-y and x-z planes for 
assembly of 1 mm diameter microspheres. During the melt dispensing process the 
following 3D plotting parameters were applied: (i) fibre spacing of 1 mm in both x 







containing the polymer heated to a temperature of 200° and pressurised to 5 Bar, 
(iv) an auger speed of 63 RPM and (v) print head fitted with a 25 gauge nozzle 
moving with a traverse speed of 500 mm/min.  
7.3.9 Automated bioassembly with cancer microspheres 
The automated assembly of a construct with cancer microspheres was 
demonstrated by 3D plotting a scaffold using the high-temperature print head 
containing Polyactive 300PEGT55PBT45 and then inserting the cell (75% SKOV3 
and 25% HFF) encapsulated microspheres using the microsphere injection head. To 
plot our assembled construct (n=3) a layer-by-layer scaffold fabrication and 
microsphere bioassembly (bottom-up) approach were adopted. In this scheme, the 
first layer of the scaffold (8 layers of fibre strands) was 3D plotted (as described 
earlier) and then 4 (2 x 2 fashion) live microspheres were inserted into the pores of 
the 3D plotted scaffold. The 3D plotting was repeated on top of the first layer to 
generate the second layer of the scaffold (4 layers of fibre strands) and then 4 more 
microspheres were inserted into the second layer. For the manually assembled 
construct, the whole scaffold was 3D plotted at once and the microspheres were 
inserted manually by hand into the pre-plotted scaffolds in a similar format to the 
ones assembled with the automated system. The manual insertion of the 
microsphere into the pore involved manually placing the microsphere on top of the 
scaffold pore with a pipette and press-fitting the microsphere into the scaffold pore 
with a spatula.  
 
For the live/dead assay, the samples were incubated at 37°C in 0.5 ml of PBS 
with 1 μM Calcein AM (Molecular Probes, USA) for 15 minutes, then 1 μM Propidium 
Iodide (Molecular Probes, USA) was added and incubated for 10 more minutes. After 
this, the samples were washed twice with PBS and a z-stack of the sample was 
imaged using the Zeiss Axioimager Z1 microscope (FITC and Texas Red filter-set). 
 
For the AlamarBlue® assay, AlamarBlue® (Invitrogen, USA) was added to the 
media containing FBS so that the final concentration was 10% (v/v) and the samples 
were incubated at 37°C for 20 hours.  The reduction in AlamarBlue® reagent was 





measuring the absorbance at 570 nm, using 600 nm as a reference wavelength 
(Fluostar Galaxy BMG Labtechnology, Germany). 
7.3.10 Efficiency of microsphere insertion 
A bilayered scaffold (n=8) was 3D plotted with 4 microspheres in each layer 
using the layer-by-layer approach described earlier. The efficiency of microsphere 
insertion (see Chapter 4, Figure 4-4) within the scaffold pore was determined by the 
number of successful microsphere insertion within the scaffold pore to the total 
attempted number of microsphere insertion with the automated system (Equation 
7-2). 
 
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛
=  
𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛  
𝑡𝑜𝑡𝑎𝑙 𝑎𝑡𝑡𝑒𝑚𝑝𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛 
          
 
7.3.11 Construct assembly   
After 1 day of fabricating the microspheres, 4 microspheres per layer (2 x 2 
manner) were assembled into a 3D plotted bilayered scaffold. SKOV3 constructs, 
HFF constructs and co-culture constructs were assembled. Each assembled 
construct was transferred to a well in a 24-well polystyrene plate (Corning, USA). 
1200 µL of cell culture media was then pipetted into the wells and the plate was 
placed in the incubator.  The media was changed twice a week. 
7.3.12 Viability of microspheres and assembled constructs over time 
Live/dead assay was performed as described earlier on SKOV3, HFF and co-
culture encapsulated microspheres and assembled constructs on day 1, 7 and 12 of 
the chemosensitivity timeline (see Figure 7-1).  
7.3.13 Chemosensitivity test  
The chemosensitivity test was used to evaluate in vitro antitumor activity of 
doxorubicin on cells in 2D, microspheres and assembled cancer constructs (see 
Figure 7-1 for a timeline of the chemosensitivity test). Doxorubicin was dissolved in 
DMSO so that the maximum final concentration of DMSO in media did not exceed 








microspheres were transferred to a 96-well plate and 150 µl of media with 5% FBS 
per well was added. On day 1 of forming the microspheres, SKOV3, HFF and co-
culture cancer constructs were manually assembled (as described earlier) and 
transferred 24-well plate with 1.2 ml of media per well. On day 7, for the 
chemosensitivity test on 2D model, SKOV3, HFF and co-culture (75% SKOV3 and 
25% HFF) cells were seeded onto a 48-well plate at 30,000 cells and 200 µl of media 
with 5% FBS per well. The next day (day 8), all samples were treated with different 
concentrations of doxorubicin – no drug control, 0.001 µM, 0.01 µM, 0.1 µM, 1 µM, 
10 µM. Media with 5% FBS containing the specific concentration of drug was 
changed every 2 days. After 4 days of exposure to the drug, AlamarBlue® assay was 
conducted to measure metabolic activity of the samples. For the AlamarBlue® assay, 
all samples were transferred to a fresh well plate, AlamarBlue® was added to the 
media containing FBS so that the final concentration was 10% (v/v) and the and the 
microspheres and assembled construct were incubated for 20 hours and the cells in 
2D were incubated for 3.5 hours at 37°C. Fluorometric measurements were made at 
an excitation wavelength of 545 nm and an emission wavelength of 590 nm and 
these values were curve fitted to estimate the half maximal inhibitory concentration 
(IC50) using GraphPad Prism v.6.0. The microspheres from the chemosensitivity test 






7.3.14 Histology and immunofluorescence 
Following the AlamarBlue® assay, cell-laden microspheres and cancer 
constructs from the chemosensitivity test were washed in PBS, fixed in 10% neutral 
buffered formalin for an hour, washed in PBS again, immersed for an hour in 15% 
(w/v) sucrose in PBS and then immersed overnight in 30% (w/v) sucrose in PBS at 
4˚C. The samples were then embedded in OCT (Ted Pella, Inc. USA) and were 
cryosectioned (15 µm thick sections). The slides with the sections were rinsed in 
cold PBS thoroughly and were permeabilized with 0.25% (v/v) Triton X-100 (Sigma, 
USA) in PBS for 30 minutes. The sections were rinsed in cold PBS and were exposed 





to 5% (w/v) BSA in PBS at a pH 7.4 for 60 minutes at room temperature. They were 
then rinsed in cold PBS and incubated with monoclonal anti-Ki67 (1:100 dilution; 
abcam, USA) and polyclonal anti-gamma H2AX (1:5,000 dilution; abcam, USA) anti-
bodies at 4˚C overnight. The sections were washed in PBS and were incubated with 
secondary antibodies, goat Alexa Fluor 488 anti-mouse (1:500 dilution; 
Thermofisher, USA) and goat Alexa Fluor 555 anti-rabbit (1:500 dilution; abcam, 
USA) at 37˚C for an hour. Following further washing, the sections were 
counterstained with 4.5 µM Hoechst 33342 (Invitrogen, USA) in PBS. Finally, the 
slides were washed with 0.05% Tween-20 (Sigma, USA) in cold PBS, rinsed in PBS 
and then coverslipped. The samples were imaged using a Leica TCS SP5 confocal 
microscope. The rendered images of the microspheres and assembled construct 
(Figure 7-2) shows the plane at which the cryosections were performed and the 
approximate region imaged for immunofluorescence staining. A pixel count of γ-
H2AX expression and Hoechst 33342 staining was performed on the images utilising 
the colour pixel counter plugin in ImageJ. The pixel count of γ-H2AX expression was 

















































7.3.15 Statistical analysis 
Data was presented graphically as mean ± standard deviation. Data were 
analysed using GraphPad Prism v.6.0. Statistical analysis was performed using 1-way 
ANOVA or 2-way ANOVA (if required Tukey's multiple comparisons test) or paired t-

























Section X-X Section Y-Y 
500 µm 
Figure 7-2. Rendered images of front view of the (a) microspheres and (b) 
assembled construct showing the plane at which the cryosection was performed (X-
X in the microsphere and Y-Y in the assembled construct) and the sectional top view 
of the (c) microsphere and (d) assembled construct. The dotted rectangle shows the 









7.4.1 Microsphere fabrication 
For validation of the automated tissue bioassembly system, Ø1 mm 
microspheres of regular size and shape were required. The requirement for Ø1 mm 
tissue units has been discussed and shown in Chapter 4. This subsection describes 
the fabrication of cancer cell-laden GelMA microspheres to meet these desired 
requirements along with a consistent number of encapsulated cells in the 
microspheres. The viability and proliferation of the cells in the microspheres was 
also investigated.  
7.4.1.1 Size distribution of fabricated cell-laden microspheres  
SKOV3, HFF and co-culture microspheres were successfully fabricated with the 
microfluidic device. For the purpose of initial validation, the automated tissue 
assembly system was designed for optimal handling of Ø1 mm sized tissue units. 
Therefore, microspheres with a uniform size distribution of Ø1 mm was essential for 
the efficient handling of the microspheres by the automated tissue assembly system. 



























Figure 7-3. Size (average diameter of the microspheres) distribution curves of (a) 
SKOV3 (b) HFF and (c) co-culture encapsulated microspheres in 10% GelMA visible 






The average diameter (Table 7-1) of the microspheres encapsulated with 
different cell types varied from 0.995 mm to 1.015 mm. There was also no significant 
difference (p>0.05) between the average diameter (Table 7-1) of the SKOV3, HFF or 
co-culture encapsulated microspheres. The coefficient of variation reveals that the 
dispersion in microsphere size is low and that the microfluidics process adopted is 
able to fabricate microspheres in large quantity and with a very accurate and 
uniform size distribution.  
 
 
Cells  SKOV3 HFF Co-culture 
Average diameter (mm) 1.015 ± 0.054 0.996 ± 0.042 0.995 ± 0.045 




7.4.1.2 DNA content – microspheres 
After fabricating the microspheres, the number of cells per microsphere (Table 
7-2) was determined for day 0 to confirm that the variation in the cells per 
microspheres was low. The determined average cell number for the specific cell 
types varied from 5610 to 6168 cells per microsphere and there was no significant 
difference (p>0.05) in the cells per microsphere for SKOV3, HFF or co-culture 
microspheres. The coefficient of variation affirms that the variation in the cells per 
microsphere between the samples was low. This shows that with the micro-fluidic 
system, it is possible to fabricate microspheres in a high-throughput fashion with 





Cells  SKOV3 HFF Co-culture 
Cells per microsphere 5828.63 ± 263.31 6168.01 ± 158.77 5609.71 ± 540.06 
Coefficient of variation 0.045 0.025 0.096 
Table 7-1. Average diameter (mm) and coefficient of variation for different types 
of cells encapsulated in microspheres. 
a Distribution plotted in Figure 7-3. 
b n=50  
c No significant difference (p>0.05) between microspheres of different cell types. 
d Statistical analysis: 1-way ANOVA. 
 
 
Table 7-2. Cells per microsphere after fabrication (day 0).  
a n=3 
b No significant difference (p>0.05) between microspheres of different cell types. 








7.4.1.3 Cell viability and proliferation of microspheres over time 
The DNA content was quantified and live/dead assay was performed on the 
microspheres to assess if the cells were affected during the microsphere fabrication 
process and also to assess if the cells proliferated and remained viable over time in 
in vitro culture. The viability of the SKOV3, HFF, and co-culture encapsulated 
microspheres (Figure 7-4) on day 1, 7 and 12 was visualised from the live/dead 
fluorescence microscopy images. The day 1 images of the microspheres (Figure 7-4 
a, b and c) do not indicate a noticeable number of dead cells suggesting that the 
viability of the cells were not affected during the microsphere fabrication process. 
In the SKOV3 and co-culture microspheres, a greater number of dead cells were 
visualised on day 7 and 12. However, in the HFF microspheres, fewer dead cells were 
observed. A thick cell monolayer formed around the co-culture microspheres on day 
7 and 12 (Figure 7-4f and I). The monolayer had a tendency to easily separate from 
the day 12 microsphere sample during the washing step of the live/dead staining, 
hence the more non-uniform cell monolayer (i.e. monolayer still present only on 







































The n-fold change in DNA content for SKOV3, HFF and co-culture microspheres 
cultured up to day 12 is shown in Figure 7-5. There was a significant difference 
(p<0.05) between the n-fold change in DNA content from day 0 to 12 in all the 
samples (SKOV3 - 1.75 ± 0.34, HFF - 1.02 ± 0.07, co-culture - 4.53 ± 0.73  fold 
increase). There were no significant changes (p>0.05) in DNA content of HFF 
microspheres over time (constant across time), indicating no proliferation. However, 
there was a significant increase (p<0.05) in DNA between day 0 and 12 (1.75 ± 0.34 
fold increase) for the SKOV3 microspheres suggesting that the cells proliferated. 

















Figure 7-4. Fluorescence microscopy images of SKOV3, co-culture and HFF 
encapsulated microspheres on day 1, 7 and 12 stained with Calcein AM (live cells, 
green) and Propidium Iodide (dead cells, red). Arrows point to the monolayer. Scale 















(p<0.05) was observed from day 0 to day 12 (4.53 ± 0.73 fold increase), which was 
at a much higher level compared to the SKOV3 microspheres suggesting a higher 
proliferation rate. This observation suggested that there might be a paracrine 

























7.4.2 Cancer construct bioassembly 
In this subsection, we report the capacity of the prototype automated 
bioassembly system to viably handle and assemble the fabricated cancer cell-laden 
hydrogel microspheres into a construct.  
7.4.2.1 Reliability and efficiency of microsphere singularisation  
The efficiency of singularisation (n=100) (see Chapter 4, Figure 4-3) was 
determined for the SKOV3, HFF and co-culture microspheres and is listed in Table 
7-3. The efficiency of singularisation for the microspheres varied from 93% to 97% 
depending on the specific cell type. The main causes of singularisation failure 
included the release of 2 microspheres at a time or a microsphere being sucked into 
the vacuum pressure port. If a singularisation failure has occurred and the device 
has failed to release a microsphere, the singularisation cycle can be repeated. If a 
Individual microspheres 
 
Figure 7-5. n-fold change in DNA content (n=3) for SKOV3, HFF and co-culture 






blockage has occurred, the device can be purged with fluid to dislodge the blocking 
microsphere and clear the bioassembly system after which normal operation of the 
device can be continued. None of the singularisation failures were critical to prevent 
further operation of the device.  
 
 
Cells SKOV3 HFF Co-culture 
Singularisation efficiency 97 ± 4.83% 95 ± 5.27% 93 ± 6.75% 
 
 
7.4.2.2 Efficiency of microsphere insertion  
The efficiency of successful microsphere insertion into the scaffold was 
ascertained to be 92.19 ± 9.3% (n=8 scaffolds, 64 microspheres). After the insertion 
process for a layer, the scaffold was visually scrutinized by the user for pores without 
microspheres after the microsphere insertion process for each layer. Next, the 
microsphere insertion process was repeated for the pores without microspheres 
and the scaffold was completely filled as designed.  
7.4.2.3 Viability of assembled construct 
During the 3D plotting process, the temperature in the thermoplastic print 
head was approximately 200°C. Even though the extruded fibre cools down quickly, 
we had to ascertain whether the molten polymer being plotted on the first layer of 
assembled construct during the layer-by-layer plotting did not affect the viability of 
the microspheres. Likewise, we had to determine that the handling of the 
microspheres by the automated bioassembly system did not affect the viability of 
the microspheres. 
 
Cancer constructs were assembled using the automated tissue bioassembly 
system with co-culture microspheres via the layer-by-layer approach and were 
compared for viability with the manually assembled construct. Visual inspection of 
the live/dead fluorescence microscopy images (Figure 7-6) of the manually 
assembled construct and the construct assembled using the assembly system 
showed no obvious differences. The results from the AlamarBlue® assay (Figure 7-7) 








supported this observation as there was no significant difference (p>0.05) in the 
percentage of AlamarBlue® reduced between the manually assembled construct 
(60.93 ± 1.62%) and the construct assembled using the automated tissue assembly 
system (58.59 ± 2.10%). 
 
 






















Figure 7-6. Fluorescence microscopy images of (a) manually assembled construct 
and a (b) construct assembled using the automated tissue assembly system 
inserted with microspheres encapsulated with (SKOV3:HFF 75:25) stained with 
Calcein AM (live cells, green) and Propidium Iodide (dead cells, red). Scale bar = 0.2 

































7.4.2.4 Viability of assembled constructs over time 
Live/dead assay was performed to assess the viability of the assembled 
construct cultured in vitro. The viability of the constructs assembled with SKOV3, 
HFF and co-culture microspheres (Figure 7-8) was visualised from the live/dead 
fluorescence microscopy images on day 1, 7 and 12. There were very few dead cells 
observed in the SKOV3 and co-culture assembled constructs on day 1 (Figure 7-8 a 
and c), however on day 7 (Figure 7-8 d and f) and 12 (Figure 7-8 g and i), a 
considerably greater number of dead cells was visualised. In the HFF assembled 
constructs (Figure 7-8 b, e and h), a fewer number of dead cells was observed over 
time. Similar to the co-culture microspheres (Figure 7-4 f and I), an uneven cell 



























Figure 7-7. Percentage of AlamarBlue reduced to determine the viability of the 
manually assembled construct and the construct assembled using the automated 
system with cancer cell (SKOV3:HFF 75:25) encapsulated microspheres. The data is 






7 (Figure 7-8 d and f) and 12 (Figure 7-8 g and i), and in addition, the cells appeared 
to proliferate on the scaffold fibres. As in the case of the microspheres, the monolayer 
in the assembled construct had a tendency to separate from the construct during the 



















7.4.2.5 Cell distribution in co-culture microspheres and assembled 
construct 
The SKOV3 and HFF cells were labelled with Qtracker 800 and 655 respectively 
and the co-culture (SKOV3:HFF 75:25) microspheres and assembled constructs 
were fabricated and cultured. See Appendix 7.A for sectioned fluorescence 
microscope images of the microspheres and assembled construct on day 1 and 12 of 

















Figure 7-8. Fluorescence microscopy images of SKOV3, assembled constructs and 
HFF on day 1, 7 and 12 stained with Calcein AM (live cells, green) and Propidium 















intense on day 12 compared to day 1. The reduction of the Qtracker signal from day 
1 to 12 could possibly be due to the proliferation of cells which led to a lower number 
of fluorophores per cell resulting in a fainter fluorescence signal. The low intensity 
made the tracking of the labelled cells challenging. However, close examination of 
the day 12 images suggested no particular redistribution of the two cells types either 
in the microspheres or in the assembled construct.  
7.4.3 Drug response  
In this subsection, the response of cells in 2D, individual microspheres and 
engineered cancer constructs were assessed with varying concentrations of 
doxorubicin. Doxorubicin is a clinically relevant anticancer drug used to treat a range 
of tumours including ovarian cancer and is often used in combination chemotherapy 
[46-48]. Dividing or cycling cells are preferentially targeted by doxorubicin [49]. 
7.4.3.1 Chemosensitivity test  
Cells in 2D, microspheres and the assembled constructs were exposed to 
doxorubicin for 4 days to evaluate the anticancer activity of the drug in vitro and 
their dose-response curves are plotted in Figure 7-9. The accurate IC50 estimation 
requires a sufficient number of values in the upper and lower plateau region of the 
dose-response curves [50]. A maximum drug concentration of 10 µM for the 
experiment was selected based on the value of 3.75 µM reported for the peak 
concentration of free doxorubicin available to act on the cells in clinical 
chemotherapy [51]. However, the dose-response curves of the assembled constructs 
(Figure 7-9 c) did not achieve a lower plateau region. Moreover, the lowest value of 
the percentage growth control values were just slightly below 50% of growth control 
(SKOV3 – 37.38 ± 1.96% (at 10 µM), HFF – 37.98 ± 4.90% (at 1 µM), and co-culture 
– 41.36 ± 2.65% (at 10 µM)), unlike the cells in 2D (Figure 7-9 a) and microspheres 
(Figure 7-9 b), making the IC50 estimation for the assembled constructs less 
accurate. Nevertheless, the estimated IC50 values based on the available dose-
response curves were used for comparative purposes among the different models.  
 
It was observed that for cells cultured in 2D, HFF had the highest IC50 value 
(0.16 µM) compared to SKOV3s (0.05 µM) or co-culture (0.08 µM) samples (Table 7-





microspheres had the highest IC50 value (0.29 µM), followed by HFF (0.18 µM) and 
SKOV3 (0.15 µM) microspheres. A similar trend was observed in the assembled 
constructs, where the co-culture samples had a much higher IC50 value (5.56 µM), 
compared to HFF (3.81 µM) and SKOV3 (2.41 µM). Comparison between all the 
different models (2D, microspheres, assembled constructs) revealed a general trend 
where the IC50 values (Table 7-4) were the lowest for cells in 2D, slightly higher for 
the microspheres (1-4 fold increase compared to cells in 2D) and highest for the 
assembled constructs (48-70 fold increase compared to cells in 2D, 16-21 fold 
increase compared to microspheres). The higher drug resistance of the assembled 
constructs compared to microspheres highlights the significance of a larger more 
complex assembled 3D construct model compared to a smaller microsphere model 
or 2D model and could potentially be more efficient and reliable drug screening 
model. Likewise, the cell-dependent response of the 3D models accentuates the need 































































































Figure 7-9. Dose-response curves for doxorubicin for (a) cells in a 2D (b) 
microspheres (c) assembled constructs. The response was for SKOV3, HFF, and co-

















SKOV3 0.05 0.15 2.41 2.96 16.33 48.32 
HFF 0.16 0.18 3.81 1.14 21.41 24.32 
Co-culture 0.08 0.29 5.56 3.63 19.34 70.14 
 
 
 The DNA content expressed in percentage of control against drug 
concentration for the microspheres is shown in Figure 7-10. The trend of decreasing 
DNA content normalised to control with increasing drug concentration is similar to 
the dose-response curve (Figure 7-9 b). In the SKOV3 and co-culture microspheres, 
there was significant decrease (p<0.05) in normalised DNA content from 0.01 
(SKOV3 - 77.48 ± 25.28%, co-culture - 72.40 ± 26.52%) to 0.1 µM (SKOV3 - 36.20 ± 
4.09%, co-culture - 33.99 ± 2.22%) concentration of drug. With the HFF 
microspheres, there was a lag in the reduction of normalised DNA content with 
increasing drug concentration compared to SKOV3 and co-culture microspheres and 
the significant decrease (p<0.05) in DNA content was seen from 0.1 (85.01 ± 
11.19%) to 1 µM (11.03 ± 1.78%) of concentration of drug. There was also a 
significant difference in normalised DNA content at 0.001 µM between the HFF 














a Data obtained from Figure 7-9. 























7.4.3.2 Histology and immunofluorescence 
Immunofluorescence staining for Ki67, γ-H2AX and Hoechst 33342 were 
performed on cryosections of SKOV3, HFF, co-culture microspheres and assembled 
cancer constructs after the chemosensitivity test.  
 
From the Hoechst 33342 staining, a cell monolayer can be observed around the 
periphery of the SKOV3 (Figure 7-11 a) and co-culture (Figure 7-11 i)  microspheres 
and SKOV3 (Figure 7-11 c) and co-culture (Figure 7-11 k)  assembled construct as 
indicated by the arrow in the images, but not in the HFF microspheres (Figure 7-11 
e) or HFF assembled constructs (Figure 7-11 g). The non-uniform monolayer seen 
in the samples with the monolayer (especially the control co-culture assembled 
construct (Figure 7-11 k)) was due to the tendency of the monolayer around the 






















































DNA – Individual microspheres 
 
Figure 7-10. Doxorubicin dose dependent DNA content normalised to no drug 
control for SKOV3, HFF and co-culture individual microspheres measured after 4 
days of exposure to the drug. The data is presented as mean ± SD (n=6). *Significant 
differences between columns are below the ends of each line (p<0.05). Statistical 






live/dead staining of the co-culture microsphere (Figure 7-4 i), the monolayer on the 
SKOV3 microsphere (Figure 7-4 a) was not obvious and observable from the day 12 
live/dead staining compared to the sectioned Hoechst 33342 staining of the SKOV3 
microsphere (Figure 7-11 a).  
 
 Interestingly a higher Ki67 expression was not specifically observed in the 
monolayer on the surface of the SKOV3 (Figure 7-11 a and b), co-culture (Figure 7-11 
i and j) microspheres, and SKOV3 (Figure 7-11 c and d) and co-culture (Figure 7-11 
k and l) assembled construct, but proportionally a higher number of cells expressing 
Ki67 was observed in cells within the microspheres and assembled constructs. Ki67 
protein is a nuclear marker that is strictly associated with cell proliferation and is 
present in all active phases of the cell cycle and exclusively not present in the G0 



















































Doxorubicin causes double-strand breaks in DNA which correlates with the 
drug cytotoxicity [54]. These double-stranded breaks in DNA causes the 
phosphorylation of H2AX which is a highly amplified response [55, 56]. The pixel 
count of γ-H2AX expressed in percentage of Hoechst 33342 for SKOV3, HFF and co-
culture microspheres and assembled construct exposed to different concentrations 
of the drug are shown in Figure 7-12. The pixel count of γ-H2AX expressed in 
percentage of Hoechst 33342 (see Figure 7-12) confirmed a significantly higher 
(p<0.05) expression of γ-H2AX in all 3D models at 0.1 µM (SKOV3 microspheres - 
35.52 ± 9.98%, HFF microspheres - 32.75 ± 2.87%, co-culture microspheres - 46.31 
Figure 7-11. Immunofluorescence staining for Ki67 (yellow) and Hoechst 33342 
(cell nuclei, blue) imaged using a confocal microscope for SKOV3, HFF co-culture 
microspheres and assembled construct for no drug control. Arrows point to the 
monolayer and the dotted lines represent the outer edge of the sample. Scale bar = 
200 µm for all images. See Appendix 7.A for higher magnification images and other 
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± 4.92%, SKOV3 assembled construct - 42.91 ± 3.02%, HFF assembled construct - 
35.85 ± 3.50%, co-culture assembled construct - 35.03 ± 5.86%) compared to no 
drug control and lower concentrations of drug (at 0.01 µM;  SKOV3 microspheres - 
2.14 ± 0.74%, HFF microspheres - 11.97 ± 3.50%, co-culture microspheres - 10.46 ± 
3.20%, SKOV3 assembled construct - 6.43 ± 0.55%, HFF assembled construct - 12.37 
± 3.90%, co-culture assembled construct - 22.72 ± 5.76%). The immunofluorescence 
staining for γ-H2AX and Hoechst 33342 staining for selected concentration of drugs 
(for drug control, 0.1 µM and 1 µM) for microspheres and assembled construct is 
shown in Figure 7-13 and Figure 7-14 respectively. From the visualisation of the 
immunofluorescence staining for γ-H2AX and Hoechst 33342 staining it can be 
observed that the proportion of cells expressing γ-H2AX is higher at 0.1 µM 
concentration of drug for all 3D models.  
 
At 1 µM of doxorubicin, the Hoechst 33342 staining and also γ-H2AX 
expression was observed only in the SKOV3 (Figure 7-14 c and f) and co-culture 
(Figure 7-14 o and s) assembled constructs and the staining was negligible in the 
SKOV3 (Figure 7-13 c and f) and co-culture (Figure 7-13 o and s) microspheres and 
in the HFF microsphere (Figure 7-13 i and l) and assembled construct (Figure 7-14 
i and l). The pixel count of γ-H2AX expressed in percentage of Hoechst 33342 (Figure 
7-12) was therefore only plotted for the SKOV3 and co-culture assembled constructs 
at a drug concentration of 1 µM, as the very low value of pixel count might lead to 
erroneous values. The proportion of cells that expressed γ-H2AX in the SKOV3 
(Figure 7-14 c and f) and co-culture (Figure 7-14 o and s) assembled constructs at 1 
µM of the drug was visualised to be high. The pixel count of γ-H2AX expressed in 
percentage of Hoechst 33342 (Figure 7-12) suggested a significantly higher (p<0.05) 
expression of γ-H2AX in the SKOV3 and co-culture assembled constructs at 1 µM 
(SKOV3 assembled construct – 56.72 ± 5.32%, co-culture assembled construct - 
65.22 ± 5.40%) compared to 0.1 µM (SKOV3 assembled construct - 42.91 ± 3.02%, 
co-culture assembled construct - 35.03 ± 5.86%). With an increasing drug 
concentration, the monolayer around the SKOV3 and co-culture 3D models reduced 
(see Figure 7-13 a, b, c, m, n and o, Figure 7-14 a, b, c, m, n and o, and Appendix 7.A) 


























Figure 7-12. Pixel count of γ-H2AX expressed in percentage of Hoechst 33342 for 
SKOV3, HFF and co-culture (SKOV3:HFF 75:25) microspheres and assembled 
construct for no drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM concentration of 
doxorubicin. Data obtained from Figures 7.A-vi to 7.A-xi, Appendix 7.A. The data is 
presented as mean ± SD (n=4). *Significant differences between columns are below 
the ends of each line (p<0.05). #the values were not determined at 1 µM for these 






















































































































































Figure 7-13. Immunofluorescence staining for γ-H2AX (magenta) and Hoechst 
33342 (cell nuclei, blue) imaged using a confocal microscope for SKOV3, HFF and co-
culture (SKOV3:HFF 75:25) microspheres for no drug control, 0.1 µM and 1 µM 
concentration of doxorubicin. The dotted line represent the outer edge of the sample. 
Scale bar = 200 µm for all images. See Appendix 7.A for higher magnification images 
other concentrations of drug. 
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Figure 7-14. Immunofluorescence staining for γ-H2AX (magenta) and Hoechst 
33342 (cell, nuclei, blue) imaged using a confocal microscope for SKOV3, HFF and 
co-culture (SKOV3:HFF 75:25) assembled constructs for no drug control, 0.1 µM and 
1 µM concentration of doxorubicin. The dotted line represent the outer edge of the 
sample.  Scale bar = 200 µm for all images. See Appendix 7.A for higher magnification 





7.5 Discussion  
We biofabricated an in vitro 3D cancer model assembled with cell-laden 
hydrogel microspheres. The cancer construct was manufactured using a bottom-up 
or modular assembly based tissue engineering strategy which focuses on the 
assembly of cancer cell-laden micro-scale tissue units or modules (i.e. microspheres) 
into a larger macro-scale object (i.e. cancer construct) [57, 58]. Bottom-up 
approaches offer potential advantage in recreating the micro-architectural features 
of native tissues [40]. As many native tissues consist of repeating functional units, it 
is logical to go down the path of assembling smaller tissue modules to fabricate a 
larger tissue [40]. Utilising the prototype automated bioassembly system that we 
built, cancer constructs were successfully assembled without affecting the viability 
of the individual subunits. The developed flexible prototype automated bioassembly 
system was proven to reliably and efficiently handle the microspheres by tweaking 
the system’s soft parameters and did not inflict any adverse effects by handling the 
microspheres or assembling the construct. Large constructs of complex architecture 
based on mathematical models or anatomical models can be fabricated using the 
layer-by-layer strategy that we have employed.  
 
Previously, we created an in vitro 3D cancer model assembled with cell-only 
micro-tissues using a modular assembly based approach (see Chapter 6). The innate 
problem with the micro-tissue based model was that the manual or automated 
tissue bioassembly is possible with only compact micro-tissues and not all cell types 
form compact micro-tissues thereby limiting its application to a narrow range of 
cells types [7-10]. To overcome this, we alternatively encapsulated the cells in a 
GelMA hydrogel microsphere and assembled the microspheres to fabricate an in 
vitro 3D cancer model.  
 
Apart from enabling us to fabricate microspheres with cells that tend not to 
form compact micro-tissues, encapsulating cells in a hydrogel eliminates a rate 
limiting step by reducing the time required for the formation of a robust compact 
micro-tissues. Depending on the method and cell type used, the formation of a 
micro-tissue can range from 24 hours to several days [59]. Micro-tissues had to be 





the automated bioassembly system (see chapter 6). On the other hand, fabricating 
the microspheres (approximately 500 microspheres) when the microfluidic system 
has already been setup takes less than an hour. Moreover, about 6,000 cells per 
microsphere is required at a concentration of 10 million cells/ml, whereas the 
fabrication of Ø1 mm micro-tissues required 120,000 cells. Therefore, the number 
of cells required to fabricate each modular subunit for the microsphere model was 
reduced by approximately 20 fold compared to the micro-tissue model. The above-
stated advantages would also allow shorter experimental timelines and a reduction 
in man-power and resources, adding to the cost and complexity of the screening 
process. 
 
In resorting to a microfluidic system to fabricate the microspheres, a large 
number of uniform microspheres can be quickly and conveniently fabricated. 
Studies by Young et al. demonstrated that the microspheres exhibit a smooth, 
spherical morphology, and was due to the fact that in an emulsion the surface tension 
causes the droplets to contract into a sphere to minimise the surface energy [25, 60].  
 
By using GelMA, the mechanical properties, pore size, degradation rates, and 
swelling ratio can be tuned by varying either the polymer or photo-initiator 
concentrations, the degree of functionalization or the light exposure time to suit a 
desired cell type or application [61, 62]. Previous studies in the literature have 
utilised a UV light photopolymerisation system, however, we adopted a visible light 
photopolymerisation system in this study which has been shown to result in 
significantly greater cell viability compared to UV polymerisation [43]. One 
drawback of using GelMA, however, is that the gel needs to be optimised (i.e. 
stiffness) for different cell types and applications and there could be batch-to-batch 
variations in GelMA making it impractical to correlate work from different lab 
groups [61, 63]. 
 
Fibroblasts are known to have a well-recognised role in cancer development 
and progression, making their presence critical in a cancer model [64]. Our data 
suggest that the co-culture of SKOV3 and fibroblasts (HFFs) has a synergistic 
proliferation effect on each other, where the observed significant increase in DNA 





microspheres, or the HFF only microspheres (Figure 7-5). This is in line with most 
in vitro co-culture studies that have shown that the presence of fibroblasts can 
promote proliferation of tumour cells [65-68]. However, there is some controversy 
in the literature and the inhibition of tumour cells by fibroblasts has also been 
reported [69, 70]. Early stages of tumour development and dissemination are 
thought to be represented by cancer models co-cultured with normal (non-cancer-
associated) fibroblasts rather than the co-culturing cancer cells with cancer-
associated fibroblasts (CAF), which tend to reflect later stages of tumour 
development [9]. Cancer-associated fibroblasts are activated fibroblasts associated 
with malignant tumours and are known to enhance tumour progression [71-73]. 
Our model could be made to signify early or late-stage cancer model depending on 
whether the model is co-cultured with normal or cancer-associated fibroblast.  
 
To track the distribution of the SKOV3 and HFF cells and to investigate any self-
assembly or arrangement of cells in the co-culture microspheres and assembled 
construct, the cells were labelled with Qtracker (photostable fluorophores). 
Qtracker has previously been shown to not affect cell viability and photo-bleaches 
very little over time [74, 75]. However, the loss of the cell labelling Qtracker 
nanoparticles over the culture time made it challenging to precisely track the 
position of fibroblasts and SKOV3 cells in the co-culture microspheres and 
assembled constructs. Nevertheless, the faint signal from the confocal images did 
not suggest any specific arrangement (see Appendix 7.A). We could also not 
conclude if the predominantly proliferating cells in the co-culture microspheres and 
assembled construct were SKOV3s or HFFs. However, live/dead images of the co-
culture microspheres and assembled constructs resembled the SKOV3 microspheres 
and assembled constructs rather than the HFF microspheres or assembled 
constructs, potentially suggesting that the prominently proliferating cells on the 
surface of the microspheres and assembled construct could be SKOV3s. The loss in 
the Qtracker signal could possibly be due to the proliferation of cells which resulted 
in a reduction in the number of fluorophores per cell and therefore a fainter 
fluorescence signal. Alternatively, in future experiments, the cells could potentially 
be labelled with green fluorescent protein (GFP) and red fluorescent protein (RFP) 






During our preliminary experiments, the 5% wt GelMA SKOV3 and co-culture 
microspheres that were fabricated and cultured in vitro degraded over time (data 
not presented). It is well known that matrix metalloproteinases (MMPs) play an 
important role in ECM remodelling, tumour invasion and proliferation and GelMA 
contains MMP degradable motifs [62, 76]. The secretion of MMPs by SKOV3s in the 
SKOV3 and co-culture microspheres could have resulted in the degradation of the 
5% wt GelMA microspheres [77]. However with the stiffer 10% wt GelMA hydrogel 
microspheres and assembled constructs which we utilised for this experiment, the 
MMPs produced during the culture time was probably not sufficient to completely 
degrade the hydrogels.  
 
The proliferation of cells in the hydrogel is known to be affected by the 
hydrogel type, stiffness and cell type [5, 78, 79]. An increase in DNA content (Figure 
7-5) was observed over time (day 0 to 12) in the SKOV3 and co-culture microspheres 
but not in the HFF microspheres. As GelMA contains MMP degradable motifs and 
SKOV3s produces MMPs, the MMPs produced by the SKOV3s could be aiding the 
remodelling of the hydrogel and aiding cell proliferation [62, 76, 77]. It has been 
previously shown that with cell spheroids in a hydrogel, their proliferation in a MMP-
sensitive hydrogel was enhanced compared to a MMP-insensitive hydrogel 
suggesting the importance of the role of MMPs and hydrogel type in cell proliferation 
[5]. The proliferation rate of cells in a hydrogels is also dependent on the stiffness of 
the hydrogels. With SKOV3s, the proliferation rate has been reported to be higher in 
less stiff hydrogels and contrastingly with fibroblasts, it has been reported to be 
higher in more stiff hydrogels [5, 79].  The observed increase in DNA content (Figure 
7-5) over time (day 0 to 12) in the SKOV3 (Figure 7-11 a) and co-culture (Figure 7-11 
i) microspheres also correlates in part with the formation of a monolayer around the 
microspheres which was not seen in the HFF microspheres (Figure 7-11 e). 
Interestingly, a higher Ki67 (marker for proliferation) expression was not 
specifically observed in the monolayer on the surface of the microspheres (Figure 
7-11 b and j), but proportionally a higher number of cells expressing Ki67 was 
observed in cells within the microsphere. It has been shown that the fraction of 
cycling cells in a confluent monolayer culture is lesser than a subconfluent 
monolayer and this could be why a reduced Ki67 expression was observed in the 






In this study, the efficacy of cancer drug on cells in 2D, microspheres and 
assembled constructs was evaluated by exposing the models to varying 
concentrations of doxorubicin. The observed higher chemoresistance seen in 3D 
models as opposed to the 2D model (1-4 fold increase in chemoresistance for 
microspheres and 48-70 fold increase in chemoresistance for assembled constructs 
compared to cells in 2D, Table 7-4) is in agreement with other studies and could be 
possibly attributed to many reasons [81-84]. The proportion of proliferating cancer 
cells in 2D is higher than that in 3D hydrogels [85]. As doxorubicin preferentially 
targets proliferating cells, the lower proportion of proliferating cells in the 3D 
hydrogel would lead to a lower proportion of doxorubicin-induced double-stranded 
breaks in the DNA resulting in a higher chemoresistance [86]. The hydrogel itself can 
act as an extracellular matrix diffusion barrier to the drug and decrease the 
penetration of the drug which would result in an increased chemoresistance of the 
cells in the 3D hydrogel [87]. As the ECM in tumours in vivo can be mimicked by the 
hydrogel and proliferation rate in tumours in vivo is comparable to the 3D models 
than cells in 2D, in vitro 3D models offer greater potential for recapitulating the in 
vivo tumour environment [85, 88]. The increased chemoresistance in 3D models 
compared to the cells in 2D monolayer could also be due to hypoxia, the difference 
in gene and protein expression, cell-cell interaction, and increased extracellular 
matrix components [31, 89-92].  
 
The response of the cells to the drug was noted to be dependent on the cell 
type. In the 2D model, HFFs (IC50 - 0.16 µM) was the most drug-resistant, followed 
by the co-culture (IC50 - 0.08 µM) and SKOV3 (IC50 - 0.05 µM) the least (Table 7-4). 
Fibroblasts are known to be less responsive to doxorubicin compared to cancer cells 
and an increased chemoresistance of cancer cells when co-cultured with fibroblasts 
via the secretion of growth factors, cytokines, and MMP has previously been 
reported [93]. However, with the microspheres and assembled constructs, co-
culture microspheres (IC50 - 0.29 µM) and assembled constructs (IC50 - 5.56 µM) 
were the most resistant, followed by the HFF microspheres (IC50 - 0.18 µM) and 
assembled constructs (IC50 - 5.56 µM) and the SKOV3 microspheres (IC50 - 0.15 µM) 
and assembled constructs (IC50 - 2.41 µM) the least. Along with being aided by the 





constructs, the higher chemoresistance of the co-culture models could also be due 
to the presence of the confluent like monolayer of cells around the hydrogel with a 
low fraction of cycling cells (Figure 7-11 i, j, k and l) making the models less effective 
against the anticancer drug [93-95]. Also, the high density of the monolayer could 
cause a decreased penetration of the drug thereby assisting in the higher 
chemoresistance [96]. The monolayer observed in the periphery of the 
microspheres and assembled constructs could potentially reflect the vascularized 
regions of tumours in vivo where there is better delivery of oxygen, nutrients and 
drug to the tumour cells [31]. The monolayer could also represent the superficially 
invasive nature of ovarian cancer cells that disseminate in within the peritoneal 
cavity [97]. The observed significant decrease (p<0.05) in normalised DNA content 
(Figure 7-10) was from 0.01 to 0.1 µM concentration of drug in the SKOV3 and co-
culture microspheres, but in the HFF microspheres it was at a higher drug 
concentration which was from 0.1 to 1 µM. Although the observed trend where a 
decrease in normalised DNA content correlated with the trend for the IC50 values for 
the HFF (0.18 µM) and SKOV3 (0.15 µM) microspheres, the trend was not in line with 
the IC50 values for co-culture (0.29 µM) and HFF (0.18 µM) microspheres. The SKOV3 
(Figure 7-13 a, b and c) and co-culture (Figure 7-13 m, n and o) microspheres have 
a monolayer which reduced with increasing drug concentration resulting in a 
greater decrease of DNA content in the samples treated with the drug compared to 
the control. However, in the HFF microspheres (Figure 7-13), as the monolayer is not 
present, the decrease in DNA content was less pronounced in the samples treated 
with the drug compared to the control. This, along with the cell-dependent response 
of the cells to the drug, could possibly be why the observed significant decrease in 
DNA content was at a higher drug concentration in the HFF microspheres compared 
to the co-culture or SKOV3 microspheres.  
 
 The assembled constructs were less vulnerable (16-21 fold increase in IC50 
values compared to the microspheres, Table 7-4) to the anticancer drug compared 
to the individual microspheres and this could be attributed to many reasons. 
Likewise, at 1 µM concentration of the drug, in the SKOV3 and co-culture 
microspheres, negligible Hoechst 33342 staining could be observed, however in the 
SKOV3 and co-culture assembled constructs the Hoechst 33342 staining and also γ-





chemoresistance of the microspheres compared the assembled construct. The 
hydrogel matrix as in the case of the ECM in tumours in vivo can slow down the 
movement of nutrients, drugs and oxygen resulting in a concentration gradient of 
these molecules [31, 87, 89, 91]. The reduced diffusion and increased concentration 
gradient of the anticancer drug towards the core in the larger assembled construct 
compared to the microspheres would mean that the effectiveness of the drug on the 
cells distal to the periphery to the construct would be compromised, resulting in the 
increased chemoresistance of the assembled construct compared to the 
microspheres [31, 89]. The size-dependent response is relevant to tumours in vivo 
(average ovarian cancer tumour size can range from 4.6 to 11.8 cm) as the treatment 
of tumours becomes more challenging with increasing tumour size [27, 29]. The 
higher chemoresistance of the larger assembled construct compared to the smaller 
microspheres accentuates the need for larger 3D models for the reliable screening 
of candidate anticancer drugs.  
 
Native in vivo tumour tissues are composed of heterotypic cell types which 
include cancer stem cells [98], primary stem cells, fibroblasts [71], endothelial [99] 
and immune cells [100]. However, one drawback of the oncological model that we 
have fabricated is that it consisted of only ovarian cancer cells and fibroblasts, and 
creating a model analogous to an in vivo tumour would make the incorporation of 
other tumour cells types into the model necessary [101]. For example, the tumour 
models could also include a combination of microspheres fabricated from different 
types of cells which could also be either healthy or tumour origin cells to investigate 
and analyse the effect on targeted and non-targeted cells by the drug [101]. Likewise 
metastatic models can be fabricated, for example, microspheres encapsulated with 
tumour cells could potentially be assembled into a construct with microspheres 
encapsulated with bone cells to simulate osteolysis and bone invasion or with nerve 
cells to simulate tumour invasion of nerves [102, 103]. The liver plays an important 
role in drug metabolism, and models including hepatocyte encapsulated 
microspheres could be included to simulate drug and toxin metabolism [104, 105]. 
Furthermore, by utilising the deconstruction-reconstruction approach, complex 
tumours could be deconstructed to its individual basic cell type and a cancer model 
of varying complexity could be shaped. This would be beneficial in understanding 





[101]. It is well known that the stroma plays an important role in the progress or 
inhibition of cancer [106]. The stroma consists of connective tissues, blood vessels, 
and inflammatory cells [107]. A biphasic construct with one phase containing the 
tumor cells and the other containing elements of the stroma could be potentially 
fabricated a 3D model that recapitulates the tumour-stroma interaction in vivo. The 
above described schemes for a 3D plotted tumour model could be easily fabricated 
in a desired predetermined arrangement using the automated tissue assembly 
system described herein.  
 
Drug discovery is a costly process with a low success rate [108]. Presently, cost 
of developing a new drug is about US $ 2.6 billion and the probability that a 
candidate drug that enters Phase I trial would reach the market is just 8% [109, 110]. 
The monetary and ethical implications of a failed candidate drug is higher when they 
are narrowed down for animal testing and clinical trials on humans [111, 112]. It is 
crucial to accurately screen candidate drugs earlier during the drug discovery 
process to predict whether they would potentially fail or not in the later stages [111, 
112]. Therefore, in vitro 3D oncological models that can reliably predict the 
outcomes of the candidate drugs have an increasingly significant part to play in drug 
screening [111, 112]. High-throughput screening (HTS) has been vital in biology and 
drug discovery and to be able to rapidly screen a large number of drugs in an 
industrial environment it is essential to be able to adapt the model for medium or 
high-throughput screening [1, 113]. To handle a large number of compounds being 
tested, laboratories employ robots and liquid handling devices to execute the high-
throughput screening of candidate drugs in standard well-plate formats [114]. Our 
fluidic-based prototype automated tissue assembly system could serve as a blue 
print for developing a state-of-art industrial standard tissue handling system that 
can be integrated with liquid handling systems presently being used. Furthermore, 
the tumour model that we have developed could then be adopted to easily fabricate 
and produce large and complex custom tumour constructs in a high-throughput 
fashion using the automated assembly system for both in vitro and in vivo 
applications.  
 
Frequently, high-throughput screening is carried out in cell spheroids of up to 





cell-matrix interactions and approximate and 3D cancer environment [115-117]. 
However,  micro-tissues greater than 500 µm in diameter have a pH, nutrient and 
waste removal gradient, become compact and compartmentalized and tend to show 
a more similar characteristics to in vivo solid tumours [118]. For this reason it is 
essential to be able to cater to a wide range of microsphere sizes and microspheres 
from 50-3000 µm have been previously fabricated [18, 25, 119, 120]. However, the 
automated tissue assembly system that we have developed can only efficiently 
handle microspheres of around 1 mm diameter. Consequently, to handle 
microsphere outside this range, the physical components (i.e. tubing singularisation 
chamber and injection nozzle, see chapter 3 and 4) and the soft parameters (i.e. valve 
timing, fluid pressure) of the automated tissue assembly system would have to be 
modified. Moreover, with the maturation of the system, laminar flow, surface tension, 
diffusion and fluidic resistance start influencing the system and the research and 
development of an alternative tissue assembly system that takes these factors into 
consideration becomes unavoidable [121].  
 
An artificial tissue-specific environment that simulates the physiological 
environment in vivo can potentially be created in a bioreactor [122]. The 
development of a 96-format bioreactor is under progress in our lab and we intend 
to culture the developed tumour model in the bioreactor. An in vitro metastasis 
model could be designed and constructed by fabricating constructs of different 
tissue types and culturing them in interconnected wells through which media flows 
and the migration of cancer cells could be studied [3].  
 
We envisage in the foreseeable future that the cancer model that we have 
developed could be tailored to create a personalised patient specific model to assess 
and screen potential drugs for treatment [98]. The response of different anticancer 
drugs to normal and tumour cells of the patient could be used to predict the 
treatment efficacy and the impact on the quality of life of the patient.  
 
The possibility of specifically arranging cell-laden microspheres or self-
assembled micro-tissues of different types of cells in a scaffold to potentially 
recreate the complex organisation and architecture of native tissues and organs in a 





assembly based cancer model and tissue assembly system can cater to spectrum of 
applications especially in translational research in cancer and drug discovery. 
7.6 Conclusions  
We have described an innovative method for 3D Bioassembly of cell-laden 
microspheres for biofabricating cancer constructs for application as an in vitro 3D 
cancer model. This model can be used to assemble 3D constructs with cells types 
that do not form compact micro-tissues. We fabricated uniform cell-laden GelMA 
SKOV3, fibroblast and co-culture microspheres using the microfluidic system. The 
fabricated microspheres were Ø1mm and spherical so that they can be handled by 
the automated bioassembly system. With our prototype automated tissue assembly 
system, we successfully demonstrated the efficient and reliable handling of the co-
culture microspheres and the layer-by-layer assembly of a construct without 
significantly affecting the viability of the cells. The response of the cells in 2D, 
individual microsphere and the assembled construct to an anticancer drug - 
doxorubicin was quantified. 3D Bioassembled constructs showed the highest 
chemoresistance, whereas cells in 2D showed lowest resistance and the 
microsphere showed an intermediate resistance. A cell-dependent response was 
also observed. A broad range of high-throughput format based application in cancer 
biology research and in drug screening can be catered to by employing the malleable 
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8.1 Introduction  
The in vitro fabrication of artificial living tissues is a complex process with a 
magnitude of scientific challenges. Engineering tissues not only requires 
components such as cells, growth factors and biodegradable 3D scaffolds but also 
the technologies to manufacture the tissue [1-4]. Presently, we are unaware of any 
existing technologies in the area of biofabrication or bioassembly that can assemble 
tissue subunits together into a 3D plotted scaffold to create a larger engineered 
tissue with a specific architecture. Therefore, in this thesis, we aimed at developing 
an automated bioassembly system that can assemble tissue units into a 3D plotted 
thermoplastic scaffold for application in two areas – cartilage engineering and 
tumour engineering. 
8.2 Thesis conclusions  
8.2.1 The design and development of a prototype integrated system for 
automated 3D Bioassembly of tissue units for biofabrication of tissue 
engineered constructs.  
We developed a novel and flexible 3D Bioassembly platform capable of 
automated bioassembly of tissue units into a 3D plotted scaffold. The developed 
system essentially consisted of two parts (i) a singularisation module and (ii) an 
injection module. The singularisation module was designed to separate a large 
number of Ø1 mm sized tissue units and deliver an individual tissue unit to the 
injection module. The injection module with the aid of the 3D positioning system 
could insert the tissue unit into a target location within a 3D plotted thermoplastic 
polymer scaffold. The developed singularisation and injection module were 
incorporated into a commercial 3D bioprinter and this made up the automated 
bioassembly system. The flexibility of the constructed prototype tissue assembly 
system permitted the simple adjustment of the various soft parameters (i.e. valve 
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timings, pressure), thereby allowing the optimization of the device to handle 
different types of tissue units for the desired modular tissue assembly approach. The 
prototype device developed allowed us to validate the automated bioassembly 
system for cartilage and tumour engineering applications. Furthermore, 
mathematical models or anatomical models generated through imaging techniques 
(i.e. computed tomography (CT) or magnetic resonance imaging (MRI)) could also 
potentially be translated to a computer aided manufacturing (CAD/CAM) file. These 
CAD/CAM flies can then be converted to G-code to fabricate constructs of a desired 
shape, size, geometry and arrangement of tissue units [5, 6].  
8.2.2 Validation and characterisation of an integrated system for 
automated 3D Bioassembly of micro-tissues for biofabrication of tissue 
engineered cartilage constructs 
The developed integrated automated 3D Bioassembly system was validated for 
using cartilage engineering as a model application for biofabricating a micro-tissue 
based tissue engineered construct. We demonstrated that the developed device 
could efficiently (singularisation efficiency of 97.0 ± 6.6%) and reliably handle 
cartilage micro-tissues and could also insert the micro-tissues into the 3D plotted 
scaffold with an efficiency of 79.2 ± 18.8%. The viability of micro-tissues was not 
affected by being handled by the fluidic approach for micro-tissue capture, 
singularisation and bioassembly. The automated bioassembly system was designed 
so constructs could be bioassembled via both top-down and bottom-up bioassembly 
approaches to maximize the flexibility of the biofabrication process. The top-down 
bioassembly approach involved 3D plotting of a complete scaffold and injection of 
specific tissue units into the scaffold to fabricate a simple construct. The bottom-up 
approach involved a layer-by-layer strategy that combined 3D plotting of a scaffold 
layer and co-assembly of specific tissue units into the scaffold to allow fabrication of 
complex hybrid constructs. The layer-by-layer or bottom-up bioassembly of a 
cartilage construct was demonstrated and there was no difference in viability 
observed between the construct assembled manually and with the automated 
bioassembly system. The absence of any noticeable detrimental effect on the 
viability and shape of the micro-tissue after being handled by the automated tissue 
assemble system suggests the gentle nature of the designed fluidic-based system. A 
hemisphere construct (chapter 4, Figure 4-13) was also assembled with the 
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automated tissue bioassembly system demonstrating the possibility of 
bioassembling biphasic osteochondral anatomically shaped constructs.  
 
Presently, as many cartilage repair strategies have a poor long-term outcome 
due to fibrocartilage formation other repair strategies which include tissue 
engineering and regenerative medicine are being investigated [7-9]. High-
throughput fabrication techniques have been previously been demonstrated for 
generating ex vivo cartilage-like micro-tissues [10, 11]. The ability to assemble large 
numbers of the cartilage micro-tissues into a scaffold would be highly beneficial in 
fabricating tissue engineered constructs that can be employed as an alternative 
cartilage repair strategy. The approach would provide the cells and ECM 
components for simulating cartilage repair and regeneration and would also provide 
the required initial mechanical properties. The fabricated cartilage construct would 
then be completely be replaced by mature ECM over time leading to the formation 
of a functional cartilage [12]. However, one of the challenges with the envisaged 
cartilage repair strategy was the lack of an automated bioassembly system capable 
of fabricating the tissue engineered construct. We have established an automated 
tissue assembly technology that would facilitate the fabrication of complex 
anatomically-shaped 3D constructs of clinically relevant sizes that can be fabricated 
with the desired geometry and controlled spatial position of the micro-tissues, with 
precision, in large numbers, and with reduced construction time. The constructs 
could be tailor-made to suit the needs of an individual patient. Moreover, the 
employment of an automated system to fabricate a tissue construct would reduce 
human involvement and would also reduce human error in the tissue fabrication 
process.  
8.2.3 Validation an integrated system for automated 3D Bioassembly of 
cell-laden microspheres for biofabrication of tissue engineered cartilage 
constructs including proof-of-concept and chondrogenic characterisation 
of the assembled construct 
The developed integrated automated 3D Bioassembly system was validated for 
application in cartilage engineering for biofabricating a cell-laden hydrogel 
microsphere based cartilage construct. Visible light photopolymerised cell-free 5% 
and 10% GelMA microspheres and human articular chondrocyte (HAC)-laden 9.5% 
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GelMA-0.5% HepMA microspheres were fabricated utilising the microfluidic system. 
The generated microspheres showed a condition dependent average diameter close 
to Ø1 mm size with a narrow size distribution. We demonstrated that the automated 
bioassembly system can efficiently and reliably handle and deliver microspheres 
into a 3D plotted scaffold. The flexibility of the automated tissue bioassembly system 
was shown by assembling constructs with coloured microspheres which 
represented microspheres of either different cell types, hydrogel types or 
microspheres containing different bioactive molecules in various desired 
arrangements. The layer-by-layer or bottom-up bioassembly of a cartilage construct 
with HAC-laden 9.5% GelMA-0.5% HepMA hydrogel microspheres was 
demonstrated and there was no difference in viability observed between the 
construct assembled manually and with the automated bioassembly system. 
Individual HAC-laden 9.5% GelMA-0.5% HepMA hydrogel microspheres and 
assembled constructs (8 microspheres arranged in a 2 x 2 x 2 fashion) were cultured 
in vitro over time. The immunofluorescence staining for aggrecan showed 
neocartilage formation. Higher aggrecan expression was visualised in the assembled 
constructs compared to individual microspheres. A graduated assembled construct 
(arranged in a 4 x 3 x 2 fashion) with HAC, co-culture (50% HAC and 50% MSC) and 
MSC laden HAC-laden 9.5% GelMA-0.5% HepMA microspheres was cultured in vitro 
over time and staining for aggrecan showed neocartilage formation. The aggrecan 
visualised in the MSC only microspheres was lower than the HAC or co-culture 
microspheres. We further established the potential of the automated tissue 
assembly system to fabricate complex constructs with microspheres and 
demonstrated neocartilage formation for application in cartilage engineering.  
 
Encapsulating cells in a hydrogel provides a hydrated 3D native tissue-like 
environment to the cells and a pro-chondrogenic phenotype can be promoted or 
directed by forcing the cells to maintain a rounded morphology [13-18]. 
Encapsulating chondrocytes or chondroprogenitor cells in hydrogels can overcome 
some of the drawbacks of employing a micro-tissue based strategy (chapter 5). 
Fabricating a Ø1 mm micro-tissue (250,000 cells) requires 31-fold higher number of 
cells in comparison to fabricating a Ø1 mm hydrogel microspheres (at a 
concentration of 15 million cells/ml). As chondrocytes have a limited proliferative 
potential when expanded by culturing in 2D, it is highly favourable to utilise a 
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strategy that requires lesser cells. The rate-limiting step of culturing the cell pellet 
(7 days) to form the micro-tissues before they can be assembled into a construct can 
be eliminated with the hydrogel microspheres. A hydrogel microsphere based 
system would also be highly beneficial in a single surgery strategy where the tissue 
is harvested, chondrocytes or chondroprogenitor cells are isolated from the tissue 
and encapsulated, the cartilage construct is fabricated with the cell encapsulated 
hydrogel microspheres and transplanted into the patient straight away.  Although 
we have utilised GelMA, other hydrogels that have been researched for cartilage 
engineering such as alginate [19], agarose [20], collagen [21], fibrin [22], 
poly(ethylene glycol) (PEG) [23], poly(ethylene oxide) (PEO)[16] and poly(vinyl 
alcohol) (PVA) [24] could also potentially be adapted to similarly fabricate a 
cartilage construct. 
8.2.4 Validation of an integrated system for high-throughput fabrication 
and automated 3D Bioassembly of micro-tissues for biofabrication of an 
in vitro cancer model, including proof-of-concept characterisation of the 
assembled tumour construct compared to existing 2D and 3D in vitro 
models  
The developed integrated automated 3D Bioassembly system was validated for 
application in tumour engineering by biofabricating a cancer micro-tissue based in 
vitro 3D cancer model. Fabrication of compact and spherical Ø1 mm cancer micro-
tissues that could be handled by the automated bioassembly system required the co-
culture of SKOV3s with human foreskin fibroblasts (HFFs). The cells in the co-culture 
micro-tissues self-segregated to form a predominantly fibroblast core enveloped by 
ovarian cancer cells in the periphery. When the micro-tissues were assembled into 
a scaffold, the cells in the assembled construct maintained their micro-tissue 
arrangement. Fibroblasts are an integral part of tumours and they are known to play 
a significant role in the progress, growth and spread of cancers and are associated 
with cancer cells at all stages of progression [25, 26]. Tumour stroma supports the 
tumour cells in vivo and the rearrangement of SKOV3s and HFFs could potentially 
mimic the in vivo tumour cell-stroma interactions [27]. We demonstrated the 
reliable and efficient handling of the cancer co-culture (75% SKOV3 and 25% HFF) 
micro-tissues by the automated bioassembly system. The layer-by-layer or bottom-
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up bioassembly of a cancer construct was demonstrated and there was no difference 
in viability observed between the construct assembled manually and with the 
automated bioassembly system. The response of cells in 2D monolayer, 3D micro-
tissues and the co-culture 3D assembled cancer construct was evaluated with 
doxorubicin. An increased chemoresistance was observed in the 3D micro-tissues 
compared to cells in 2D and this enhanced chemoresistance observed in 3D models 
is in line with other studies [28-32]. A cell-dependent response was observed 
between SKOV3, HFF and co-culture individual micro-tissues and cells in 2D. A 
higher chemoresistance was observed in the co-culture assembled construct 
compared to the co-culture micro-tissues. The observed higher chemoresistance of 
the assembled construct compared to the individual micro-tissues could possibly be 
due to the larger gradients in nutrients, drugs and oxygen in the larger assembled 
construct compared to the smaller individual micro-tissues which resulted in lower 
drug efficacy [33-35]. Form the immunohistochemistry, the expression of Ki67 was 
observed to be cell dependent. The expression of γ-H2AX was visualized to be higher 
at higher drug concentrations demonstrating DNA double-stranded breaks caused 
by the drug. The developed model and bioassembly technology together open the 
platform for the fabricating modular assembly based tailor-made cancer constructs 
with controlled spatial position of micro-tissues that could potentially be applied in 
cancer research and high-throughput screening of anticancer drugs. Moreover, the 
average ovarian cancer tumour size in vivo can range from 4.6 to 11.8 cm and a larger 
assembled construct tumour model would be more relevant for anticancer drug 
testing compared to a smaller micro-tissue model  [36, 37]. However, the developed 
cancer micro-tissue in vitro model can only be fabricated with cell types that form 
compact spherical micro-tissues.  
8.2.5 Validation of an integrated system for automated 3D Bioassembly 
of cell-laden microspheres for biofabrication of an in vitro cancer model, 
including proof-of-concept characterisation of the assembled tumour 
construct compared to existing 2D and 3D in vitro models 
The developed integrated automated 3D Bioassembly system was validated for 
application in tumour engineering by biofabricating a cell-laden hydrogel 
microsphere based in vitro 3D cancer model. Cell-laden 10% GelMA SKOV3, HFF and 
co-culture (75% SKOV3 and 25% HFF) microspheres were fabricated with the 
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microfluidic system. The generated microspheres had an average diameter close to 
1 mm size with a narrow size distribution. We demonstrated that the automated 
bioassembly system can efficiently and reliably handle the microspheres. The layer-
by-layer or bottom-up bioassembly of a cancer construct was demonstrated and 
there was no difference in viability observed between the construct assembled 
manually and with the automated bioassembly system. The response of SKOV3, 
fibroblast and co-cultures in 2D monolayer, individual microspheres and assembled 
constructs was evaluated with doxorubicin. The 3D assembled constructs were 
more chemoresistant than the individual microspheres and the cells in 2D had the 
lowest chemoresistance. A cell-dependent drug response was also observed. The 
expression of γ-H2AX was visualized to be higher at higher drug concentrations in 
all 3D models demonstrating DNA double-stranded breaks caused by the drug. By 
encapsulating cells in hydrogel microspheres, 3D cancer constructs could be 
fabricated with cell types that do not form compact micro-tissues. This enables the 
fabrication of modular assembly based cancer constructs with controllable spatial 
position of microspheres with cells types that do not form compact spherical micro-
tissues. A hydrogel based model is also advantageous in that lower number of cells 
are required and the rate limiting step (24 hours to several days) of fabricating a 
micro-tissue can be eliminated compared to fabricating a micro-tissue based model 
[38]. Moreover, encapsulating cells in a hydrogel is attractive as it provides a 
hydrated tissue-like environment similar to the native extracellular matrix (ECM) of 
many tissues. The developed tailorable in vitro 3D cancer model could potentially be 
employed in cancer research and high-throughput screening of anticancer drugs.  
 
The downside of employing GelMA to encapsulate the cells is that there could 
be batch-to-batch variations in manufactured GelMA making it impracticable to 
correlate work form different laboratories and also the properties of the hydrogel 
would have to be optimised (i.e. stiffness) depending on the cell type and application 
[39, 40]. The fabrication of microspheres with hydrogel-based matrices such as 
reconstituted basement membrane protein (Matrigel) [41] and type I collagen [42] 
which are commonly used to fabricate cancer models could potentially be possible 
with few modifications of the micro-fluidic system (i.e. temperature controlled 
environment for the temperature sensitive Matrigel) and the automated 
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bioassembly system. The fabricated microspheres could then be assembled to create 
Matrigel or type I collagen-based cancer constructs. 
 
In both the micro-tissue and hydrogel microspheres models, a higher 
chemoresistance was seen in the individual microspheres or micro-tissues 
compared to cells in 2D and a higher chemoresistance was observed in the 
assembled constructs compared to the individual microspheres or micro-tissues. 
The observed trend of higher chemoresistance in 3D models compared to cells in 2D 
is comparable to other studies reported in the literature [28-32]. The trend also 
highlights the need for conducting drug testing in 3D models and more importantly 
with larger 3D models as their response would be more comparable to tumours in 
situ. Although we have fabricated cancer constructs with only fibroblasts and SKOV3, 
tumour models of different cell types (including a combination of healthy and 
tumour cells) could potentially be assembled into a construct with complex 
architecture. The assembled tumour models could also potentially be fabricated to 
simulate and investigate other aspects in drug testing and cancer research such as 
drug and toxin metabolism, tumour-stroma interaction, osteolysis, tumour invasion 
of bone or tumour invasion of nerves [43-46].  
8.3 Future work  
8.3.1 Hypoxic culture of cell-laden individual hydrogel microspheres and 
assembled constructs for cartilage engineering  
The oxygen concentration in a healthy articular cartilage is low - typically 
around 1% and oxygen apart from being an essential nutrient is known to direct and 
influence cartilage formation [47, 48]. The significance of a hypoxic environment for 
chondrocyte differentiation have been reported inconsistently [47]. However, 
numerous studies have shown that a hypoxic environment simulates chondrogenic 
differentiation in vitro [49-51]. Moreover, we have shown that the expression of 
aggrecan to be higher in an assembled construct compared to an individual 
microsphere. This difference in the aggrecan expression could possibly be due to an 
oxygen gradient and a more hypoxic environment in the assembled constructs 
compared to the individual microspheres. We cultured the microspheres and 
assembled constructs in a normoxic condition. Further studies to investigate the 
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effect of a hypoxic environment by carrying out the experiment in a hypoxic chamber 
at different oxygen tensions on both individual microspheres and assembled 
constructs would be beneficial in revealing the optimum oxygen tension for 
promoting chondrogenic differentiation and neocartilage formation. Moreover, the 
microsphere model could be compared with the micro-tissue based model to assess 
cartilage formation. As the HepMA incorporated into the hydrogel interferes with 
the GAG quantification and safranin-O staining for GAG, methods that do not cause 
interference by the incorporation of HepMA such as immunofluorescence staining 
and gene expression of collagen type I and II and aggrecan would give us a clearer 
insight into neocartilage formation [52]. The developed cartilage construct could 
also be potentially implanted in vivo in an animal (i.e. sheep, goat or rabbit) to 
investigate the effect of a low oxygen environment and the outcome it has on tissue 
formation and integration of the transplanted construct with the surrounding tissue.   
8.3.2 Fabrication of an osteochondral construct 
An osteochondral construct could cater to a full thickness lesion of articular 
cartilage and it would also allow for improved fixation of the construct with the bony 
section of the defect and the integration of the construct with the surrounding 
cartilage [53, 54]. Ideally, an osteochondral construct would have a similar 
distribution and organization of cells and ECM components to native articular 
cartilage [54]. We demonstrated the fabrication of an anatomically shaped construct 
(chapter 4, Figure 4-11), a chondral construct (chapter 5, Figure 5-11), and a 
graduated chondral construct with MSCs and HACs (chapter 5, Figure 5-13) [55]. 
Based on similar principles, the developed automated bioassembly system could 
potentially be utilised to fabricate a biphasic osteochondral construct with pre-
differentiated micro-tissues or microspheres or both. The fabricated microspheres 
and micro-tissues could be produced from either a combination of 
chondrocytes/MSCs or osteoblasts/osteocytes/MSCs. The automated aspect of the 
bioassembly system would aid the large-scale fabrication of the complex biphasic 
osteochondral constructs. The constructs could be cultured in media formulated to 
maintain both chondrogenesis and osteogenesis. Chondrogenesis associated genes 
such as collagen type II and aggrecan and osteogenesis-associated genes such as 
alkaline phosphatase, bone sialoprotein and osteocalcin could be investigated to 
assess neotissue formation [52, 54]. Likewise, histological examination with alizarin 
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red for bone and alcian blue or immunofluorescence staining for aggrecan and 
collagen type II for cartilage could be visually examined for neotissue formation in 
the chondral layer, transition zone and the osseous layer [52, 54]. In vivo animal 
studies could also be undertaken to investigate the tissue formation and integration 
of the transplanted construct with the surrounding tissue with the developed 
cartilage construct.  
8.3.3 Vascularisation of the in vitro cancer model 
Tumours in vivo have abnormal vascularisation and angiogenesis is required 
for tumour growth, invasion, progression, and metastasis [29, 56]. Vascularisation 
of a cancer constructs would not only mimic and recapitulate the in vivo tumour 
environment but would be also essential for the long-term survival of cells in larger 
constructs [29, 57]. Improved vascularisation in a tumour would lead to the better 
drug and oxygen infiltration to the cells in a tumour and could have an impact on the 
outcome of chemotherapy [58]. Patients with intermediately vascularised tumours 
have been shown to respond better to chemotherapy than patients with low or high 
vascularisation [58]. A vascularised model could have a higher capacity to anticipate 
the outcome of a candidate drug during drug screening. Co-culture cancer (SKOV3s 
and fibroblasts)  micro-tissues or cancer cell-laden microspheres could be coated 
with endothelial cells and cultured so that they form a confluent layer on the surface 
after which they could be assembled as desired into a cancer construct and be 
fabricated in large numbers with the developed automated bioassembly system [59]. 
The interstitial spaces between the assembled microspheres or micro-tissues would 
potentially form the interconnected vascular structure [59]. Alternatively, 
endothelial cells could be co-cultured with cancer cells and fibroblasts to fabricate 
cancer micro-tissues or endothelial and cancer cells together could be used to 
fabricate cell-laden hydrogel microspheres and the micro-tissues or microspheres 
could be assembled into a construct with the intention that the structure would 
vascularise over time [57]. The constructs would have to be cultured in a media 
formulation containing exogenous growth factors for vascularisation [57]. IC50 
values could be determined to gauge the model and immunofluorescence staining 
for CD31 which is expressed by endothelial cells [60] Ki67 which is a marker for 
proliferation [61, 62], and γ-H2AX which is a marker for double-stranded breaks in 
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DNA [63, 64] could be performed no the samples to investigate the distribution of 
cells, cell proliferation and the effect of the drug on the vascularised constructs.  
8.3.4 Validating the in vitro cancer model with different cancer cell types 
The ability to fabricate in vitro cancer models from a range of different cell lines 
is highly significant as this would allow the specific screening of anticancer drugs 
which are tumour specific or receptor-specific [65]. We have already demonstrated 
the fabrication of an ovarian cancer in vitro tumour model based on cancer micro-
tissues and cancer cell-laden microspheres with SKOV3s with the automated tissue 
assembly system. Further studies could be aimed at validating the plausibility of 
fabricating cancer constructs from cancer cell lines originating from different tissues 
types including breast, prostate, bone, lung, colon or liver or with receptor positive 
or negative cell lines such as estrogen receptor-positive MCF-7 and estrogen 
receptor-negative MDA-MB-231 [65]. The validation would demonstrate the ability 
to fabricate in vitro cancer models from a range of cancer cell types with the 
automated tissue assembly system for application in high-throughput screening of 
anticancer drugs. We had previously shown that we were not able to fabricate 
compact spherical micro-tissues with MDA-MB-231s and MCF-7s and we could 
investigate co-culturing these cell lines with fibroblasts to try and fabricate compact 
spherical micro-tissues. Likewise, the MDA-MB-231s and MCF-7s could also be 
encapsulated into the hydrogel microspheres to fabricate a microsphere based 
construct. As we have previously executed, IC50 values could be determined to gauge 
the model and immunofluorescence staining for Ki67 [61, 62] and γ-H2AX [63, 64] 
could be performed on the samples to investigate cell proliferation and the effect of 
the drug on the constructs.  
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Figure 5.A-i. Brightfield microscopy images of HAC-laden 9.5% GelMA-0.5% HepMA 
microspheres on day 1, 14 and 35. Scale bar = 100 µm for all images. 
 
Day 14 Day 35 
Brightfield 
(a) (b) (c) 
Figure 5.A-ii. Brightfield microscopy images of HAC-laden 9.5% GelMA-0.5% HepMA 
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Figure 5.A-iii. Metabolic activity expressed in terms of percentage of AlamarBlue® reduced at day 
1, 7, 14, 21, 28 and 35 of the graduated assembled construct with HAC, co-culture (50% HAC and 
50% MSC) and MSC encapsulated 9.5% GelMA-0.5% HepMA microspheres assembled in a 4 x 3 x 
2 fashion. The data is presented as mean ± SD (n=3). *Significant differences between columns 
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Figure 5.A-iv. Total GAG per microsphere for light crosslinked individual 9.5% GelMA-0.5% 
HepMA microspheres without cells, HAC-laden individual microspheres and assembled 
constructs on day 0, 14 and 35. The data is presented as mean ± SD (n=4). *Significant 






























Figure 5.A-v. Histological staining (safranin O/haematoxylin/fast green) for cell-free 9.5% 
GelMA-0.5% HepMA microspheres, HAC-laden 9.5% GelMA-0.5 HepMA microspheres, HAC-
laden 9.5% GelMA-0.5% HepMA assembled constructs on day 14 and 35. Scale bar = 1 mm 
for all images. 
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Figure 5.A-vi. Immunofluorescence staining for Aggrecan and Hoechst 33342 (cell nuclei) and 
Collagen type I, Collagen type II and Hoechst 33342 (overlaid) imaged using a fluorescence 
microscopy for HAC-laden 9.5% GelMA-0.5% HepMA microspheres and assembled constructs 
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Figure 5.A-vii. Immunofluorescence staining for Collagen type II and Hoechst 33342 (cell 
nuclei) imaged using a fluorescence microscopy for HAC-laden 9.5% GelMA-0.5% HepMA 
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Figure 5.A-viii. Immunofluorescence staining for Collagen type I and Hoechst 33342 (cell 
nuclei) imaged using a fluorescence microscopy for HAC-laden 9.5% GelMA-0.5% HepMA 
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Figure 5.A-ix. Immunofluorescence staining for (overlaid) Collagen type I, Collagen type II and 
Hoechst 33342 imaged using a fluorescence microscopy for HAC-laden 9.5% GelMA-0.5% 
HepMA individual microspheres and assembled constructs on day 14 and 35. Scale bar = 100 
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Figure 5.A-x. Histological staining (safranin O/haematoxylin/fast green) for graduated 
assembled construct (HAC, co-culture (50% HAC and 50% MSC) and MSC laden 9.5% GelMA-
0.5% HepMA microspheres) and micro-tissues on (a) day 14 and (b) day 35. Scale bar = 1 mm 
























































Figure 5.A-xi. Immunofluorescence staining for Collagen type I, Collagen type II and Hoechst 
33342 (cell nuclei) imaged using a confocal fluorescence microscopy for a graduated 
assembled construct (HAC, co-culture (50% HAC and 50% MSC) and MSC-laden 9.5% GelMA-
0.5% HepMA microspheres) on day 14 and 35. The dotted lines shows the division in the 
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Figure 5.A-xii. Immunofluorescence staining for Collagen type II and Hoechst 33342 (cell 
nuclei) imaged using a fluorescence microscopy for HAC, co-culture (50% HAC and 50% MSC) 
and MSC laden 9.5% GelMA-0.5 HepMA microspheres that were assembled as a construct on 
day 1, 14 and 35. Scale bar = 100 µm for all images. 
(a) (b) (c) 
(d) (e) (f) 
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Figure 5.A-xiii. Immunofluorescence staining for Collagen type I and Hoechst 33342 (cell 
nuclei) imaged using a fluorescence microscopy for HAC, co-culture (50% HAC and 50% MSC) 
and MSC laden 9.5% GelMA-0.5 HepMA microspheres that were assembled as a construct on 
day 1, 14 and 35. Scale bar = 100 µm for all images. 
(a) (b) (c) 
(d) (e) (f) 
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Figure 5.A-xiv. Immunofluorescence staining for Collagen type I, Collagen type II and Hoechst 
33342 (cell nuclei) imaged using a fluorescence microscopy for HAC, co-culture (50% HAC and 
50% MSC) and MSC laden 9.5% GelMA-0.5 HepMA microspheres that were assembled as a 
construct on day 1, 14 and 35. Scale bar = 100 µm for all images. 
(a) (b) (c) 
(d) (e) (f) 




































Figure 5.A-xv. Confocal microscope images of the sectioned graduated assembled construct 
(HAC, co-culture (50% HAC and 50% MSC) and MSC laden 9.5% GelMA-0.5 HepMA 
microspheres) on day 1, 14 and 35. HAC (Qtracker 655), MSC (Qtracker 800) and Hoechst 33342. 
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Whole micro-tissue 
(a) (b) 
Figure 6.A-i. Fluorescence microscope images of whole micro-tissues (a and b) and micro-
tissues sections (c and d) with SKOV3 (Qtracker 800; red) and HFF (Qtracker 655; green) (a 
and c), and Hoechst 33342 (cell nuclei, blue; b and d). The ratio of SKOV3 to HFF are in rows. 
































































Figure 6.A-ii. Fluorescence microscopy and darkfield images of SKOV3, co-culture and HFF 
micro-tissues on day 7 and day 12. The samples were stained with Calcein AM (live cells, 

















The visual inspection of the live/dead fluorescence microscopy images of micro-tissues 
(Figure 6.A-ii) on day  7 and 12 showed mostly viable cells which was also true of the 


























Figure 6.A-iii. Fluorescence microscopy of assembled cancer construct after 5 days of 
assembly (a) top view  and (b) side view. The samples were stained with Calcein AM (live 























Figure 7.A-i. Fluorescence microscopy images of SKOV3, HFF, and co-culture encapsulated 
microspheres on day 1, 7 and 12 stained with Calcein AM (live cells, green) and Propidium 














































Figure 7.A-ii. Darkfield microscopy images of SKOV3, HFF, and encapsulated microspheres on 















































Figure 7.A-iii. Brightfield microscopy images of SKOV3, HFF and co-culture encapsulated 
microspheres on day 0, 7 and 12. Scale bar = 100 µm for all images. For lower magnification 















































Figure 7.A-iv. Darkfield microscopy images of SKOV3, HFF, and co-culture encapsulated 


















Figure 7.A-v. Fluorescence microscope images of the co-culture (SKOV3:HFF 75:25) 
microspheres and assembled construct sections on Day 1 and 12. SKOV3 (Qtracker 800, 
red), HFF (Qtracker 655, green) and Hoechst 33342 (cell nuclei, blue). The dotted line 




















































































Figure 7.A-vi. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for SKOV3 
microspheres and assembled construct on day 1 and day 12 (no drug control). Arrows 
point to the monolayer and the dotted line represent the outer edge of the sample. Scale 





























































































Figure 7.A-vii. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for HFF 
microspheres and assembled construct on day 1 and day 12 (no drug control). Arrows 
point to the monolayer and the dotted line represent the outer edge of the sample. Scale 





























































































Figure 7.A-viii. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for co-culture 
(SKOV3:HFF 75:25) microspheres and assembled construct on day 1 and day 12 (no drug 
control). Arrows point to the monolayer and the dotted line represent the outer edge of 






























































Figure 7.A-ix. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for SKOV3 
microspheres for no drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM concentration of 
doxorubicin. Arrows point to the monolayer and the dotted line represent the outer edge 


















































































Cell nuclei γ-H2AX  Ki67 
HFF microspheres 
Figure 7.A-x. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for HFF 
microspheres for no drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM concentration of 
doxorubicin. The dotted line represent the outer edge of the sample. Scale bar = 200 µm 























Figure 7.A- xi. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for co-culture 
(SKOV3:HFF 75:25) microspheres for no drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM 
concentration of doxorubicin. Arrows point to the monolayer and the dotted line represent 
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Figure 7.A-xii. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for SKOV3 
assembled construct for no drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM 
concentration of doxorubicin. Arrows point to the monolayer and the dotted line 
represent the edge of the sample. Scale bar = 200 µm for all images. See for Figure 7.A-xvi 
higher magnification images. 







Figure 7.A-xiii. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for HFF assembled 
construct for no drug control, 0.001 µM, 0.01 µM, 0.1 µM and 1 µM concentration of 
doxorubicin. The dotted line represent the edge of the sample. Scale bar = 200 µm for all 
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Figure 7.A-xiv. Immunofluorescence staining for Ki67 (yellow), γ-H2AX (magenta), and 
Hoechst 33342 (cell nuclei, blue) imaged using a confocal microscope for co-culture 
(SKOV3:HFF 75:25) assembled construct for no drug control, 0.001 µM, 0.01 µM, 0.1 µM 
and 1 µM concentration of doxorubicin. The dotted line represent the outer edge of the 
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